UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 001-39783

FOXO TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Delaware

85-1050265

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer

Identification No.)

729 N. Washington Ave., Suite 600

Minneapolis, MN

55401

(Address of principal executive offices)

(Zip Code)

(612) 562-9447

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:	Trading Symbol(s)	Name of Each Exchange on Which Registered:
Class A Common Stock, par value $0.0001	FOXO	~~NYSE American~~
~~Warrant, each whole warrant exercisable for one share of Class A Common Stock for $11.50 per share~~	~~FOXO.WS~~	NYSE American

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, “smaller reporting company” and “emerging growth company” in Rule 12b-2.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 18, 2022,~~January 19, 2024, there were ~~31,187,069~~8,946,032 shares of Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) of the registrant issued and outstanding.

FOXO ~~Technologies inc.~~TECHNOLOGIES INC.

FORM 10-Q FOR THE ~~QUARTER~~QUARTERLY PERIOD ENDED ~~SEPTEBMER~~SEPTEMBER 30, ~~2022~~2023

TABLE OF CONTENTS

PART I –- FINANCIAL INFORMATION:		1
Item 1.	Financial Statements	1
	Unaudited Condensed Consolidated Balance Sheets as of September 30, ~~2022 (Unaudited)~~2023 and December 31, ~~2021~~2022	~~F-1~~1
	Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022	~~F-2~~2
	Unaudited Condensed Consolidated Statements of Changes in Stockholders’ ~~Deficit~~Equity (Deficit) for the Three and Nine Months ended September 30, ~~2022~~2023 and ~~2021~~2022	~~F-3~~3
	Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, ~~2022~~2023 and ~~2021~~2022	~~F-4~~4
	Notes to Unaudited Condensed Consolidated Financial Statements	~~F-5~~5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	124
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	1943
Item 4.	Controls and Procedures	1943

PART II –- OTHER INFORMATION:
		44
Item 1.	Legal Proceedings	2044
Item 1A.	Risk Factors	2045
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
~~Item 3.~~49	~~Defaults Upon Senior Securities~~	21
~~Item 4.~~	~~Mine Safety Disclosures~~	21
Item 5.	Other Information	2149
Item 6.	Exhibits	2250
SIGNATURES		2351

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION
CONTAINED IN THIS REPORT

This Quarterly Report on Form 10-Q, or this Report, and the documents incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which include, without limitation, Statements regarding estimates and forecasts of financial and performance metrics, projections of market opportunity and market share, potential benefits and the commercial attractiveness to its customers of our products and services, the potential success of our marketing and expansion strategies, realization of the potential benefits of the Business Combination (including with respect to stockholder value and other aspects of our business identified in this Report), as well as other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors including, without limitation, the direct and indirect effects of coronavirus disease 2019, or COVID-19, and related issues that may arise therefrom.

Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects,” or similar expressions are intended to identify forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or other events occur in the future. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described in Part I., Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2023, and elsewhere in this Report such as, but not limited to:

●

we have a history of losses and may not achieve or maintain profitability in the future;

●

our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern, which could limit our ability to raise additional capital;

●

we will require additional capital to commercialize our product and service offerings and grow our business, which may not be available on terms acceptable to us or at all;

●

the loss of the services of our current executives or other key employees, or failure to attract additional key employees;

●

the strength of our brands and our ability to develop, maintain and enhance our brands and our ability to develop and expand our customer base;

●

access to the substantial resources to continue the development of new products and services;

●

our ability to commercialize our technology enabled products and services with a high level of service at a competitive price, achieve sufficient sales volumes to realize economies of scale and create innovative new products and services to offer to our customers;

●

our ability to effectively and in a cost-feasible manner acquire, maintain and engage with our targeted customers;

●

the impact on our business of security incidents or real or perceived errors, failures or bugs in our systems and/or websites

●

the impact of changes in the general economic conditions;

●

our success and ability to establish and grow our epigenetic testing service and the development of epigenetic biomarkers;

●

our ability to apply the relatively new field of epigenetics to the industries in which we seek to operate;

●

our ability to validate and improve the results of our 2019 Pilot Study;

●

the impact of competition in the personal health and wellness testing market;

●

our ability to procure materials and services from third-party suppliers for our epigenetic testing services;

●

our ability to maintain compliance now or in the future to laws and regulations relating to laboratory testing, our consumer engagement services and our use of epigenetic biomarkers;

●

our ability to maintain focus on our main business line initiatives, while providing ancillary product and service offerings that support our baseline technology;

●

our ability to satisfy the regulatory conditions that our business operates in;

●

the ability to contract or maintain relationships related to selling life insurance products underwritten and issued by third-party carriers;

●

competition in the industries in which we operate or seek to operate;

●

the dependence on search engines, social media platforms, content-based online advertising and other online sources to attract customers to our website;

●

our ability to comply with customer privacy and data privacy and security laws and regulations;

●

our ability to prevent or address the misappropriation of our data;

●

our ability to comply with current and changes to regulations in the jurisdiction in which we operate;

●

the impact of new legislation or legal requirements affecting how we communicate with our customers;

●

our ability to obtain sufficiently broad protection of our intellectual property throughout the world;

●

the impact of changes in trademark or patent law in the United States and other jurisdictions;

●

the impact of claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secret of their former employers;

●

lawsuits and other claims by third parties or investigations by various regulatory agencies that we may be subjected to and are required to report to, including but not limited to, the SEC;

●

our ability to successfully register and enforce our trademarks;

●

the impact of claims challenging the inventorship of our patents and other intellectual property;

●

the adequacy of our patent terms to protect our competitive position; and

●

the risks to our proprietary software and source code from our use of open source software.

Unless expressly indicated or the context requires otherwise, the terms “FOXO,” the “Company,” “we,” “us” or “our” in this Report refer to FOXO Technologies Inc., a Delaware corporation, and, where appropriate, its subsidiaries.

iii

PART I –- FINANCIAL INFORMATION

~~Item~~ITEM 1. ~~Financial Statements~~FINANCIAL STATEMENTS

FOXO technologies inc. and subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands, except per share data)

(Unaudited)

September 30, December 31,
2022 2021
(unaudited)
Assets
Current assets
Cash and cash equivalents $ 10,454 $ 6,856
Supplies 2,057 295
Prepaid expenses 511 444
Prepaid consulting fees 4,758 -
Other current assets 20 23
Total current assets 17,800 7,618

Property and equipment, net 136 187
Intangible assets 2,071 191
Investments 100 100
Reinsurance recoverables 18,754 19,463
Cloud computing arrangements 4,709 2,745
Forward purchase collateral 27,919 -
Total assets $ 71,489 $ 30,304

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable $ 2,706 $ 3,456
Related party payable 500 -
Shares payable 384 -
Parallel run advance 256 -
Accrued and other liabilities 504 402
Forward purchase put derivative 1,284 -
Forward purchase collateral derivative 27,378 -
Related party convertible debentures - 9,967
Convertible debentures - 22,236
Total current liabilities 33,012 36,061
Warrant liability 1,038 -
Long term debt 2,918 -
Policy reserves 18,754 19,463
Total liabilities 55,722 55,524
Commitments and contingencies (Note 13)
Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, none issued or outstanding as of September 30, 2022 - -
Class A common stock, $0.0001 par value, 500,000,000 shares authorized, 33,027,830 issued and outstanding as of September 30, 2022 3 -
Undesignated preferred stock, $.00001 par value; 90,000,000 shares authorized, none issued and outstanding as of December 31, 2021) - -
Non-redeemable preferred stock series A, $.00001 par value; 10,000,000 shares authorized, 8,000,000 shares issued and outstanding as of December 31, 2021 - 21,854
Common stock class A, $.00001 par value; 800,000,000 shares authorized; 30,208 shares issued and outstanding as of December 31, 2021) - -
Common stock class B, $.00001 par value, 100,000,000 shares authorized; 2,000,000 shares issued and outstanding as of December 31, 2021) - -
Additional paid-in capital 144,672 4,902
Accumulated deficit (128,908 ) (51,976 )
Total stockholders’ equity (deficit) 15,767 (25,220 )
Total Liabilities and Stockholders’ Equity (Deficit) $ 71,489 $ 30,304

	September 30,			December 31,
	2023			2022

Assets
Current assets
Cash and cash equivalents	$	42		$	5,515
Supplies		1,131			1,313
Prepaid expenses		1,306			2,686
Prepaid consulting fees		-			2,676
Other current assets		106			114
Total current assets		2,585			12,304
Intangible assets		428			2,043
Reinsurance recoverables		-			18,573
Cloud computing arrangements		-			2,225
Other assets		118			263
Total assets	$	3,131		$	35,408

Liabilities and Stockholders’ (Deficit) Equity
Current liabilities
Accounts payable	$	4,816		$	3,466
Related party payables		747			500
Senior PIK Notes		4,006			1,409
Accrued severance		1,528			1,045
Accrued settlement		2,300			-
Accrued and other liabilities		119			493
Total current liabilities		13,516			6,913
Warrant liability		67			311
Senior PIK Notes		-			1,730
Policy reserves		-			18,573
Other liabilities		651			1,173
Total liabilities		14,234			28,700
Commitments and contingencies (Note 12)
Stockholders’ (deficit) equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, none issued or outstanding as of September 30, 2023 and December 31, 2022		-			-
Class A common stock, $0.0001 par value, 500,000,000 shares authorized, 5,916,852 and 2,966,967 issued, and 5,916,852 and 2,752,890 outstanding as of September 30, 2023 and December 31, 2022, respectively		6			3
Treasury stock, at cost, 0 and 214,077 as of September 30, 2023 and December 31, 2022, respectively		-			-
Additional paid-in capital		161,180			153,936
Accumulated deficit		(172,289	)		(147,231	)
Total stockholders’ (deficit) equity		(11,103	)		6,708
Total liabilities and stockholders’ (deficit) equity	$	3,131		$	35,408

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

Foxo Technologies INc. and subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars in thousands, except per share data)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021			Three Months Ended September 30,						Nine Months Ended September 30,
													2023			2022			2023			2022
Total revenue	$	14		$	31		$	93		$	93		$	10		$	14		$	35		$	93
Cost of sales														70			-			70			-
Gross profit														(60	)		14			(35	)		93
Operating expenses:
Research and development		558			1,665			2,160			4,321			283			558			925			2,160
Management contingent share plan expense (forfeitures)														(1,553	)		-			(141	)		-
Impairment of intangible assets and cloud computing arrangements														-			-			2,633			-
Selling, general and administrative		8,269			2,721			17,239			7,640			4,717			8,269			15,052			17,239
Total operating expenses		8,827			4,386			19,399			11,961			3,447			8,827			18,469			19,399
Loss from operations		(8,813	)		(4,355	)		(19,306	)		(11,868	)		(3,507	)		(8,813	)		(18,504	)		(19,306	)
Non-cash change in fair value of convertible debentures		(3,697	)		(22,571	)		(28,180	)		(24,890	)		-			(3,697	)		-			(28,180	)
Change in fair value of warrant liability		1,349			-			1,349			-			36			1,349			244			1,349
Change in fair value of forward purchase put derivative		(1,284	)		-			(1,284	)		-			-			(1,284	)					(1,284	)
Change in fair value of forward purchase collateral derivative		(27,378	)		-			(27,378	)		-			-			(27,378	)					(27,378	)
Other expense		(779	)		(2	)		(883	)		(31	)
Loss from PIK Note Amendment and 2022 Debenture Release																	-			(3,521	)		-
Interest expense		(424	)		(313	)		(1,250	)		(825	)		(148	)		(424	)		(865	)		(1,250	)
Total other expense		(32,213	)		(22,886	)		(57,626	)		(25,746	)
Other income (expense)														(41	)		(779	)		54			(883	)
Total non-operating expense														(153	)		(32,213	)		(4,088	)		(57,626	)
Loss before income taxes		(41,026	)		(27,241	)		(76,932	)		(37,614	)		(3,660	)		(41,026	)		(22,592	)		(76,932	)
Provision for income taxes		-			-			-			-			-			-			-
Net loss	$	(41,026	)	$	(27,241	)	$	(76,932	)	$	(37,614	)	$	(3,660	)	$	(41,026	)	$	(22,592	)	$	(76,932	)
Deemed dividend related to the Exchange Offer														-			-			(2,466	)		-
Net loss to common stockholders													$	(3,660	)	$	(41,026	)	$	(25,058	)	$	(76,932	)

Net loss per Class A common stock, basic and diluted	$	(6.70	)	$	(4.68	)	$	(12.88	)	$	(6.47	)
Net loss per share of Class A common stock, basic and diluted													$	(0.75	)	$	(67.04	)	$	(7.48	)	$	(128.65	)

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

FOXO TECHNOLOGIES INC. and subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY ~~(DEFICIT)~~

(Dollars in thousands)

(Unaudited)

				FOXO Technologies Operating Company																FOXO Technologies Inc.													FOXO Technologies Operating Company																FOXO Technologies Inc.
	Stockholder Subscription			Series A Preferred Stock						Common Stock (Class A)					Common Stock (Class B)					Common Stock (Class A)				Additional Paid-in-			Accumulated						Series A Preferred Stock						Common Stock (Class A)					Common Stock (Class B)					Common Stock (Class A)					Treasury Stock			Additional Paid-			Accumulated
	Receivable			Shares			Amount			Shares			Amount		Shares			Amount		Shares		Amount		Capital			Deficit			Total
Three Months Ended September 30, 2021
Balance, June 30, 2021	$	(1,250	)		8,000,000		$	21,854			30,000		$	-		2,000,000		$	-		-	$	-	$	4,447		$	(23,861	)	$	1,190
Net loss		-			-			-			-			-		-			-		-		-		-			(27,241	)		(27,241	)
Lease contributions		-			-			-			-			-		-			-		-		-		137			-			137
Equity-based compensation		-			-			-			-			-		-			-		-		-		45			-			45
Subscriptions received		1,250			-			-			-			-		-			-		-		-		-			-			1,250
Balance, September 30, 2021	$	-			8,000,000		$	21,854			30,000		$	-		2,000,000		$	-		-	$	-	$	4,629		$	(51,102	)	$	(24,619	)

Nine Months Ended September 30, 2021
Balance, December 31, 2020	$	(3,750	)		8,000,000		$	21,854			-		$	-		2,000,000		$	-		-	$	-	$	4,104		$	(13,488	)	$	8,720
Net loss		-			-			-			-			-		-			-		-		-		-			(37,614	)		(37,614	)
Lease contributions		-			-			-			-			-		-			-		-		-		410			-			410
Equity-based compensation		-			-			-			-			-		-			-		-		-		102			-			102
Subscriptions received		3,750			-			-			-			-		-			-		-		-		-			-			3,750
Warrants issued		-			-			-			-			-		-			-		-		-		13			-			13
Issuance of shares for restricted stock		-			-			-			30,000			-		-			-		-		-		-			-			-
Balance, September 30, 2021	$	-			8,000,000		$	21,854			30,000		$	-		2,000,000		$	-		-	$	-	$	4,629		$	(51,102	)	$	(24,619	)
																																	Shares			Amount			Shares			Amount		Shares			Amount		Shares			Amount		Shares			in-Capital			Deficit			Total
Three Months Ended September 30, 2022
Balance, June 30, 2022	$	-			8,000,000		$	21,854			1,545,154		$	-		2,000,000		$	-		-	$	-	$	12,026		$	(87,882	)	$	(54,002	)		800,000		$	21,854			154,516		$	-		200,000		$	-		-		$	-		-		$	12,026		$	(87,882	)	$	(54,002	)
Activity prior to the business combination:
Net loss		-			-			-			-			-		-			-		-		-		-			(9,531	)		(9,531	)
Net loss to common stockholders																																		-			-			-			-		-			-		-			-		-			-			(9,531	)		(9,531	)
Equity-based compensation		-			-			-			-			-		-			-		-		-		211			-			211			-			-			-			-		-			-		-			-		-			211			-			211
Effects of the business combination:																															-
Conversion of Series A Preferred Stock		-			(8,000,000	)		(21,854	)		8,000,000			-		-			-		-		-		21,854			-			-			(800,000	)		(21,854	)		800,000			-		-			-		-			-		-			21,854			-			-
Conversion of Bridge Loans		-			-			-			15,172,729			-		-			-		-		-		88,975			-			88,975			-			-			1,517,273			-		-			-		-			-		-			88,975			-			88,975
Conversion of Class B Common Stock		-			-			-			2,000,000			-		(2,000,000	)		-		-		-		-			-			-			-			-			200,000			-		(200,000	)		-		-			-		-			-			-			-
Conversion of existing Class A Common Stock		-			-			-			(26,717,883	)		-		-			-		15,518,705		1		-			-			1			-			-			(2,671,789	)		-		-			-		1,551,871			1		-			-			-			1
Reverse recapitalization		-			-			-			-			-		-			-		8,143,649		1		19,677			-			19,678			-			-			-			-		-			-		814,365			1		-			19,677			-			19,678
Activity after the business combination:		-			-			-			-			-		-			-		-		-		-			-
Net loss		-			-			-			-			-		-			-		-		-		-			(31,495	)		(31,495	)
Net loss to common stockholders																																		-			-			-			-		-			-		-			-		-			-			(31,495	)		(31,495	)
Equity-based compensation		-			-			-			-			-		-			-		9,175,000		1		329			-			330			-			-			-			-		-			-		917,500			1		-			329			-			330
Cantor Commitement Fee		-			-			-			-			-		-			-		190,476		-		1,600			-			1,600
Cantor Commitment Fee																																		-			-			-			-		-			-		19,048			-		-			1,600			-			1,600
Balance, September 30, 2022	$	-			-		$	-			-		$	-		-		$	-		33,027,830	$	3	$	144,672		$	(128,908	)	$	15,767			-		$	-			-		$	-		-		$	-		3,302,784		$	3		-		$	144,672		$	(128,908	)	$	15,767

Nine Months Ended September 30, 2022
Balance, December 31, 2021	$	-			8,000,000		$	21,854			30,208		$	-		2,000,000		$	-		-	$	-	$	4,902		$	(51,976	)	$	(25,220	)		800,000		$	21,854			3,021		$	-		200,000		$	-		-		$	-		-		$	4,902		$	(51,976	)	$	(25,220	)
Activity prior to the business combination:
Net loss		-			-			-			-			-		-			-		-		-		-			(45,437	)		(45,437	)
Net loss to common stockholders																																		-			-			-			-		-			-		-			-		-			-			(45,437	)		(45,437	)
Lease contributions		-			-			-			-			-		-			-		-		-		225			-			225			-			-			-			-		-			-		-			-		-			225			-			225
Equity-based compensation		-			-			-			-			-		-			-		-		-		717			-			717			-			-			-			-		-			-		-			-		-			717			-			717
Warrant repurchase		-			-			-			-			-		-			-		-		-		(507	)		-			(507	)		-			-			-			-		-			-		-			-		-			(507	)		-			(507	)
Issuance of shares for exercised stock options		-			-			-			14,946			-		-			-		-		-		-			-			-			-			-			1,495			-		-			-		-			-		-			-			-			-
Issuance of shares for consulting agreement		-			-			-			1,500,000			-		-			-		-		-		6,900			-			6,900			-			-			150,000			-		-			-		-			-		-			211			-			211
Effects of the business combination:
Conversion of Series A Preferred Stock		-			(8,000,000	)		(21,854	)		8,000,000			-		-			-		-		-		21,854			-			-			(800,000	)		(21,854	)		800,000			-		-			-		-			-		-			21,854			-			-
Conversion of Bridge Loans		-			-			-			15,172,729			-		-			-		-		-		88,975			-			88,975			-			-			1,517,273			-		-			-		-			-		-			88,975			-			88,975
Conversion of Class B Common Stock		-			-			-			2,000,000			-		(2,000,000	)		-		-		-		-			-			-			-			-			200,000			-		(200,000	)		-		-			-		-			-			-			-
Conversion of existing Class A Common Stock		-			-			-			(26,717,883	)		-		-			-		15,518,705		1		-			-			1			-			-			(2,671,789	)		-		-			-		1,551,871			1		-			-			-			1
Reverse recapitalization		-			-			-			-			-		-			-		8,143,649		1		19,677			-			19,678			-			-			-			-		-			-		814,365			1		-			19,677			-			19,678
Activity after the business combination:
Net loss		-			-			-			-			-		-			-		-		-		-			(31,495	)		(31,495	)
Net loss to common stockholders																																		-			-			-			-		-			-		-			-		-			-			(31,495	)		(31,495
Equity-based compensation		-			-			-			-			-		-			-		9,175,000		1		329			-			330			-			-			-			-		-			-		917,500			1		-			329			-			330
Cantor Commitement Fee		-			-			-			-			-		-			-		190,476		-		1,600			-			1,600
Cantor Commitment Fee																																		-			-			-			-		-			-		19,048			-		-			1,600			-			1,600
Balance, September 30, 2022	$	-			-		$	-			-		$	-		-		$	-		33,027,830	$	3	$	144,672		$	(128,908	)	$	15,767			-		$	-			-		$	-		-		$	-		3,302,784		$	3		-		$	144,672		$	(128,908	)	$	15,767

Three Months Ended September 30, 2023
Balance, June 30, 2023																																		-		$	-			-		$	-		-			-		4,648,096		$	5		-		$	161,594		$	(168,629	)	$	(7,030	)
Net loss to common stockholders																																		-			-			-			-		-			-		-			-		-			-			(3,660	)		(3,660	)
Stock-based compensation																																		-			-			-			-		-			-		(329,032	)		-		-			(1,447	)		-			(1,447	)
Private placements net of issuance costs																																		-			-			-			-		-			-		929,376			1		-			443			-			444
Issuance of shares to Joseph Gunner																																																		276,875								221						221
Issuance of shares to MSK																																																		292,867								234			-			234
Issuance of shares to employees																																		-			-			-			-		-			-		98,670			-		-			135			-			135

Balance, September 30, 2023																																		-		$	-			-		$	-		-		$	-		5,916,852		$	6		-		$	161,180		$	(172,289	)	$	(11,103	)

Nine Months Ended September 30, 2023
Balance, December 31, 2022																																		-		$	-			-		$	-		-		$	-		2,966,967		$	3		(214,077	)		153,936			(147,231	)		6,708
Net loss to common stockholders																																		-			-			-			-		-			-		-			-		-			-			(25,058	)		(25,058	)
Stock-based compensation																																		-			-			-			-		-			-		(365,132	)		-		-			226			-			226
2022 Debenture Release																																		-			-			-			-		-			-		703,500			1		-			2,180			-			2,181
PIK Note Amendment																																		-			-			-			-		-			-		432,188			-		-			1,339			-			1,339
Exchange Offer																																		-			-			-			-		-			-		795,618			1		-			2,466			-			2,467
Private placements net of issuance costs																																																		929,376			1					443						443
Issuance of shares to employees																																																		98,670								135						135
Issuance of shares to MSK																																																		292,867								234						234
Issuance of shares to Joseph Gunner																																																		276,875								221						221
Treasury stock																																		-			-			-			-		-			-		(214,077	)		-		214,077			-			-			-
Balance, September 30, 2023																																		-		$	-			-		$	-		-		$	-		5,916,852		$	5		-		$	161,180		$	(172,289	)	$	(11,103	)

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

FOXO TECHNOLOGIES INC. and subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

(Unaudited)

	Nine Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2023			2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(76,932	)	$	(37,614	)	$	(22,592	)	$	(76,932	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		159			71
Depreciation and amortization								1,251			159
Loss from PIK Note Amendment and 2022 Debenture Release								3,521			-
Equity-based compensation		1,002			8			361			1,002
Cantor Commitment Fee		1,600			-			-			1,600
Amortization of consulting fees		2,954			-
Amortization of consulting fees paid in common stock								2,221			2,954
Impairment of intangible assets and cloud computing arrangements								2,633			-
Change in fair value of convertible debentures		28,180			24,890			-			28,180
Change in fair value of forward purchase agreement collateral derivative		27,378			-			-			27,378
Change in fair value of warrants		(1,349	)		-			(244	)		(1,349	)
Change in fair value of forward purchase agreement put derivative		1,284			-			-			1,284
Conversion of accrued interest		593			-			-			593
PIK interest								419			-
Amortization of debt issuance costs								448			-
Contributions in the form of rent payments		225			410			-			225
Amortization of right-of-use assets		20			-
Accretion of operating lease liabilities		(20	)		-
Recognition of prepaid offering costs upon election of fair value option		107			-			-			107
Accretion of interest earned on investment in convertible promissory note		-			(26	)
Other		-			13			100			-
Changes in operating assets and liabilities:
Supplies		(1,762	)		(296	)		182			(1,762	)
Prepaid expenses, consulting fees, and other current assets		(1,002	)		55
Prepaid expenses and consulting fees								1,835			(1,002	)
Other current assets								3			-
Cloud computing arrangements		(1,941	)		(1,701	)		-			(1,941	)
Reinsurance recoverables		709			88			18,573			709
Accounts payable		(489	)		2,247			1,806			(489	)
Accrued and other liabilities		761			197			1,891			761
Policy reserves		(709	)		(88	)		(18,573	)		(709	)
Net cash used in operating activities		(19,232	)		(11,746	)		(6,165	)		(19,232	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(108	)		(73	)		-			(108	)
Asset acquisition, net of cash acquired		-			(63	)
Development of internal use software		(1,622	)		(9	)		-			(1,622	)
Acquisition of convertible promissory note		-			(50	)
Net cash used in investing activities		(1,730	)		(195	)		-			(1,730	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of related party convertible debentures		-			3,250
Proceeds from issuance of convertible debentures		28,000			7,250			-			28,000
Warrant repurchase		(507	)		-			-			(507	)
Senior PIK Notes proceeds		3,458			-			-			3,458
Reverse recapitalization proceeds		23,226			-			-			23,226
Forward purchase agreement escrow		(29,135	)		-			-			(29,135	)
Forward purchase agreement proceeds		484			-			-			484
Forward purchase agreement collateral release to Meteora		733			-			-			733
Private placements								744			-
Related party promissory note								247			(1,160	)
Deferred offering costs		(539	)		-			(299	)		(539	)
Related party promissory note		(1,160	)		-
Proceeds received from stockholder subscription receivable		-			3,750
Net cash provided by financing activities		24,560			14,250			692			24,560
Net increase in cash and cash equivalents		3,598			2,309
Net change in cash and cash equivalents								(5,473	)		3,598
Cash and cash equivalents at beginning of period		6,856			8,123			5,515			6,856
Cash and cash equivalents at end of period	$	10,454		$	10,432		$	42		$	10,454

NONCASH INVESTING AND FINANCING ACTIVITIES:
Conversion of phantom equity to stock options	$	-		$	54
2022 Debenture Release							$	2,181		$	-
PIK Note Amendment							$	1,339		$	-
Exchange Offer							$	2,466		$	-
Conversion of debt	$	88,382		$	-		$	-		$	88,382
Conversion of preferred stock	$	21,854		$	-		$	-		$	21,854
Accrued internal use software	$	239		$	-		$	-		$	239

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

Note 1 DESCRIPTION OF BUSINESS

FOXO Technologies Inc. (“FOXO” or the “Company”), ~~f/k/a~~formerly known as Delwinds Insurance Acquisition Corp. (“Delwinds”), a Delaware corporation, was originally formed in April 2020 as a publicly traded special purpose company for the purpose of effecting a merger, capital stock exchange, asset acquisition, reorganization, or similar business combination involving one or more businesses. FOXO is a leader in commercializing epigenetic biomarker technology to support groundbreaking scientific research and disruptive next-generation business initiatives. The Company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness and aging. ~~The~~On October 29^th, 2023 the Company ~~has been building~~entered into a ~~life insurance business~~Letter Agreement with KR8 AI Inc. to ~~support the~~develop a Direct to Consumer app (iOS and Android) combining its AI Machine Learning technology to provide a commercial ~~applications~~application of ~~its~~Foxo’s epigenetic biomarker ~~underwriting~~ technology ~~and~~as a subscription consumer engagement ~~platform service business. On August 20, 2021,~~platform. The Letter Agreement limits the distribution of any such apps to consumers in North America. The Letter Agreement provides that KR8 will grant the Company ~~completed its acquisition~~a non-provisional exclusive License with a perpetual term upon the parties’ signing of ~~Memorial Insurance Company of America (“MICOA”) and renamed it FOXO Life Insurance Company.~~a definitive license agreement.

The Company manages and reports results of operations for ~~two reportable business segments: FOXO Life, the Company’s life insurance business operations, and FOXO Labs,~~ the Company’s epigenetic biomarker technology business operations.

The Business Combination

On February 24, 2022, Delwinds entered into a definitive Agreement and Plan of Merger, dated as of February 24, 2022, as amended on April 26, 2022, July 6, 2022 and August 12, 2022 (the “Merger Agreement”), with FOXO Technologies Inc., now known as FOXO Technologies Operating Company (“FOXO Technologies Operating Company” or “Legacy FOXO”), DWIN Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Delwinds (“Merger Sub”), and DIAC Sponsor LLC (the “Sponsor”), in its capacity as the representative of the stockholders of Delwinds from and after the closing (the “Closing”) of the transactions contemplated by the ~~FOXO Transaction~~Merger Agreement (collectively, the ~~“Transaction” or the~~ “Business Combination”). Simultaneously with the execution of the Merger Agreement, Delwinds entered into a Common Stock Purchase Agreement (the “ELOC Agreement”) with CF Principal Investments LLC (the “Cantor Investor”), pursuant to which, assuming satisfaction of certain conditions and subject to limitations set forth in the ELOC Agreement, the Company would have the right, from time to time to sell the Cantor Investor up to $40,000 in shares of the Company’s Class A common stock (the “Class A Common Stock”) until the first day of the next month following the 36-month anniversary of when the Securities and Exchange Commission (“SEC”) has declared effective a registration statement covering the resale of such shares of Class A Common Stock or until the date on which the facility has been fully utilized, if earlier.

The Business Combination was approved by Delwinds’ stockholders on September 14, 2022 and closed on September 15, 2022 (the “Closing Date”) whereby Merger Sub merged into FOXO Technologies Operating Company, with FOXO Technologies Operating Company surviving the merger as a wholly owned subsidiary of the Company (the “Combined Company”), and with FOXO Technologies Operating Company security holders becoming security holders of the Combined Company. Immediately upon the Closing, the name of Delwinds was changed to FOXO Technologies Inc.

Following the Closing, FOXO is a holding company whose wholly-owned subsidiary, FOXO Technologies Operating Company, conducts all of the core business operations. FOXO Technologies Operating Company maintains its two wholly-owned subsidiaries, FOXO Labs Inc. and FOXO Life, LLC. FOXO Labs maintains a wholly-owned subsidiary, Scientific Testing Partners, LLC, while FOXO Life Insurance Company iswas a wholly-owned subsidiary of FOXO Life, LLC. See Note 10 for more information on FOXO Life Insurance Company. References to “FOXO” and the “Company” in these ~~unaudited~~condensed consolidated financial statements refer to FOXO Technologies Operating Company and its wholly-owned subsidiaries prior to the Closing and FOXO Technologies Inc. following the Closing.

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

In accordance with the terms of the Merger Agreement, at Closing, the Company (i) acquired 100% of the issued and outstanding FOXO Technologies Operating Company Class A common stock (the “FOXO Class A Common Stock”) in exchange for equity consideration in the form of the Company’s Class A Common Stock, (ii) acquired 100% of the issued and outstanding shares of FOXO Technologies Operating Company Class B common stock (the “FOXO Class B Common Stock”) in exchange for equity consideration in the form of the Company’s Class A Common Stock.

~~Immediately prior to the Closing, the following transactions occurred:~~

●

~~8,000,000 shares of FOXO Technologies Operating Company Series A preferred stock (the “FOXO Preferred Stock”) were exchanged for 8,000,000 shares of FOXO Class A Common Stock.~~

●

~~The 2021 Bridge Debentures (as defined in Note 5) in the principal amount, together with accrued and unpaid interest, of $24,402 were converted into 6,759,642 shares of FOXO Class A Common Stock.~~

●

The holders of the 2022 Bridge Debentures (as defined in Note 5) in the principal amount, together with accrued and unpaid interest, of $34,496 were converted into 7,810,509 shares of FOXO Class A Common Stock.

As a result of and upon the Closing, among other things, (1) all outstanding shares of FOXO Class A Common Stock (after giving effect to the conversion of the FOXO Preferred Stock, the 2021 Bridge Debentures, and 2022 Bridge Debentures into share of FOXO Class A Common Stock) and FOXO Class B Common Stock were converted into 15,518,705 shares of the Company’s Class A Common Stock, (2) all FOXO options and FOXO warrants outstanding immediately before the Closing (“Assumed Options” and “Assumed Warrants”, as applicable) were assumed and converted, subject to adjustment pursuant to the terms of the Merger Agreement, into options and warrants, respectively, of the Company, exercisable for share of the Company’s Class A Common Stock and (3) other than the Assumed Options and Assumed Warrants, all other convertible securities and other rights to purchase capital stock of FOXO Technologies Operating Company were retired and terminated, if they were not converted, exchanged or exercised for FOXO Technologies Operating Company stock immediately prior the Closing.

Note 2 ~~LIQUIDITY~~GOING CONCERN UNCERTAINTY AND MANAGEMENT’S PLAN

The Company’s history of losses requires management to critically assess its ability to continue operating as a going concern. For the three and nine months ended September 30, ~~2022,~~2023, the Company incurred a net loss of ~~$41,026~~$3,660 and ~~$76,932,~~$22,592 respectively. As of September 30, ~~2022,~~2023, the Company had an accumulated deficit of ~~$128,908.~~$172,289. Cash used in operating activities for the nine months ended September 30, ~~2022~~2023 was ~~$19,232.~~$6,165. As of September 30, ~~2022,~~2023, the Company had ~~$5,453~~$42 of available cash and cash ~~equivalents, excluding amounts required to be held as statutory capital and surplus by FOXO Life Insurance Company.~~equivalents.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

The Company’s ability to continue as a going concern is dependent on generating revenue, raising additional equity or debt capital, reducing losses and improving future cash flows. The Company will continue ongoing capital raise initiatives and has demonstrated previous success in raising capital to support its operations. For instance, in the first and second quarters of 2022, the Company issued convertible debentures for $28,000 that ~~has~~ subsequently converted to equity. The Company also completed its transaction with Delwinds that was initially intended to provide up to $300,000 of capital to the Company. An equity line of credit agreement, a backstop agreement, and forward purchase agreement were also part of the Business Combination and were intended to provide capital. Ultimately, the series of transactions associated with the Business Combination did not result in any net proceeds for the Company. Additionally, we are unlikely to receive proceeds from the exercise of outstanding warrants as a result of the difference between our current trading price of the Company’s Class A Common Stock and the exercise price of the various warrants.

During the first quarter of 2023, the Company completed the sale of FOXO Life Insurance Company in order to gain access to the cash held as statutory capital and surplus at FOXO Life Insurance Company. See Note 10 for more information. The Company used the cash previously held at FOXO Life Insurance Company to fund its operation as it continues to (i) pursue additional avenues to capitalize the Company and (ii) commercialize its products to generate revenue. See Notes 5 and 7 for additional information on the Exchange Offer and PIK Note Offer to Amend that were structured to allow the Company to more easily raise capital. See Note 13 for information on the 2023 Private Placement.

On June 12, 2023, the Company received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation (“NYSE”) stating that the Company is below compliance with Section 1003(a)(i) in the NYSE American Company Guide since the Company reported stockholders’ deficit of $(30) at March 31, 2023, and losses from continuing operations and/or net losses in its two most recent fiscal years ended December 31, 2022. As required by the NYSE American Notice, on July 12, 2023, the Company submitted a compliance plan (the “Plan”) to NYSE advising of actions it has taken or will take to regain compliance with the NYSE American continued listing standards by December 12, 2024, and if NYSE accepts the Plan, the Company has an eighteen (18) month period to comply with the Plan. Should the Plan not be accepted or the Company be unable to comply with the Plan, then it may make it more difficult for the Company to raise capital.

However, the Company can provide no assurance that these actions will be successful or that additional sources of financing will be available on favorable terms, if at all. As such, until additional equity or debt capital is secured and the Company begins generating sufficient revenue, there is substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the issuance of these ~~unaudited~~condensed consolidated financial statements. In the event that the Company is unable to secure additional financing by mid-January 2024, it may be unable to fund its operations and will be required to evaluate further alternatives, which could include further curtailing or suspending its operations, selling the Company, dissolving and liquidating its assets or seeking protection under the bankruptcy laws. A determination to take any of these actions could occur at a time that is earlier than when the Company would otherwise exhaust its cash resources.

As previously disclosed, on September 20, 2022, the Company issued to certain investors 15% Senior Promissory Notes (the “PIK Notes”) in an aggregate principal amount of $3,457,500, each with a maturity date of April 1, 2024 (the “Maturity Date”). Pursuant to the terms of the PIK Notes, commencing on November 1, 2023, and on each one month anniversary thereof, the Company is required to pay the holders of the PIK Notes an equal amount until their outstanding principal balance has been paid in full on the Maturity Date, or, if earlier, upon acceleration or prepayment of the PIK Notes in accordance with their terms. The Company failed to make the payments due on November 1, 2023, which constitutes an event of default under the PIK Notes.

As a result of this event of default, the interest rate of the PIK Notes increased from 15% per annum (compounded quarterly on each December 20, March 20, June 20 and September 20) to 22% per annum (compounded annually and computed on the basis of a 360-day year). In addition, the holders of the PIK Notes may, among other remedies, accelerate the Maturity Date and declare all indebtedness under the PIK Notes due and payable at 130% of the outstanding principal balance.

In October 2023, the Company announced that the Company is in discussions with the holders of the PIK Notes with respect to certain amendments to the PIK Notes to cure the event of default; however, there has been no agreement that the PIK Note holders will agree to amend the PIK Notes.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

Note 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION ~~AND PRINCIPLES OF CONSOLIDATION~~

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial ~~reporting. Accordingly,~~reporting, and thus the accompanying unaudited condensed consolidated financial statements do not include all information and footnotes necessary for a complete presentation of financial position, results of operations or cash flows. The unaudited condensed consolidated financial statements should be read in conjunction with the ~~Company’s~~ audited consolidated financial statements as of and for the year ended December 31, ~~2021~~2022 and the notes thereto. The consolidated balance sheet data as of December 31, ~~2021~~2022 was derived from the audited consolidated financial statements as of that date but does not include all disclosures required by U.S. GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments of a normal or recurring nature, which are necessary for a fair presentation of financial position, operating results and cash flows for the periods presented. Operating results for the three and nine months ended September 30, ~~2022~~2023 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2022.~~2023.

Pursuant to the Business Combination, the acquisition of FOXO Technologies Operating Company by Delwinds was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method, Delwinds was treated as the “acquired” company for financial reporting purposes. For accounting purposes the Reverse Recapitalization was treated as the equivalent of FOXO Technologies Operating Company issuing equity securities for the net assets of Delwinds, accompanied by a recapitalization. The net assets of Delwinds are stated at historical cost, with no goodwill or other intangible asset being recorded. The condensed assets, liabilities and results of operations prior the Reverse Recapitalization are those of FOXO Technologies Operating Company.

The unaudited condensed consolidated financial statements include the accounts of FOXO and its wholly-owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation.

~~EMERGING GROWTH COMPANY~~

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, ~~and~~ as modified by the Jumpstart Our Business Startups Act of 2012, and it thus may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, and reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult because of the potential differences in accounting standards used.companies.

~~USE OF ESTIMATES~~

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and ~~liabilities at~~liabilities. For further information regarding the ~~date~~Company’s basis of presentation and use of estimates, refer to the audited consolidated financial statements as of and for the ~~reported amounts of revenue~~year ended December 31, 2022. The policies and ~~expenses during~~estimates described in that report are used for preparing the reported period. Management evaluates these estimates and judgments on an ongoing basis and bases its estimates on experience, current and expected future conditions, third-party evaluations and various other assumptions that management believes are reasonable under the circumstances. It is reasonably possible that actual experience could differ from the estimates and assumptions utilized. All revisions to accounting estimates are recognized in the period in which the estimates are revised. A description of each critical estimate is incorporated within the discussion of the related accounting policies which follow.

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~Company’s quarterly unaudited condensed consolidated financial statements.

~~CASH AND CASH EQUIVALENTS~~

The company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value. At times, cash account balances may exceed insured limits. The Company has not experienced any losses related to such accounts and believes it is not exposed to any significant credit risk on its cash and cash equivalents.

~~PROPERTY AND EQUIPMENT, NET~~

Property and equipment is recorded at cost. The cost of additions and betterments are capitalized and expenditures for repairs and maintenance are expensed in the period incurred. When property and equipment is sold or retired, the related cost and accumulated depreciation are removed from the consolidated balance sheets and any gain or loss is included in the consolidated statements of operations as incurred. When property and equipment is abandoned before the end of its previously estimated useful life the depreciable life is revised to the shorter remaining useful life. Property and equipment is presented net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which are generally three years for computers and office equipment and seven years for furniture and fixtures. Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the lease.

~~IMPAIRMENT OF LONG-LIVED ASSETS~~

The Company reviews its long-lived assets, including property and equipment and right-of-use assets, to determine potential impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be fully recoverable. Recoverability is measured by comparing the carrying amount of the asset group with the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, an impairment loss would be measured by comparing the amount by which the carrying value exceeds the fair value of the long-lived assets. Management determined that there was no impairment of long-lived assets as of September 30, 2022 and December 31, 2021.

~~CAPITALIZED IMPLEMENTATION COSTS~~

The Company capitalizes certain development costs associated with internal use software and cloud computing arrangements incurred during the application development stage. The Company expenses costs associated with preliminary project phase activities, training, maintenance, and any post-implementation costs as incurred. Capitalized costs related to projects to develop internal use software are included within intangible assets on the consolidated balance sheets, while capitalized costs related to cloud computing arrangements are included within cloud computing arrangements on the consolidated balance sheets. Capitalized costs will be amortized on a straight-line basis once application development is complete based on the estimated life of the asset or the expected term of the contract, as applicable. Application development was ongoing as of September 30, 2022 for all such projects and thus no amortization has been recorded to date.

~~FAIR VALUE OF FINANCIAL INSTRUMENTS~~

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

~~Level 1 – defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets.~~

Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active.

Level 3 – defined as unobservable inputs in which little or no market data exits, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

In some circumstances, the inputs used to measure the fair value might be categorized within different levels of the fair value hierarchy. In these instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

~~DERIVATIVE INSTRUMENTS~~

The Company does not use derivative instruments to hedge exposure to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments, including stock purchase warrants and forward share purchase obligations, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480, ~~“Distinguishing Liabilities from Equity,”~~ ~~and ASC 815-15,~~ ~~“Derivatives and Hedging – Embedded Derivatives.”~~ ~~The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period.~~

~~DEBT~~

The Company issued convertible debentures to related and nonrelated parties, which included original issue discounts, conversion features and detachable warrants, as further discussed in Note 5 to these consolidated financial statements. The detachable warrants represent freestanding, separable equity-linked financial instruments recorded at fair value. The fair value of the detachable warrants is calculated using a Black-Scholes valuation model. The Company elected the fair value option for the convertible debt, which requires recognition at fair value upon issuance and on each balance sheet date thereafter. Changes in the estimated fair value are recognized as non-cash change in fair value of convertible debentures in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the issuance of the convertible debt were expensed and not deferred.

~~REVENUE RECOGNITION~~

The Company’s revenues consist of royalties based on the Company’s epigenetic biomarker research, agents’ commissions earned on the sale, servicing and placement of life insurance policies, and epigenetic testing services sold primarily to research organizations. Revenues are recognized when control of the promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. To recognize revenues, the Company applies the following five step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenues when a performance obligation is satisfied. The Company accounts for a contract when it has approval and commitment from all parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company applies judgment in determining the customer’s ability and intention to pay based on a variety of factors including the customer’s historical payment experience. As of September 30, 2022 and December 31, 2021, the Company had no contract assets or liabilities related to revenue arrangements or transactions.

~~FOXO Labs — Epigenetic biomarker royalties~~

The Company has granted a license to Illumina, Inc. (“Illumina”) for the exclusive right to manufacture and sell infinium mouse methylation arrays using the Company’s research on epigenetic biomarkers in exchange for a royalty on global sales. Illumina provides reporting to the Company so that revenue can be properly recognized as the license is used. Revenue is recorded net as the Company is not considered the principal in the transaction. Epigenetic biomarker royalties are recorded with the FOXO Labs reportable segment. During the third quarter of 2022, the royalty was reduced from 5% to 1.25% in exchange for eliminating a purchase commitment for mouse methylation arrays as further discussed in Note 13.

~~FOXO LIFE — Life insurance commissions~~

FOXO Life, LLC, currently an insurance agency, receives insurance commission revenue from the distribution and sale of life insurance policies based on a percentage of the premiums paid by its customers. These commission revenues are substantially recognized at a point in time on the effective date of the associated policies when control of the policy transfers to the client, as well as deferring certain revenues to reflect delivery of services over the contract period and are reported within the FOXO Life reportable segment. Commissions are fixed at the contract effective date and generally are based on a percentage of premiums for insurance coverage. Commission rates vary depending on a variety of factors, including the type of risk being placed, the particular underwriting enterprise’s demand, expected loss experience of the particular risk of coverage, and historical benchmarks surrounding the level of effort necessary for the Company to place and service the insurance contract.

The Company recognizes approximately 80% of commissions earned from the initial life insurance placement on the effective date of the underlying insurance contract. The amount of revenue recognized is based on costs to provide services up and through that effective date, including an appropriate estimate of profit margin on a portfolio basis (a practical expedient as defined in ASC 606, ~~Revenue from Contracts with Customers~~). Based on the proportion of additional services provided in each period after the effective date of the insurance contract, including an appropriate estimate of profit margin, the Company recognizes approximately 15% of commission and fee revenues in the first three months, and the remaining 5% thereafter. These periods may be different than the underlying premium payment patterns of the insurance contracts, but the vast majority of services are fully provided within one year of the insurance contract effective date.

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

~~FOXO Labs — Epigenetic biomarker services~~

FOXO Labs receives epigenetic biomarker services revenue from the performance of lab services. The Company’s performance obligation is satisfied when the Company completes the epigenetic biomarker data analysis. At the completion of the biomarker testing, results are reviewed and released to the customer. The Company subsequently bills the organization for the epigenetic biomarker data based on the transaction price, which reflects the amount the Company has rights to under present contracts. Revenue is recognized and reported within the FOXO Labs reportable segment over the life of the contract as work is performed, as FOXO Labs has an enforceable right to payment as the performance is being completed. The Company elected the practical expedient to expense contract costs as incurred related to services provided because the contract term is less than one year.

~~EQUITY-BASED COMPENSATION~~

The Company measures all equity-based payments, including options and restricted stock to employees, service providers and nonemployee directors, using a fair-value based method. The cost of services received from employees and nonemployee directors in exchange for awards of equity instruments is recognized in the consolidated statements of operations based on the estimated fair value of those awards on the grant date or reporting date, if required to be remeasured, and amortized on a straight-line basis over the requisite service period. The Black-Scholes valuation model requires the input of assumptions, including the exercise price, volatility, expected term, discount rate, and the fair value of the underlying stock on the date of grant. These inputs are provided at the grant date for an equity classified award and each measurement date for a liability classified award. See Note 8 for additional disclosures regarding the equity-based compensation program.

~~RESEARCH AND DEVELOPMENT COSTS~~

Research and development costs are expensed as incurred. Research and development expenses consist primarily of personnel costs and related benefits, as well as costs for outside consultants and professional services.

~~INCOME TAXES~~

Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company is required to analyze its filing positions open to review and believes all significant positions have a “more-likely-than-not” likelihood of being upheld based on their technical merit and accordingly the Company has not identified any unrecognized tax benefits.

~~NET LOSS PER SHARE~~

Net loss per share of common stock is calculated by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The Company follows the provisions of ASC Topic 260, ~~Earnings Per Share~~ for determining whether outstanding shares that are contingently returnable are included for purposes of calculating net loss per share and determining whether instruments granted in equity-based compensation arrangements are participating securities for purposes of calculating net loss per share. See Note 10, ~~Net Loss Per Share~~.

~~ASSET ACQUISITIONS~~

~~The Company follows the guidance in ASC 805,~~ ~~Business Combinations~~ for determining the appropriate accounting treatment for asset acquisitions. When an acquisition does not meet the definition of a business combination because either: (i) substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, or group of similar identified assets, or (ii) the acquired entity does not have an input and a substantive process that together significantly contribute to the ability to create outputs, the company accounts for the acquisition as an asset acquisition and goodwill is not recognized. The cost of the acquisition includes the fair value of consideration transferred and direct transaction costs attributable to the acquisition. Any excess cost over the fair value of the net assets acquired is allocated to the assets acquired based on their relative fair value; however, no excess acquisition cost is allocated to non-qualifying assets including financial assets or indefinite-lived intangible assets subject to fair value impairment testing.

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

~~REINSURANCE~~

The Company is subject to a 100% coinsurance agreement with the seller of MICOA, Security National Life Insurance Company. The amounts reported in the consolidated balance sheets as reinsurance recoverables include amounts billed to reinsurers on losses paid as well as estimates of amounts expected to be recovered from reinsurers on insurance liabilities that have not yet been paid. Reinsurance recoverables on unpaid losses are estimated based upon assumptions consistent with those used in establishing the liabilities related to the underlying reinsured contracts. Insurance liabilities are reported gross of reinsurance recoverables. Management believes reinsurance recoverables are appropriately established. Reinsurance premiums are reflected in income in a manner consistent with the recognition of premiums on the reinsured contracts. Reinsurance does not extinguish the Company’s primary liability under the policies written. The Company regularly evaluates the financial condition of the reinsurer and establishes allowances for uncollectible reinsurance recoverables as appropriate.

Revenues on traditional life insurance products subject to this reinsurance agreement consist of direct premiums reported as earned when due. Premium income includes premiums on reinsured policies and is reduced by premiums ceded. Expenses under the reinsurance agreement are also reduced by the amount ceded.

~~POLICY RESERVES~~

The Company establishes liabilities for amounts payable under insurance policies, including traditional life insurance and annuities. Generally, amounts are payable over an extended period. Liabilities for future policy benefits of traditional life insurance have been computed by using a net level premium method based upon estimates at the time of issue for investment yields, mortality and withdrawals. These estimates include provisions for experience less favorable than initially expected. Mortality assumptions are based on industry experience expressed as a percentage of standard mortality tables. Annuity liabilities are primarily associated with deferred annuity contracts. The deferred annuity contracts credit interest based on a fixed rate. Liabilities for deferred annuities are included without reduction for potential surrender charges. The liability is equal to accumulated deposits, plus interest credited, less policyholder withdrawals. Reserving assumptions for interest rates, mortality and expense are “locked in” upon the acquisition date for traditional life insurance contracts; significant changes in experience or assumptions may require the Company to provide for extended future losses by establishing premium deficiency reserves. Premium deficiency reserves are determined based on best estimate assumptions that exist at the time the premium deficiency reserve is established and do not include a provision for adverse deviation.

~~RECENTLY ISSUED ACCOUNTING STANDARDS~~

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 removed certain exceptions to the general principles in ASC 740 and clarified and amended existing guidance to improve consistent application. This amended guidance was effective for public entities for interim and annual periods beginning after December 15, 2021. The Company adopted ASU 2019-12 effective January 1, 2022 and it did not have a material impact on the Company’s consolidated financial statements.

Other pronouncements issued by the FASB with future effective dates are either not applicable or are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Note 4 INTANGIBLE ASSETS AND CLOUD COMPUTING ARRANGEMENTS

The components of intangible assets and cloud computing arrangements as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022 were as follows:

	September 30, 2022			December 31, 2021		September 30, 2023			December 31, 2022
Insurance license	$	63		$	63
Longevity pipeline		512			75
Methylation pipeline						$	592		$	592
Underwriting API		839			53		840			840
Longevity API		657	��		-		717			717
Less: accumulated amortization and impairment							(1,721	)		(106	)
Intangible assets	$	2,071		$	191	$	428		$	2,043

	September 30, 2023			December 31, 2022
Digital insurance platform	$	2,966		$	2,966
Less: accumulated amortization and impairment		(2,966	)		(741	)
Cloud computing arrangements	$	-		$	2,225

Amortization of the Company’s intangible assets and cloud computing arrangements is recorded on a straight-line basis within selling, general and administrative expenses. The Company recognized amortization expense of $49 and $1,208 for the three and nine months ended September 30, 2023 and did not have any amortization expense for the three and nine months ended September 30, 2022.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

~~The acquisition~~In April of ~~MICOA was accounted~~2023 and as part of the Company’s planning, the Company finalized its objectives and key results (“OKRs”) for ~~as an asset acquisition~~the second quarter of 2023. As part of the OKR process the Company’s goals to support the digital insurance platform indicated that the manner in which the digital insurance platform is used and ~~an indefinite-lived~~corresponding cash flows would no longer support the asset. Accordingly, the Company recognized a $1,425 impairment loss in April of 2023 representing the remaining unamortized balance of the digital insurance ~~license intangible asset was recognized for $63. As this intangible asset has been deemed to have an indefinite life,~~platform at the ~~asset is not subject to amortization, but is assessed for impairment annually, unless conditions arise that necessitate more frequent evaluation.~~date of impairment.

~~During the year ended December 31, 2021,~~In June of 2023, the Company ~~began developing internal use software related to~~determined that both the ~~development~~underwriting API and longevity API were fully impaired as it no longer forecasted positive cash flows from the longevity report or underwriting report. For the longevity report, the Company sells the product at cost. For the underwriting report, the Company no longer expects sales during the amortization period. Accordingly, the Company has determined the assets are not recoverable and the cash flows no longer support the assets. The Company recognized impairment charges of a$630 and $578 for the underwriting API and longevity ~~methylation pipeline~~API, respectively. The Company recognized an impairment loss of $0 and $2,633 for ~~epigenetic data~~the three and ~~underwriting application programming interface (“API”). During the~~ nine months ended September 30, 2022, the Company began developing a longevity API to show the results derived from the longevity pipeline. The Company has capitalized costs incurred during the application development stage and has determined that once completed, these intangible assets will have a finite life. Application development on these projects is ongoing as of September 30, 2022. Amortization will be recorded on a straight-line basis when the assets are ready for their intended use.

~~The components of cloud computing arrangements as of September 30, 2022 and December 31, 2021 were as follows:~~

September 30,
2022 December 31,
2021
Digital insurance platform $ 2,966 $ 1,980
Health study tool 1,743 765
Cloud computing arrangements $ 4,709 $ 2,745

The Company entered into a cloud computing arrangement to develop a digital insurance platform and health study tool. Costs related to the application development phase are included in cloud computing arrangements. As of September 30, 2022, the application development phase remains ongoing for the digital insurance platform and health study tool. Amortization will be recorded on a straight-line basis over the expected term of the contract when the assets are ready for their intended use.

The Company’s internal use software and cloud computing arrangements, including the longevity pipeline, underwriting API, longevity API, digital insurance platform and health study tool, include amounts capitalized for interest.2023, respectively.

Note 5 DEBT

~~15% Senior PIK Notes~~

On September 20, 2022, the Company entered into separate Securities Purchase Agreements with accredited investors pursuant to which the Company issued its 15% Senior ~~PIK~~Promissory Notes (the “Senior PIK Notes”) in the aggregate principal amount of $3,458. The Company received net proceeds of $2,918, after deducting fees and expenses of $540.

The Senior PIK Notes bear interest at 15% per annum, paid in arrears quarterly by payment in kind through ~~increasing~~ the ~~principal amount.~~issuance of additional Senior PIK Notes (“PIK Interest”). The Senior PIK Notes mature on April 1, 2024 (the “Maturity Date”). Commencing on November 1, 2023, the Company is required to pay the holders of the Senior PIK Notes and on each one month anniversary thereof an equal amount until the outstanding principal balance has been paid in full on the Maturity Date. In addition, the Company has agreed that any proceeds from the sale of shares of Class A Common Stock under the ELOC Agreement will be used only for the amortization of the Senior PIK Notes until paid in full. If the Senior PIK Notes are prepaid in the first year, the Company is required to pay the holders ~~in addition to~~ the ~~original~~outstanding principal ~~amount the interest that would have been payable through the first year.~~balance, excluding any increases as a result of PIK Interest, multiplied by 1.15.

The Company ~~has~~had agreed to nonot obtain additional equity or debt financing, without the consent of a majority of the holders of the Senior PIK Notes, other than ~~to be utilized for amortization of~~if a financing pays amounts owed on the Senior PIK ~~Notes.~~Notes, with the exception of certain exempt issuances. The Company shall not incur other indebtedness, except for certain exempt indebtedness, until such time the Senior PIK Notes are repaid in ~~full,~~full; however, the Senior PIK Notes are unsecured.

PIK Note Amendment

On May 26, 2023, the Company consummated two issuer tender offers: (i) the Exchange Offer (as described below in Note 7) and (ii) the Offer to Amend 15% Senior Promissory Notes and Consent Solicitation, commenced on April 27, 2023 (the “PIK Note Offer to Amend”), pursuant to which the Company offered all holders of Senior PIK Notes 0.125 shares of Class A Common Stock for every $1.00 of the Original Principal Amount (as defined in the Senior PIK Notes) of such holder’s Senior PIK Notes, in exchange for the consent by such holder of Senior PIK Notes to amendments to the Senior Promissory Note Purchase Agreement, dated September 20, 2022, between the Company and each purchaser of Senior PIK Notes (the “PIK Note Purchase Agreement”).

Pursuant to the PIK Note Offer to Amend, the Company solicited approval from holders of Senior PIK Notes to amend the PIK Note Purchase Agreement to permit the following issuances by the Company of Class A Common Stock and Common Stock Equivalents (as defined in the PIK Note Purchase Agreement), without prepaying the PIK Notes: (i) the issuance of shares of Class A Common Stock in connection with the PIK Offer Note Offer to Amend, (ii) the issuance of shares of Class A Common Stock in connection with the Exchange Offer (as defined in Note 7), (iii) the issuance of shares of Class A Common Stock or Common Stock Equivalents (as defined in the PIK Note Purchase Agreement) in connection with the 2022 Bridge Debenture Release (as defined in Note 7), (iv) the issuance of shares of Class A Common Stock or Common Stock Equivalents (as defined in the PIK Note Purchase Agreement) in (a) a private placement of the Company’s equity, equity-linked or debt securities resulting in gross proceeds to the Company no greater than $5 million (a “Private Placement”) and/or (b) a registered offering of the Company’s equity, equity-linked or debt securities resulting in gross proceeds to the Company no greater than $20 million (a “Public Financing”); provided that (A) the proceeds of a Private Placement resulting in gross proceeds to the Company of at least $2 million are used by the Company to prepay not less than 25% of the Outstanding Principal Balance (as defined in the Senior PIK Notes) as of the date of prepayment on a pro rata basis upon the closing of such Private Placement, and (B) the proceeds of a Public Financing resulting in gross proceeds to the Company of at least $10 million are used by the Company to prepay all of the Outstanding Principal Balance as of the date of prepayment upon the closing of such Public Financing, and (v) the issuance of shares of Class A Common Stock or Common Stock Equivalents (as defined in the PIK Note Purchase Agreement) as Private Placement Additional Consideration (as defined below) (collectively, the “PIK Note Amendment”).

The Company received consents from all Senior PIK Note holders and all required approvals, including stockholder approval, and issued on a pro rata basis to the holders of the Senior PIK Notes 432,188 shares of Class A Common Stock in consideration for the PIK Note Amendment.

The Company accounted for the PIK Note Amendment as an extinguishment as the consideration of $1,339 paid to Senior PIK Note holders in the form of Class A Common Stock caused the cash flows after the PIK Note Amendment to change by more than 10%. Due to the short-term nature of the Senior PIK Notes, the Company determined the reacquisition price of debt was equal to the principal amount at the time of the amendment. The Company recognized $1,596 of expense related to the PIK Note Amendment consisting of $256 of unamortized debt issuance costs and $1,339 for the issuance of Class A Common Stock

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

~~2021 Bridge Debentures~~The Company will continue to pay PIK Interest until maturity or repayment.

~~During~~As per the first quarter of 2021, the Company entered into separate Securities Purchase Agreements with accredited investors (the “2021 Bridge Investors”), pursuant to which the Company issued its 12.5% Original Issue Discount (“OID”) Convertible Debentures for $11,812 in aggregate principal (“2021 Bridge Debentures”). The Company received net proceeds of $9,612 from the sale of the 2021 Bridge Debentures, after an OID of 12.5% and deducting fees and expenses of $888. The 2021 Bridge Debentures were executed in three tranches, with $7,883 in aggregate principal issuedCurrent Report on January 25, 2021, $3,367 in aggregate principal issued on February 23, 2021, and $562 in aggregate principal issued on March 4, 2021. Convertible debentures for $3,656 in aggregate principal that were issued on January 25, 2021 to the Company’s Chief Executive Officer, Chief Operating Officer, and to an individual who provides consulting services to the Company were presented as related party debt.

Each issuance of 2021 Bridge Debentures included detachable warrants for the right to purchase up to a total of 1,905,853 shares, after giving effect to the conversion of FOXO Class A Common Stock to the Company’s Class A Common Stock. Additional detachable warrants were issued to the underwriter of the issuance of the 2021 Bridge Debentures. The Company concluded the detachable warrants represent freestanding equity-linked financial instruments to be recorded at their fair value on each respective issuance date. The fair value of the detachable warrants was determined using a Black-Scholes valuation model. The additional underwriter warrants were subsequently assigned and surrendered to the Company in exchange for cash payments of approximately $507 during the second quarter of 2022.

The 2021 Bridge Debentures accrued interest at a rate of 12% per annum and require interest only payments on a quarterly basis. The 2021 Bridge Debentures initially had a term of twelve months, but the Company retained the right to extend the maturity date for each issuance for an additional three-month period, a right which was exercised for each issuance during the first quarter 2022. In the first quarter of 2022, the Company entered into an amendment with the 2021 Bridge Investors (the “2021 Bridge Amendment”). The 2021 Bridge Amendment was executed to provide the Company additional time to finalize the Business Combination. The 2021 Bridge Amendment amended the terms of the 2021 Bridge Debentures to, among other things: (i) permit the Company to undertake another offering of convertible debentures, (ii) allow the Company to extend the maturity dates of the 2021 Bridge Debentures an additional five months following the end of the initial three-month extension period, discussed above, and (iii) implement additional amounts owed on the outstanding balance of the 2021 Bridge Debentures under certain circumstances, the first of which related to the signing of the Merger Agreement and resulted in an increase in the outstanding balance of approximately 135%, which was followed by an additional increase of approximately 145% of the outstanding balance when the 2021 Bridge Debentures remained outstanding at the end of the initial three-month extension period.

~~2022 Bridge Debentures~~

During the first and second quarters of 2022, the Company entered into separate Securities Purchase Agreements with accredited investors (the “2022 Bridge Investors”), pursuant to which the Company issued its 10% OID Convertible Debentures for $30,800 in aggregate principal (“2022 Bridge Debentures”). The Company received net proceeds of $28,000 from the sale of the 2022 Bridge Debentures, after an OID of 10%. The 2022 Bridge Debentures were issued in three tranches, with $16,500 in aggregate principal issued on March 1, 2022, $8,250 in aggregate principal issued on March 3, 2022 and the remaining $6,050 in aggregate principal issued on April 27, 2022.

The 2022 Bridge Debentures had a term of twelve months from the initial issuance dates and accrued interest at a rate of 12% per annum, of which 12 months was guaranteed. The Company retained the right to extend the maturity date for each issuance for an additional three-month period and incur an extension amount rate of 130% of the outstanding balance. The Company also had the option to prepay the 2022 Bridge Debentures at an amount equal to 120% of the sum of the outstanding principal and unpaid interest thereon if done within 365 days of the original issue date and 130% if during the extension period.

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

In connection with the sale of the 2022 Bridge Debentures, FOXO entered into a letter agreement between FOXO and an in institutional investor (the “Bridge Investor Side Letter”) pursuant to which FOXO agreed to issue such investor in connection with the Closing, such number of shares of FOXO Class A Common Stock, to be issued immediately prior to the Closing, that would be exchangeable into 350,000 shares of Class A Common Stock.Form 8-K filed November 2, 2023, Pursuant to the terms of the ~~Bridge Investor Side Letter,~~PIK Notes, commencing on November 1, 2023, and on each one month anniversary thereof, the ~~institutional investor was issued 602,578 shares~~Company is required to pay the holders of ~~FOXO Class A Common Stock~~the PIK Notes an equal amount until their outstanding principal balance has been paid in full on the Maturity Date, or, if earlier, upon acceleration or prepayment of the PIK Notes in accordance with their terms. The Company failed to make the payments due on November 1, 2023, which ~~were then exchanged for 350,000 shares~~constitutes an event of ~~Class A Common Stock.~~default under the PIK Notes.

~~During~~As a result of this event of default, the interest rate of the PIK Notes increased from 15% per annum (compounded quarterly on each December 20, March 20, June 20 and September 20) to 22% per annum (compounded annually and computed on the basis of a 360-day year). In addition, the holders of the PIK Notes may, among other remedies, accelerate the Maturity Date and declare all indebtedness under the PIK Notes due and payable at 130% of the outstanding principal balance.

Given the Company’s current cash constraints, the Company is currently in discussions with the holders of the PIK Notes with respect to certain amendments to the PIK Notes to cure the event of default; however, there can be no assurance that the PIK Note holders will agree to amend the PIK Notes.

As of September 30, 2023, the Company has recorded $4,006 balance as current liabilities based on the monthly installments payment schedule. For the three and nine months ended September 30, 2023 the Company recognized $145 and $420, respectively of contractual interest expense on the Senior PIK Notes; and $0 and $448, respectively related to the amortization of debt issuance costs on the Senior PIK Notes. The amortization of debt issuance costs includes $256 of unamortized debt issuance costs at the time of the PIK Note Amendment. Additionally, the Company recognized $593 and $1,627 of contractual interest expense related to the 12.5% Original Issue Discount Convertible Debentures issued in 2021 by Legacy FOXO (the “2021 Bridge Debentures”) for the three and nine months ended September 30, 2022 ~~the Company recognized contractual interest expense~~ of ~~$1,627 on the 2021 Bridge Debentures, comprised of~~which $181 and $508, respectively is for related party ~~holders and $1,119 for nonrelated party~~ holders. During the three months ended September 30, 2022, the Company recognized contractual interest expense of $593 on the 2021 Bridge Debentures, comprised of $181 for related party holders and $412 for nonrelated party holders. The contractual interest expense on the 2022 Bridge Debentures was included in the fair value of the debt since the amount was known at the time of each issuance. The contractual interest on the 2022 Bridge Debentures as well as for the three months ended September 30, 2022 on the 2021 Bridge Debentures converted to shares of FOXO Class A Common Stock and subsequently exchanged for the Company’s Class A Common Stock as part of the Business Combination.

Note 6 RELATED PARTY TRANSACTIONS

Office Space

The Company subleased its office space from ~~the holder of the FOXO Preferred Stock~~an investor through May of 2022. The ~~holder of the FOXO Preferred Stock~~investor paid all lease costs, including common area maintenance and other property management fees, on the Company’s behalf. These payments were treated as additional capital contributions.

2021 Bridge Debentures

Prior to the conversion of the 2021 Bridge Debentures to shares of FOXO Technologies Operating Company Class A Common Stock and subsequent exchange for Class A Common Stock of the Company at Closing of the Business Combination, ~~there were~~certain related ~~party borrowings which are described~~parties invested in ~~more detail in Note 5.~~the 2021 Bridge Debentures.

~~Promissory Note~~

On June 6, 2022, the Company executed a promissory note, pursuant to which it loaned Delwinds an aggregate principal amount of $1,160, which represented $0.035 per share of Delwinds Class A common stock that was not redeemed in connection with the extension of the SPAC’s termination date from June 15, 2022 to September 15, 2022. The Company loaned Delwinds $387 per month in June 2022, July 2022, and August 2022 prior to Closing of the Business Combination. The outstanding balance on the promissory note eliminated upon consolidation with the Closing of the Business Combination.

Sponsor Loan

In order to finance transaction costs in connection with ~~a Business~~the business Combination, the Sponsor or an affiliate of the Sponsor loaned Delwinds funds for working capital. As of September 30, ~~2022,~~2023, $500 was remaining due to the ~~sponsor~~Sponsor and is shown as a related party payable in the consolidated balance sheet.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

Demand Promissory Note

On September 19, 2023, the Company obtained a $247 loan from Andrew J. Poole, a former director of the Company (the “Loan”), to be used to pay for directors’ and officers’ insurance through November 2023. The Company issued to Mr. Poole a demand promissory note for $247 evidencing the Loan (the “Note”). The Note does not bear interest. The Note is due on demand, and in the absence of any demand, the Note will be due one year from the issuance date. The Note may be prepaid, in whole or in part, without penalty at any time.

Consulting Agreement

In April 2022, the Company executed a consulting agreement (the “Consulting Agreement”) with an individual (the “Consultant”) considered to be a related party of the Company as a result of his investment in the 2021 Bridge Debentures. The agreement, ~~has~~which expired in April 2023, had a minimum term of twelve months, over which the Consultant is to provide services that include, but are not limited to, advisory services relating to the implementation and completion of the Business Combination. Following the execution of the agreement, as compensation for such services to be rendered as well as related expenses over the term of the contract, the Consultant was paid a cash fee of $1,425. The ~~consulting agreement~~Consulting Agreement also calls for the payment of an equity fee as compensation for such services. The Company issued ~~1,500,000~~150,000 shares of Legacy FOXO Class A Common Stock to the Consultant during the second quarter of 2022 to satisfy the equity ~~fee.~~fee that converted into 87,126 shares of Class A Common Stock. The Company has determined that all compensation costs related to the ~~consulting agreement,~~Consulting Agreement, including both cash fees and the equity fee, represent remuneration for services to be rendered evenly over the contract term. Thus, all such costs were initially recorded at fair value as prepaid consulting fees in the consolidated balance sheet and are being recognized as selling, general and administrative expenses in the condensed consolidated statement of operations on a straight-line basis over the term of the contract. For the three and nine months ended September 30, ~~2022, $2,081~~2023, $0 and ~~$3,568~~$2,676, respectively, in expenses ~~respectively,~~ were recognized related to the ~~consulting agreement.~~Consulting Agreement. For both the three and nine months ended September 30, 2022 the Company recognized $2,081 and $3,568, respectively, in expenses for the Consulting Agreement.

Contractor Agreement

In October 2021, FOXO entered into a Contractor Agreement with Dr. Murdoc Khaleghi, one of its former directors, under which Dr. Khaleghi served as FOXO’s Chief Medical Officer. The Company paid Dr. Khaleghi $0 in 2023 and $27 and $81 for the three and nine months ended September 30, 2022, respectively.

Board and Executive Departures:

In addition to Dr. Khaleghi who resigned in 2022, the following Board members resigned in 2023;

Mr. Tyler Danielson resigned as Interim Chief Executive Officer on September 14, 2023

Mr. Robert Potashnick resigned as Chief Financial Officer effective September 13, 2023

Andrew Poole resigned as director on November 21, 2023

Board Appointment:

Mark White was appointed on September 19, 2023 as Interim Chief Executive Officer and Director.

Executive Appointment:

Martin Ward was appointed on September 19, 2023 as Interim Chief Financial Officer

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

Note 7 STOCKHOLDERS’ (DEFICIT) EQUITY

~~The unaudited consolidated statements of stockholders’ equity (deficit) reflects the Reserve Recapitalization.~~ In connection with the Business Combination, the Company adopted the second amended and restated certificate of incorporation (the “Amended and Restated Company Charter”) to, among other things, ~~increased~~increase the total number of authorized shares of all capital stock, par value $0.0001 per share, to 510,000,000 shares, consisting of (i) 500,000,000 shares of Class A Common Stock and (ii) 10,000,000 shares of preferred stock.

Also in connection with the Business Combination, 632,500 shares of Class B Common Stock were converted, on a one-to-one basis, into shares of Class A Common Stock, and as of September 30, 2022, there were no ~~shares of Class B Common Stock issued or outstanding.~~

~~ELOC Agreement~~

Under the ELOC Agreement, the Company has the right to sell to the Cantor Investor up to $40,000 in shares of Class A Common Stock for a period until the first day of the month next following the 36-month anniversary of when the SEC has declared effective a registration statement covering the resale of such share of Class A Common Stock or until the date on which the facility has been fully utilized, if earlier. The purchase price of the shares of Class A Common Stock will be 97% of the volume weighted average price per share (“VWAP”) of the Class A Common Stock during the applicable purchase date on which the Company has timely delivered written notice to the Cantor Investor directing it to purchase shares of Class A Common Stock under the ELOC Agreement.

The ELOC Agreement provides for a commitment fee (the “Cantor Commitment Fee”) payable to the Cantor Investor at Closing for its irrevocable commitment to purchase shares of Class A Common Stock upon the terms and conditions of the ELOC Agreement. The Cantor Commitment fee was paid by the issuance of 190,476 shares of Class A Common Stock and is recorded in selling, general and administrative expenses in the consolidated statement of operations.

The Company has the right to terminate the ELOC Agreement at any time, at no cost or penalty, upon 10 trading days’ prior written notice. Additionally, the Cantor Investor has the right to terminate the ELOC Agreement on the seventh trading day following the Closing if the total market capitalization of the Company is less than $100 million as of such date.

Preferred Stock

The Amended and Restated Company Charter authorizes the Company to issue 10,000,000 shares of preferred stock with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, ~~2022,~~2023, there were no shares of preferred stock issued or outstanding.

Warrants

Public Warrants and Private Placement Warrants

The Company issued ~~10,062,500~~1,006,250 common stock warrants in connection with Delwinds’ initial public offering (the “IPO”) (the “Public Warrants”). Simultaneously with the closing of the IPO, Delwinds consummated the private placement of ~~316,250~~31,623 common stock warrants (the “Private Placement Warrants”).

Public Warrants may only be exercised for a whole number of shares. ~~No fractional warrants will be issued upon separation of the Units and only whole warrants will trade.~~ Each Public Warrant entitles the holder to purchase one share of Class A Common Stock at a price of ~~$11.50~~$115.00 per share, subject to adjustment. The Public Warrants ~~become~~became exercisable 30 days after the completion of a Business Combination. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

The Company is not obligated to deliver any shares of Class A Common Stock pursuant to the exercise of a warrant and has no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A Common Stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of Class A Common Stock upon exercise of a warrant unless Class A Common Stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.

The Company has agreed that as soon as practicable will file with the SEC a registration statement covering the shares of Class A Common Stock issuable upon exercise of the warrants. If the registration statement covering the shares of Class A Common Stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the foregoing, if a registration statement covering the Class A Common Stock issuable upon exercise of the warrants is not effective within a specified period following the consummation of the Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.

~~Once the warrants become exercisable, the~~ Company may redeem the Public Warrants:

●

in whole and not in part;

●

at a price of ~~$0.01~~$0.10 per warrant;

●

upon not less than 30 days’ prior written notice of redemption given after the warrants become exercisable; and

●

if, and only if, the reported last sale price of the Company’s Class A Common Stock equals or exceeds ~~$18.00~~$180.00 per share for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three business days before the Company sends the notice of redemption to the warrant holders.

If and when the warrants become redeemable by the Company, the Company may not exercise its redemption right if the issuance of shares of common stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or the Company is unable to effect such registration or qualification.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis”. The exercise price and number of shares of Class A ~~common stock~~Common Stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of Class A Common Stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

The Private Placement Warrants are identical to the Public Warrants, ~~underlying the Units sold in the Initial Public Offering,~~ except that the Private Placement Warrants and the Class A Common Stock issuable upon the exercise of the Private Placement Warrants ~~are~~were not transferable, assignable or salable until 30 days after the ~~completion of a~~ Business Combination was completed, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and beare non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

Assumed Warrants

At Closing of the Business Combination, the Company assumed common stock warrants to purchase FOXO Class A Common Stock (“Assumed Warrants”) and exchanged such ~~common stock warrants~~Assumed Warrants for common stock warrants to purchase ~~1,905,853~~190,619 shares of the Company’s Class A Common Stock. Each Assumed Warrant entitles the holder to purchase one share of Class A Common Stock at a price of ~~$6.21~~$62.10 per share, subject to adjustment. The Assumed Warrants are exercisable over a three-year period from the date of issuance. The Assumed Warrants include a down round provision that should the Company issue common stock for a consideration of less than $62.10 per share then the exercise price shall be lowered to the new consideration amount on a per share basis with a simultaneous and corresponding increase to the number of warrants. The down round provision has not been triggered.

~~Shares Payable~~Exchange Offer

The Company entered into a termination agreement with a vendor associated with the Business Combination. The Company agreed to provide 300,000 shares in connection with the agreement which have not been issued as of September 30, 2022. The obligation to issue shares is recorded in the consolidated balance sheet as shares payable.

~~Note 8 EQUITY-BASED COMPENSATION~~

~~Management Contingent Share Plan~~

On ~~September 14, 2022, the stockholders of~~May 26, 2023, the Company approved the FOXO Technologies Inc. Management Contingent Share Plan (the “Management Contingent Share Plan”). The purposes of the Management Contingent Share Plan are to (a) secure and retain the services of certain key employees and service providers and (b) incentivize such key employees and service providers to exert maximum efforts for the success of the Company andconsummated its ~~affiliates.~~

The number of shares of Class A Common Stock that may be issued under the Management Contingent Share Plan is 9,200,000 shares, subject to equitable adjustment for shares splits, share dividends, combinations, recapitalizations and the like after the Closing, including to account for any equity securities into which such shares are exchanged or converted.

The Management Contingent Share Plan provides for the grant of restricted share awards of Class A Common Stock. All of the shares of Class A Common Stock issued to a FOXO employee at the Closing were issued pursuant to a “Restricted Share Award,” the terms of which shall applytender offer commenced on April 27, 2023, to all ~~shares issued~~190,619 holders of Assumed Warrants to such recipient. For the purposes of the Management Contingent Share Plan, shares of restricted Class A Common Stock issued in accordance with such plan will be considered “vested” when they are no longer subject to forfeiture in accordance with the terms of such plan. Each restricted share award issued under the Management Contingent Share Plan will be subject to both a time-based vesting component and a performance-based vesting component.

~~Time-Based Vesting~~

~~Each restricted share award shall be subject to three service-based vesting conditions:~~

Sixty percent (60%) of a participant’s restricted share award will become vested on the third anniversary of the Closing if the participant is still employed by the company on such date (and has been continuously employed by the company from the date of grant through such vesting date).

An additional twenty percent (20%) of a participant’s restricted share award will become vested on the fourth anniversary of the Closing if the participant is still employed by the company on such date (and has been continuously employed by the company from the date of grant through such vesting date).

The final twenty percent (20%) of a participant’s restricted share award will become vested on the fifth anniversary of the Closing if the participant is still employed by the company on such date (and has been continuously employed by the company from the date of grant through such vesting date).

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

~~Performance-Based Vesting~~

~~In addition, to time-based vesting, one-third of each restricted share award may only become vested upon satisfaction of each of the following three performance-based conditions:~~

The operational launch of digital online insurance products by FOXO LIFE Insurance Company (or its functional equivalent under a managing general agency relationship with a life insurance company), with at least 100 policies sold, within one year following the Closing;

The signing of a commercial research collaboration agreement with an insurance company or reinsurance company for saliva-based epigenetic biomarkers in life insurance underwriting within two years following the Closing; and

~~The implementation of saliva-based epigenetic biomarkers in life insurance underwriting by the Company, with at least 250 policies sold using such underwriting, within two years following the Closing.~~

On July 6, 2022, the Company executed a Memorandum of Understanding and Pilot Research Agreement (the “Agreement”) with both a life insurance carrier and a reinsurer. The purpose of the Agreement is to conduct a parallel run study, using a minimum of 2,500 participants, comparing traditional medical underwriting results to those obtained through use of the Company’s saliva-based epigenetic biomarker technology. The Agreement is intended to assess the value of the Company’s technology for a saliva-based next-generation underwriting protocol and will help determine whether the parties will later enter into a commercial agreement. The Agreement commenced in the third quarter of 2022 and will continue until the sooner of project completion, project termination, or the Company and the life insurance carrier entering into a commercial agreement for the scaled rollout of FOXO’s technology in the life insurance carrier’s underwriting processes. Accordingly, the Company has met the commercial research collaboration agreement performance condition and has begun recognizing expense upon completion of the Business Combination. For both the three and nine months ended September 30, 2022 the Company has recognized $289 of expense related to the vesting of the Management Contingent Share Plan based on the fair value at grant date of $7.81 per share.

~~Service Based-Conditions~~

~~The Management Contingent Share Plan provides that in the event of the death, disability, or termination without cause of the CEO, service-based conditions will not apply.~~

~~Forfeiture of Restricted Share Awards~~

If a performance-based condition is not achieved within the specified timeframe, then the one-third portion of each restricted share award that is associated to that performance-based condition will be permanently forfeited. The Committee shall be solely responsible for monitoring and determining whether or not any performance-based condition is achieved, and any such determination shall be final and conclusive.

Any restricted stock awards that fail to vest due to a time-based vesting condition not being satisfied will be forfeited by the participant and the shares associated with that award will be permanently forfeited and cancelled.

~~Upon closing of the Business Combination 9,200,000 shares were issued and 9,175,000 remained outstanding as of September 30, 2022 under the Management Contingent Share Plan.~~

~~2022 Equity Incentive Plan~~

On September 14, 2022, the stockholders of the Company approved the FOXO Technologies Inc. 2022 Equity Incentive Plan (the “2022 Plan”). The 2022 Plan permits the grant of equity-based awards to employees, directors and consultants. The number of shares of Class A Common Stock that may be issued under the 2022 Plan is ~~3,286,235.~~

~~As of September 30, 2022, no awards were granted under the 2022 Plan.~~

~~2020 Stock Incentive Plan~~

FOXO Technologies Operating Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”) to attract, retain, incentivize and reward qualified employees, nonemployee directors and consultants. Immediately prior to Closing, vested and unvested stock options were outstanding to purchase 5,105,648 shares of FOXO Class A Common Stock. At Closing, the Combined Company assumed the stock options granted pursuant to the 2020 Plan to purchase FOXO Class A Common Stock and exchanged such stock options to purchase 2,965,500receive 48.3 shares of the Company’s Class A Common Stock in exchange for each Assumed Warrant tendered (the “Exchange Offer”). The consideration was accounted for as a deemed dividend to the warrant holders, is calculated based on the fair value of common stock at ~~a weighted-average exercise price~~consummation of ~~approximately $7.13 per share. All remaining terms~~the offering and reflected in net loss to common stockholders.

As part of the Exchange Offer, the Company also solicited consents from holders of the Assumed ~~Options~~Warrants to amend and restate in its entirety the Securities Purchase Agreement, dated as of January 25, 2021 (the “Original Securities Purchase Agreement”), by and between Legacy FOXO (and assumed by the Company in connection with the Business Combination) and each purchaser of 2021 Bridge Debentures and warrants to purchase shares of FOXO Class A Common Stock, as amended (together with the 2021 Bridge Debentures, the “Original Securities”) identified on the signature pages thereto, which governs all of the Assumed Warrants and the Original Securities (together with the Assumed Warrants, the “Securities”), pursuant to the terms of an Amended and Restated Securities Purchase Agreement, to provide that the issuance of shares of Class A Common Stock and certain issuances of Common Stock Equivalents (as defined in the Original Securities Purchase Agreement) in connection with the Exchange Offer, the PIK Note Amendment, the 2022 Bridge Debenture Release (as defined below), and a Private Placement and a Public Financing, as well as any previous issuance of Class A Common Stock or Common Stock Equivalents (as defined in the Original Securities Purchase Agreement), do not trigger, and cannot be deemed to have triggered, any anti-dilution adjustments in the Securities.

Pursuant to the Exchange Offer, an aggregate of 164,751 Assumed Warrants were ~~unchanged.~~tendered and an aggregate of 795,618 shares of Class A Common Stock were issued to the holders of Assumed Warrants resulting in a deemed dividend of $2,466. After the Exchange Offer and as of September 30, 2023, 25,868 Assumed Warrants remain outstanding. At the same time 432,188 shares of Class A Common Stock were issued as part of the PIK Note Amendment as discussed in Note 5.

2022 Bridge Debenture Release

The Company entered into two separate general release agreements in June of 2023 (the “General Release Agreements” and such transaction, the “2022 Bridge Debenture Release”). The General Release Agreements are with former registered holders (the “Investors”) of 10% Original Issue Discount Convertible Debentures issued in 2022 by Legacy FOXO (the “2022 Bridge Debentures”).

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

~~Note 9 FORWARD PURCHASE AGREEMENT~~

~~The~~Pursuant to their respective General Release Agreement, each Investor released, waived and discharged the Company ~~entered into a Forward Share Purchase~~from any and all claims that such Investor had, have or may have against the Company from the beginning of time through the effective date of their respective General Release Agreement ~~with Meteora Capital Partners~~(the “Release”). As consideration for the Release and ~~its affiliates (collectively, “Meteora”) for a forward purchase transaction. Prior~~each Investor’s other obligations, covenants, agreements, representations and warranties set forth in their respective General Release Agreement, the Company issued to ~~the Closing, Meteora agreed not to redeem 2,873,728~~each Investor 0.067 shares of Class A Common Stock ~~(the “Meteora Shares”) in connection with the Business Combination. Meteora has the right to sell the Meteora Shares~~for every $1.00 of Subscription Amount (as defined in the ~~open market and on~~securities purchase agreements governing the ~~fifteen (15) month anniversary~~2022 Bridge Debentures) of 2022 Bridge Debentures purchased by such Investor. Pursuant to the ~~Closing of the Business Combination (the” Put Date”) may obligate~~General Release Agreements, the Company ~~to purchase the~~issued an aggregate of 703,500 shares ~~from Meteora should any not have been sold in the open market.~~of Class A Common Stock.

~~In connection with~~The Company issued shares to the ~~Forward Share Purchase Agreement,~~Investors in exchange for the ~~Company~~release and ~~Meteora entered into an escrow agreement (the “Escrow Agreement”) where $29,135,~~recognized expense of $2,181 based on the ~~Meteora Shares~~shares issued and corresponding fair value of common stock at the ~~corresponding redemption price from the Business Combination, was deposited into escrow by the Company (the “Prepayment Amount”).~~ ~~There are a few scenarios in which the Forward Purchase Agreement can be settled either before or on the~~ ~~Put~~ ~~Date:~~time of issuance.

At any time prior to the Put Date, Meteora may sell the Meteora Shares to any third party following the Business Combination but before the Put Date in the open market. If Meteora sells any shares prior to the Put Date, an amount equal to the product of the number of Meteora Shares sold multiplied by 92.5% of a reset price (the “Reset Price”) will be released from the Escrow Account and paid to the Company (the “Open Market Sale Payment”), and an amount equal to the product of (a) the portion of the Meteora Shares that Meteora sells in the open market and (b) the difference between the (i) the per share escrow amount and (ii) the Open Market Sale Payment, will be released from the Escrow Account to Meteora. The Reset Price shall initially be $10.00 and, thereafter, shall be subject to weekly adjustments during the term of the Forward Purchase Agreement based on the then current Reset Price and volume weighted average trading prices (“VWAP”) of the Company’s Class A Common Stock for the immediately preceding week.

Private Placement

~~ii.~~

On the Put Date, if any of the Meteora Shares subject to the Forward Purchase Agreement remain unsold, Meteora is entitled to a) the product of the unsold Meteora Shares multiplied by the Redemption Price which will be released from the Escrow Account, and b) the Company will be required to transfer to Meteora maturity consideration equal to the product of $0.05 per Meteora Share sold to the Company and the number of days between the closing of the Business Combination and the Put Date divided by 30 days.

~~iii.~~

The Put Date may be accelerated and occur prior to the fifteen month anniversary of the Closing of the Business Combination upon the occurrence of certain events and circumstances set forth in the Forward Share Purchase Agreement, including a) if the VWAP of the Company’s Class A Common Stock falls below $2.50 per share during any 20 of 30 consecutive trading days, b) if the Forward Purchase Agreement is early terminated, or c) if the Company’s Class A Common Stock is delisted from a national exchange. If the Put Date is accelerated, the Company would follow the maturity consideration described above.

The Company has determined that the Prepayment Amount is collateral with the amount recorded in the unaudited consolidated balance sheet within forward purchase collateral. In accordance with ASC 480, Distinguishing Liabilities from Equity, From July 14, 2023 through July 20, 2023 (each such date, a “First Tranche Closing Date”), the Company ~~has determined that Meteora’s ability~~entered into three separate Stock Purchase Agreements (the SPAs), which have substantially similar terms, with three accredited investors (the “Buyers”), pursuant to ~~require~~which the Company agreed to ~~repurchase~~issue and sell to the Buyers, in a private placement (the “2023 Private Placement”), in two separate tranches each, an aggregate of up to 562,500 shares ~~in certain situations is accounted~~of the Company’s Class A Common Stock at a price of $0.80 per share, for ~~as a freestanding derivative.~~aggregate gross proceeds of $450. The ~~derivative, referred~~net proceeds from the 2023 Private Placement, after deducting placement agent fees and other offering expenses, was approximately $260. Pursuant to as the ~~forward purchase put derivative is recorded as a liability~~terms of the SPAs, the Buyers initially purchased an aggregate of 281,250 shares of Class A Common Stock on the ~~Company’s unaudited consolidated balance sheet. Additionally,~~applicable First Tranche Closing Dates, and purchased an aggregate of 281,250 additional shares of Class A Common Stock on August 4, 2023, following the effectiveness of the First Resale Registration Statement.

On August 23, 2023, the Company ~~has recorded a derivative based~~entered into three additional Stock Purchase Agreements (the “Second Round SPAs”) and Registration Rights Agreements (the “Second Round RRAs”), with the Buyers, pursuant to which the Company issued and sold to the Buyers, in the second round of the 2023 Private Placement (the “2023 PIPE Second Round”), in two separate tranches each, an aggregate of 366,876 shares of Class A Common Stock at the Per Share Price for aggregate gross proceeds of $293.5 and aggregate net proceeds of approximately $217, after deducting placement agent fees and other offering expenses. Pursuant to the terms of the Second Round SPAs, the Buyers initially purchased an aggregate of 183,438 shares of Class A Common Stock on August 23, 2023, and purchased an aggregate of 183,438 additional shares of Class A Common Stock on September 7, 2023, following the ~~amount~~effectiveness of ~~collateral that may be provided to Meteora and has recorded it as a liability, referred to as~~ the ~~forward purchase collateral derivative, on the Company’s unaudited consolidated balance sheet.~~ Second Resale Registration Statement.

Treasury Stock

The Company ~~has prepared fair value measurements for both~~cancelled the forward purchase derivatives as of the Closing and September 30, 2022, which is described in Note 11. The Company remeasures the fair value of the forward purchase derivatives each reporting period and the change in fair value is recorded in current earnings.outstanding treasury stock on April 14, 2023.

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

Note 108 NET LOSS PER SHARE

The Business Combination was accounted for as a reverse recapitalization by which FOXO Technologies Operating Company issued equity for the net assets of Delwinds accompanied by a recapitalization. Earnings per share has been recast for all historical periods to reflect the Company’s capital structure for all comparative periods.

The Company excluded the effect of the ~~9,175,000~~69,668 Management Contingent Shares outstanding and not vested as of September 30, ~~2022~~2023 from the computation of basic net loss per share infor the three and nine months ended September 30, ~~2022,~~2023, as the conditions to trigger the vesting of the Management Contingent Shares had not been satisfied as of September 30, ~~2022.~~2023. Shares issued to the Company’s former CEO pursuant to the Management Contingent Share Plan which are under review to determine if such shares should be forfeited in accordance with such plan are included in net loss per share. See Note 12 for additional information.

The Company excluded the effect of the Public Warrants, the Private Placement Warrants, the Assumed Options, and Assumed Warrants from the computation of diluted net loss per share for the three and nine months ended September 30, 2023 as their inclusion would have been anti-dilutive because the Company was in a loss position for such periods. The Assumed Options, the Assumed Warrants, and Bridge Debentures were excluded from the three and nine months ended September 30, 2022 as their inclusion would have been anti-dilutive because the Company was in a loss position for such periods. The Assumed Options, the Assumed Warrants, and the 2021 Bridge Debentures were excluded from the three and nine months ended September 30, 2021 as their inclusion would have been anti-dilutive. For the three and nine months ended September 30, 2022, the 2021 Bridge Debentures and 2022 Bridge Debentures were included in basic and diluted net loss per share from the date of closing as the Bridge Debentures were converted into FOXO Class A Common Stock and subsequently exchanged for the Company’s Class A Common Stock upon completion of the Business Combination.

The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of shares outstanding during the respective periods:

Three
Months
Ended
September 30,
2022 Three
Months
Ended
September 30,
2021 Nine
Months
Ended
September 30,
2022 Nine
Months
Ended
September 30,
2021
Net loss available to common shares $ (41,026 ) $ (27,241 ) $ (76,932 ) $ (37,614 )
Basic and diluted weighted average number of Class A Common Stock 6,122 5,826 5,975 5,817
Basic and diluted net loss available to Class A Common Stock $ (6.70 ) $ (4.68 ) $ (12.88 ) $ (6.47 )

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Net loss - basic and diluted	$	(3,660	)	$	(41,026	)	$	(22,592	)	$	(76,932	)
Deemed dividend related to the Exchange Offer		-			-			(2,466	)		-
Net loss to common stockholders - basic and diluted	$	(3,660	)	$	(41,026	)	$	(25,058	)	$	(76,932	)
Basic and diluted weighted average number of Class A Common Stock		4,878			612			3,350			598
Basic and diluted net loss per share available to Class A Common Stock	$	(0.75	)	$	(67.04	)	$	(7.48	)	$	(128.65	)

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

The following Class A common stock equivalents have been excluded from the computation of diluted net loss per common share as the effect would be antidilutive and reduce the net loss per common stock (shares in ~~thousands)~~actuals):

	As of September 30,				As of September 30,
	2022		2021		2023		2022
Series A preferred stock		-		4,646,698
2021 Bridge Debentures		-		6,759,642
2022 Bridge Debentures		-		7,810,509
Public and private warrants		10,378,750		-		1,037,873		1,037,873
Assumed warrants		1,905,853		1,905,853		25,868		190,619
Assumed options		2,965,500		2,965,500		215,094		296,579
Total antidilutive shares		15,250,103		24,088,202		1,278,835		1,525,071

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

Note 119 FAIR VALUE MEASUREMENTS

The following table presents information about the Company’s assets and liabilities that are measured on a recurring basis as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.

	Fair Value Measurements Using Inputs Considered as:								Fair Value Measurements Using Inputs Considered as:
	Fair Value		Level 1		Level 2		Level 3
September 30, 2022
September 30, 2023									Fair Value		Level 1		Level 2		Level 3
Liabilities:
Warrant liability	$	1,038	$	1,006	$	32	$	-	$	67	$	65	$	2	$	-
Forward purchase collateral derivative		27,378		-		-		27,378
Forward purchase put derivative		1,284		-		-		1,284
Total liabilities	$	29,700	$	1,006	$	32	$	28,662	$	67	$	65	$	2	$	-

	Fair Value Measurements Using Inputs Considered as:								Fair Value Measurements Using Inputs Considered as:
	Fair Value		Level 1		Level 2		Level 3
December 31, 2021
December 31, 2022									Fair Value		Level 1		Level 2		Level 3
Liabilities:
2021 Bridge Debentures	$	32,203	$	-	$	-	$	32,203
Warrant liability									$	311	$	302	$	9	$	-
Total liabilities	$	32,203	$	-	$	-	$	32,203	$	311	$	302	$	9	$	-

Warrant Liability

The Public Warrants and Private Placement Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liability on the Company’s balance sheet. The warrant liability is measured at fair value on ~~the date of the Closing and on~~ a recurring basis, with any changes, if applicable, in the fair value presented as change in fair value of warrant liability in the Company’s statement of operations.

~~Measurement at Closing and Subsequent Measurement~~

~~The Company established the fair value for the Public and Private Placement Warrants on the date of the Closing, and subsequent fair value as of September 30, 2022.~~ The measurement of the Public Warrants ~~as of Closing and as September 30, 2022~~ is classified as Level 1 due to the use of an observable market quote in an active market under ticker ~~FOXO-WT.~~FOXOW:OTCPK. As the transfer of the Private Placement Warrants to anyone outside of a small group of individuals who are permitted transferees would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, the Company determined the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant, with an insignificant adjustment for short-term marketability restrictions. As such, the Private Placement Warrants are classified as Level 2.

~~Forward Purchase Derivatives~~

The Company established the fair value of both the forward purchase put derivative and the forward purchase collateral derivative on the date of the Closing, and subsequent fair value as of September 30, 2022 with amounts included in net income as a change in fair value of forward purchase put derivative and a change in fair value of forward purchase collateral derivative. The estimated fair value of the forward purchase derivatives was calculated using a Monte Carlo simulation and used significant unobservable inputs. Future estimates of trading prices were based on volatility assumptions that impact the estimated Reset Price and Meteora’s corresponding sales in the open market. The forward purchase derivatives are classified as Level 3 due to the use of unobservable inputs. For additional information on the forward purchase derivatives see Note 9.

Bridge Debentures

The Company elected the fair value option ~~to account for~~on both the 2021 ~~Bridge Debentures~~ and 2022 Bridge Debentures ~~(collectively,~~that converted to shares of FOXO Class A Common Stock as part of the ~~“Bridge Debentures”). The Bridge Debentures are measured at~~Business Combination. Changes in the Company’s prior fair value on a recurring basis given the Company’s election of the fair value option for measuring such liabilities. The fair value of the Bridge Debentures is determined based on significant unobservable inputs including the likelihood of voluntary or mandatory conversion, and the estimated date at which conversion will take place, which causes them to be classifiedmeasurements are recorded as ~~a Level 3 measurement within the fair value hierarchy. The recorded fair value of the Bridge Debentures and the~~ non-cash change in fair value ~~recorded~~of convertible debentures in the condensed consolidated statements of operations could change materially if differing inputs and assumptions were to be utilized. However, the valuations used assumptions and estimates the Company believes would be made by a market participant in making the same valuations as of the issuance date and each subsequent reporting period.

The Company elected the fair value option to better depict the ultimate liability associated with the Bridge Debentures, including all features and embedded derivatives in the Securities Purchase Agreements. The Bridge Debentures accounted for under the fair value option election represented debt host financial instruments containing certain embedded features that would otherwise be required to be bifurcated from the debt host and recognized as separate derivative liabilities subject to initial and subsequent periodic fair value measurement in accordance with U.S. GAAP. When the fair value option election is applied to financial liabilities, bifurcation of embedded derivatives is not required, and the financial liability in totality is recorded at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis as of each balance sheet date thereafter. Upon remeasurement, the portion of a change in estimated fair value attributable to a change in instrument-specific credit risk is recognized as a component of other comprehensive income (loss) and the remaining amount of a change in estimated fair value is to be recognized in the consolidated statements of operations. ~~As a result of electing the fair value option, direct costs and fees related to the issuance of the Bridge Debentures were expensed and not deferred.~~

~~Foxo technologies inc. and subsidiaries~~

~~NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(Dollars in thousands, except per share data)~~

For all reporting periods during the year ended December 31, 2021, the estimated fair value of the 2021 Bridge Debentures was calculated using a Monte Carlo simulation, which incorporated significant unobservable inputs such as the likelihood of term extension and voluntary or mandatory conversion. Additionally, the December 31, 2021 used an implied borrowing rate of 52.0% as an input to the fair value measurement. None of the change in fair value for the was deemed to be attributable to instrument-specific credit risk and thus the full amount of such change was recognized in the consolidated statements of operations.

During 2022, prior to conversion, the estimated fair value of the Bridge Debentures was calculated using a probability-weighted expected return model. This change in valuation methodology was driven by the execution of the Merger Agreement on February 24, 2022, which made the ultimate value to holders of the Bridge Debentures upon voluntary or mandatory conversion clearer. Prior to conversion, the Bridge Debentures were recorded at their ultimate fair value based on purchase consideration attributed to the outstanding principal and using a probability-weighted expected return model. At conversion, the Company was able to determine the fair value of both the 2021 Bridge Debentures and 2022 Bridge Debentures based on the completion of the Business Combination. Immediately prior to the Closing of the Business Combination, the 2021 Bridge Debentures and 2022 Bridge Debentures were converted to 6,759,642 and 7,810,509 shares of FOXO Technologies Operating Company Class A common stock, respectively and fair value measurements were no longer performed as the debt was no longer outstanding. For further details on this conversion, stockholders’ equity of the Combined Company, and the Business Combination, refer to Notes 1, 3, 5, and 7. None of the change in estimated fair value of the Bridge Debentures from December 31, 2021 to conversion was deemed to be attributable to instrument-specific credit risk and thus the full amount of such change was recognized in the consolidated statements of operations.

~~The following tables provide a summary of changes in Level 3 liabilities measured at fair value on a recurring basis:~~

2022 Bridge
Debentures 2021 Bridge
Debentures Total
Balance, June 30, 2021 $ - $ 12,819 $ 12,819
Losses included in net loss - 22,571 22,571
Balance, September 30, 2021 $ - $ 35,390 $ 35,390

2022 Bridge
Debentures 2021 Bridge
Debentures Forward
Purchase
Put Derivative Forward
Purchase
Collateral
Derivative Total
Balance, June 30, 2022 $ 46,733 $ 37,953 $ - $ - $ 84,686
Losses included in net loss 2,810 887 - - 3,697
Balance at Conversion 49,543 38,840 - - 88,383
Transfer out (49,543 ) (38,840 ) - - (88,383 )
Losses included in net loss - - 1,284 27,378 28,662
Balance, September 30, 2022 $ - $ - $ 1,284 $ 27,378 $ 28,662

2022 Bridge
Debentures 2021 Bridge
Debentures Total
Balance, December 31, 2020 $ - $ - $ -
Debt Issuance - 10,500 10,500
Losses included in net loss - 24,890 24,890
Balance, September 30, 2021 $ - $ 35,390 $ 35,390

2022 Bridge
Debentures 2021 Bridge
Debentures Forward
Purchase
Put Derivative Forward
Purchase
Collateral
Derivative Total
Balance, December 31, 2021 $ - $ 32,203 $ - $ - $ 32,203
Debt Issuance 28,000 - - - 28,000
Losses included in net loss 21,543 6,637 - - 28,180
Balance at Conversion 49,543 38,840 - - 88,383
Transfer out (49,543 ) (38,840 ) - - (88,383 )
Losses included in net loss - - 1,284 27,378 28,662
Balance, September 30, 2022 $ - $ - $ 1,284 $ 27,378 $ 28,662

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

Note 10 FOXO LIFE INSURANCE COMPANY

On February 3, 2023, the Company consummated the previously announced sale of FOXO Life Insurance Company to Security National Life Insurance Company (the “Buyer”). At closing, all of the FOXO Life Insurance Company’s shares were cancelled and retired and ceased to exist in exchange for the assignment to the Company of FOXO Life Insurance Company’s statutory capital and surplus amount of $5,002, as of the closing date, minus $200 (the “Merger Consideration”). Pursuant to the transaction, at the closing, the Company paid the Buyer’s third-party out-of-pocket costs and expenses of $51 resulting in a total loss of $251 that was recognized within selling, general and administrative expense on the condensed consolidated statements of operations and in the FOXO Life segment. After the Merger Consideration and Buyer’s third party expenses, the transaction resulted in the Company gaining access to $4,751 that was previously held as statutory capital and surplus pursuant to the Arkansas Insurance Code.

Note 1211 BUSINESS SEGMENT

The Company manages and classifies its business into two reportable business segments:

●

FOXO Labs is commercializing proprietary epigenetic biomarker technology to be used for underwriting risk classification in the global life insurance industry. The Company’s innovative biomarker technology enables the adoption of new saliva-based health and wellness biomarker solutions for underwriting and risk assessment. The Company’s research demonstrates that epigenetic biomarkers, collected from saliva, provide measures of individual health and wellness for the factors used in life insurance underwriting traditionally obtained through blood and urine specimens.

●

FOXO Life is redefining the relationship between consumers and insurer by combining life insurance with a dynamic molecular health and wellness platform. FOXO Life seeks to transform the value proposition of the life insurance carrier from a provider of mortality risk protection products to a partner supporting its customers’ healthy longevity. FOXO Life’s multi-omic health and wellness platform will provide life insurance consumers with valuable information and insights about their individual health and wellness to support longevity. On October 19^th, 2023, the Company entered into an agreement to sell certain assets of FOXO Life thereby discontinuing, the Company’s business in life insurance due to the uneconomic nature of the business unit.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

FOXO Labs generates revenue through performing epigenetic biomarker services and by collecting epigenetic services royalties. FOXO Life generates revenue from the sale of life insurance products. ~~Asset information is not used by the Chief Operating Decision Maker (“CODM”) or included in the information provided to the CODM to make decisions and allocate resources.~~

The primary income measure used for assessing segment performance and making operating decisions is earnings before interest, income taxes, depreciation, amortization, and ~~equity-based~~stock-based compensation (“Segment Earnings”). The segment measure of profitability also excludes corporate and other costs, including management, IT, overhead costs and certain other non-cash charges or benefits, such as impairment any non-cash changes in fair value.

Summarized below is information about the Company’s operations for the three and nine months ended September 30, ~~2022~~2023 and ~~September 30, 2021~~2022 by business segment:

Three Months Ended September 30, Nine Months Ended September 30,
Revenue Earnings Revenue Earnings
2022 2021 2022 2021 2022 2021 2022 2021
FOXO Labs $ 7 $ 23 $ (499 ) $ (1,632 ) $ 71 $ 67 $ (1,952 ) $ (4,268 )
FOXO Life 7 8 (1,157 ) (831 ) 22 26 (3,070 ) (1,667 )
14 31 (1,656 ) (2,463 ) 93 93 (5,022 ) (5,935 )
Corporate and other (a) (38,946 ) (24,465 ) (70,660 ) (30,854 )
Interest expense (424 ) (313 ) (1,250 ) (825 )
Total $ 14 $ 31 $ (41,026 ) $ (27,241 ) $ 93 $ 93 $ (76,932 ) $ (37,614 )

	Three Months Ended September 30,										Nine Months Ended September 30,
	Revenue				Earnings						Revenue				Earnings
	2023		2022		2023			2022			2023		2022		2023			2022
FOXO Labs	$	6	$	7	$	(269	)	$	(500	)	$	20	$	71	$	(873	)	$	(1,952	)
FOXO Life		4		7		(139	)		(1,158	)		15		22		(1,029	)		(3,070	)
		10		14		(408	)		(1,658	)		35		93		(1,902	)		(5,022	)
Impairment (a)						-			-							(2,633	)		-
Stock issuances (b)						-			-							(3,521	)		-
Corporate and other (c)						(3,104	)		(38,944	)						(13,671	)		(70,660	)
Interest expense						(148	)		(424	)						(865	)		(1,250	)
Total	$	10	$	14	$	(3,660	)	$	(41,026	)	$	35	$	93	$	(22,592	)	$	(76,932	)

(a)

See Note 4 for additional information on the digital insurance platform, underwriting API, and longevity API impairment.

(b)	Stock issuances includes the 2022 Bridge Debenture Release and the PIK Note Amendment. See Notes 5 and 7 for additional information.

(c)

Corporate and other includes equity-based compensation, including the consulting agreement and Cantor Commitment Fee, expense of ~~$3,866~~($1,312) and ~~$42~~$3,866 as well as depreciation and amortization expense of ~~$74~~$5 and ~~$25~~$74 for the three months ended September 30, ~~2022~~2023 and ~~2021,~~2022, respectively. Corporate and other includes equity-based compensation, including the consulting agreement and Cantor Commitment Fee, expense of ~~$5,556~~$2,582 and $8$5,556 as well as depreciation and amortization expense of ~~$159~~$1,251 and ~~$71~~$159 for the nine months ended September 30, ~~2022~~2023 and ~~2021,~~2022, respectively. The three months ended September 30, 2023 and 2022 included ($36) and ~~2021 included~~ $31,010 ~~and $22,571~~ for the changes in fair value of convertible debentures, warrant liability, and forward purchase derivatives. The nine months ended September 30, ~~2022~~2023 and ~~2021~~2022 also included ~~$55,493~~($244) and ~~$24,890~~$55,493 for the changes in fair value of convertible debentures, warrant liability, and forward purchase derivatives. See Notes 5,4, 6, 7,and 9 ~~and 11~~ for additional information.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

Note 1312 COMMITMENTS ~~CONTINGENCIES,~~ AND ~~SPONSORED RESEARCH~~CONTINGENCIES

The Company is a party to various vendor and license agreements and sponsored research arrangements in the normal course of business that create commitments and contractual obligations.

~~Vendor Agreements~~

The Company entered into an agreement to purchase supplies from an unrelated party in December 2019. The agreement required a purchase of 10,000 units over the 3-year term of the contract. The Company had $788 remaining on its purchase obligation and in July of 2022, the Company amended the vendor agreement under which it was previously committed to purchasing 10,000 units of supplies over a three-year term. That amendment resulted in the elimination of the $788 commitment remaining under the agreement in exchange for a reduced royalty rate to be received by the Company on future sales of infinium mouse methylation arrays.

License Agreements

In April 2017, the Company entered into a license agreement with The Regents of University of California (the “Regents”) to develop and commercialize the DNA Methylation Based Predictor of Mortality. The agreement remains in effect through the life of the Regents’ patents related to this license agreement. The Company is required to pay license maintenance fees on each anniversary date of agreement execution. The Company is liable to the Regents for an earned royalty of net sales of licensed products or licensed methods.

In February 2021, the Company entered into another license agreement with the Regents for GrimAge and PhenoAge technology. The agreement remains in effect through the life of the Regents’ patents related to this license agreement. In consideration of the license and rights granted under the license agreement, the Company made a one-time cash payment and will make maintenance payments on each anniversary of the Agreement. The Company will pay the Regents for each assay internally used and a royalty on external net sales. Additionally, the contract includes development milestones and fees related to achieving commercial sales and a comparative longitudinal study of health outcomes.

~~Harvard University’s Brigham and Women’s Hospital~~

~~During the second quarter~~As of ~~2022,~~September 30, 2023, besides upfront payments, the Company ~~entered into an agreement and~~has only made payments related to license option with The Brigham and Women’s Hospital, Inc. (the “Hospital”) to conduct epigenetic profiling of associations between epigenetic aging and numerous behavioral, lifestyle, dietary and clinical risk factors, as well as major morbidity and mortality outcomes. The Company refers to this study as VECTOR. Specific aims of this research include: (i) to examine epigenetic association with lifestyle and dietary factors, including smoking history, physical activity, body mass index, alcohol intake, dietary patterns, dietary supplement use, and aspirin used; (ii) to examine epigenetic association with major morbidity including cardiovascular disease, cancer, type 2 diabetes, hypertension, liver disease, renal disease, and respiratory disease, (iii) to conduct an National Death Index Plus search to update and extend mortality follow upmaintenance fees on Harvard University’s Physicians’ Health Study (“PHS’), and (iv) utilizing the newly expanded PHS mortality follow-up data, to examine epigenetic association with lifespan, longevity, and mortality. In addition, the epigenetic resources contained in the PHS studies have the potential to contribute and extend to large meta-analyses and validation studies of epigenetic association and understanding of these factors and their impact on human aging acceleration.both arrangements.

The Company is responsible for payments up to $849 related to the agreement, half of which was paid upon contract execution during the second quarter of 2022. Remaining payments are due as follows: (i) 20% upon the enrollment of the first patient, (ii) 20% upon the enrollment of the final patientSupplier and (iii) 10% upon lab receipt of shipments for all initially planned assays. Costs associated with the clinical trial agreement are being recorded as research and development expenses in the consolidated statements of operations.Other Commitments

The Company made a 10,000 unit purchase commitment for supplies of which 3,000 remain outstanding as of September 30, 2023. Additionally, the Company has committed to pay advisors expense advances. Collectively, the Company has a commitment of $14 remaining in 2023 related to these commitments.

~~U.S. Department of Health and Human Services~~Legal Proceedings

~~In June 2020,~~On November 18, 2022, Smithline Family Trust II (“Smithline”) filed a complaint against the Company and Jon Sabes, the Company’s former Chief Executive Officer and a former member of the Company’s board of directors, in the Supreme Court of the State of New York, County of New York, Index 0654430/2022. The complaint asserts claims for breach of contract, unjust enrichment and fraud, alleging that (i) the Company breached its obligations to Smithline pursuant to that certain Securities Purchase Agreement, dated January 25, 2021, between FOXO Technologies Operating Company and Smithline, an accompanying 12.5% Original Issue Discount Convertible Debenture, due February 23, 2022, and Warrant to purchase shares of FOXO common stock until February 23, 2024 (collectively, including any amendment or other document entered into in connection therewith, the “Financing Documents”), (ii) the Company and Mr. Sabes were unjustly enriched as a ~~cooperative research~~result of their alleged actions and ~~development agreement (“CRADA)~~omissions in connection with the ~~U.S. Department~~Financing Documents, and (iii) the Company and Mr. Sabes made materially false statements or omitted material information in connection with the Financing Documents. The complaint claims damages in excess of ~~Health~~a minimum of $6,207 on each of the three causes of action, plus attorneys’ fees and Human Services (“HHS”) and agencies of U.S. Public Health Services within the HHS, as well as the National Institute on Deafness and other Communication Disorders (“NIDCD”), to enhance understanding of epigenetic gene regulation in Recurrent Respiratory Papillomatosis (“RRP”).costs.

~~Under~~On December 23, 2022, FOXO removed this action from the ~~CRADA agreement, the Company is granted an exclusive option to elect an exclusive or nonexclusive commercialization license, with terms~~Supreme Court of the ~~license that reflect~~State of New York, County of New York to the ~~nature of the invention, the relative contributions of the respective parties, a plan~~United States District Court for the ~~development and marketing, and the costs~~Southern District of ~~subsequent research and development needed~~New York, Case 1:22-cv-10858-VEC. The action was assigned to ~~bring the invention to market. The Company is responsible for payment of all fees related to CRADA patents.~~Judge Valerie E. Caproni.

As part of the CRADA agreement, the Company agreed to provide funding totaling $200 under the two-year term of the agreement. The Company recognized $29 and $25 in sponsored research expenses related to this agreement during the three months ended September 30, 2022 and 2021, respectively, and $75 and $29 in sponsored research expenses related to this agreement during the nine months ended September 30, 2022 and 2021, respectively. These amounts are recorded within research and development expenses in the consolidated statements of operations.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

On February 1, 2023, Defendant Jon Sabes moved to dismiss the Complaint as to Defendant Sabes pursuant to Fed. R. Civ. P. 12(b)(2) and 12(b)(6).

On February 22, 2023, Smithline filed an Amended Complaint. The Company filed its Answer to the Amended Complaint on March 8, 2023.

On March 15, 2023, Defendant Jon Sabes moved to dismiss the Amended Complaint as to Defendant Sabes pursuant to Fed. R. Civ. P. 12(b)(1), (2) & (6). On April 17, 2023, Smithline filed its opposition to Defendant Sabes’ motion. Sabes’ motion remains undecided.

On November 7, 2023, Smithline, on the one hand, and the Company and its subsidiaries, on the other hand, entered into a settlement agreement (the “Settlement Agreement”), pursuant to which the parties agreed to resolve and settle all disputes and potential claims which exist or may exist among them, including without limitation those claims asserted in the Action, as more specifically set forth in, and subject to the terms and conditions of, the Settlement Agreement. Upon the execution of the Settlement Agreement, the parties agreed to jointly dismiss the Action without prejudice.

Pursuant to the Settlement Agreement, the Company agreed to pay Smithline $2,300,000 in cash (the “Cash Settlement Payment”), payable in full no later than the date (the “Settlement Deadline”) that is the 12 month anniversary of the effective date of the Settlement Agreement (such period, the “Settlement Period”). During the Settlement Period, the Company will pay Smithline out of any equity or equity-linked financing (excluding any convertible debt financing until such convertible debt is converted into equity) following the date of the Settlement Agreement (an “Equity Financing”) a minimum of 25% of the gross proceeds of each Equity Financing within two business days of the Company’s receipt of the proceeds from such Equity Financing, and which payment to Smithline would be applied toward the Cash Settlement Payment. Notwithstanding the foregoing, in the event that the Company has received proceeds from the Strata Purchase Agreement (as defined below) prior to the effective date of the Settlement Agreement, Smithline will be entitled to a minimum of 25% of the gross proceeds thereof, payment of which to Smithline would be applied toward the Cash Settlement Payment.

~~The Children’s Hospital of Philadelphia~~

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In February 2021, the Company entered into a sponsored research agreement with The Children’s Hospital of Philadelphia (“CHOP”) to develop new methods and software implementations for the processing and analysis of Illumina Infinium DNA methylation technology, including the Infinium EPIC+ Human Array and the infinium mouse methylation array. The intent of the research agreement is to create open-source software that will be able to import data from any Infinium DNA methylation array and conduct state-of-the-art processing and quality control of the data(Dollars in ~~an automated fashion.~~

thousands, except per share data)

In consideration for sponsoring the research, the Company shall have a first and exclusive option to negotiate for a revenue-bearing exclusive license to any patent rights or other intellectual property rights for CHOP intellectual property or CHOP’s interests in any joint intellectual property. Additionally, the Company agrees to reimburse CHOP for fees relating to maintaining the patents.

As part of the CHOP Agreement, the Company will provide funding totaling $311 over a two-year period, commencing February 1, 2021. The Company recognized $40 and $38 in sponsored research expenses during the three months ended September 30, 2022 and 2021, respectively, and $119 and $101 in sponsored research expenses during the nine months ended September 30, 2022 and 2021, respectively. These amounts are recorded within research and development expenses in the consolidated statements of operations.

~~Parallel Run Study~~Former CEO Severance

~~During~~As of September 30, 2023, the ~~third quarter~~Company’s Board of ~~2022,~~Directors has yet to complete its review into whether the former CEO was terminated with or without cause. Accordingly, the Company ~~executed~~has yet to make a ~~Memorandum of Understanding and Pilot Research Agreement (the “Agreement”) with both a life insurance carrier and a reinsurer. The purpose of~~determination on its obligations under the Agreement is to conduct a parallel run study, using a minimum of 2,500 participants, comparing traditional medical underwriting results to those obtained through use of the Company’s saliva-based epigenetic biomarker technology. The Agreement is intended to assess the value of the Company’s technology for a saliva-based next-generation underwriting protocol and will help determine whether the parties will later enter into a commercialformer CEO’s employment agreement. The Agreement commenced in the third quarter of 2022 and will continue until the sooner of project completion, project termination, or the Company and the life insurance carrier entering into a commercial agreement for the scaled rollout of FOXO’s technology in the life insurance carrier’s underwriting processes. The Company has ~~determined~~accrued for his severance and has recognized expenses related to his stock-based compensation per the terms of his contract while the matter remains under review.

Should the review conclude that ~~costs associated with~~ the ~~agreement~~former CEO was terminated without cause then the former CEO will bereceive thirty-six months of severance based on his base salary, his options granted immediately vest, and his Management Contingent Share Plan related to performance-based conditions that have been met become fully vested. $955 of severance is recorded ~~as research~~within accrued severance and ~~development expenses in~~ the remaining $620 recorded within other liabilities on the condensed consolidated balance sheets. The corresponding expense was recognized within selling, general and administrative expense on the condensed consolidated statements of operations at the time of his termination during the fourth quarter of 2022.

Should the review conclude the former CEO was terminated with cause then no severance or continued benefits are due and the Company will account for the forfeiture of the shares issued pursuant to the Management Contingent Share Plan as well as reverse the accrual and corresponding expense related to his severance. The forfeiture of the shares issued pursuant to the Management Contingent Share Plan would result in ~~accordance~~the Company reversing $9,130 of expense previously recognized related to the performance condition that has been met and based on his service prior to his termination as well as the vesting upon his termination.

Additionally, the Company cancelled the shares issued pursuant to the Management Contingent Share Plan related to performance based conditions that were not met as of the termination date.

The Company accrues for costs associated with ~~accounting standards codification guidance. The agreement stipulates~~certain contingencies, including, but not limited to, settlement of legal proceedings, regulatory compliance matters and self-insurance exposures when such costs are probable and reasonably estimable. In addition, the Company accrues for legal fees incurred in defense of asserted litigation and regulatory matters as such legal fees are incurred. To the extent it is probable under our existing insurance coverage that ~~the life insurance carrier~~we are able to recover losses and ~~reinsurer will share in costs equally~~legal fees related to contingencies, we record such recoveries concurrently with the ~~Company up~~accrual of the related loss or legal fees. Significant management judgment is required to ~~$200 each. Cost sharing reimbursements received from~~estimate the ~~life~~amounts of such contingent liabilities and the related insurance ~~carrier~~recoveries. In our determination of the probability and ~~reinsurer have been~~ability to estimate contingent liabilities and related insurance recoveries we consider the following: litigation exposure based on currently available information, consultations with external legal counsel, adequacy and applicability of existing insurance coverage and other pertinent facts and circumstances regarding the contingency. Liabilities established to provide for contingencies are adjusted as further information develops, circumstances change, or contingencies are resolved; and such changes are recorded ~~within parallel run advance~~in the condensed consolidated statements of operations during the period of the change and appropriately reflected in the consolidated balance ~~sheet as~~sheets. As of September 30, ~~2022~~2023 and ~~are being recognized as contra expenses in the consolidated statement of operations as~~December 31, 2022 the Company ~~incurs costs~~has an accrual of $2.3 million and $0, respectively, related to the ~~agreement.~~settlement of legal proceedings.

~~Litigation~~

The Company ~~may be involved in~~is also party to various other legal proceedings, claims, and ~~legal actions arising~~regulatory, tax or government inquiries and investigations that arise in the ordinary course of ~~business. In~~business, and we may in the ~~opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s financial position or liquidity. The Company is not aware of any material~~future be subject to additional legal ~~or regulatory matters threatened or pending against the Company.~~proceedings and disputes.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

Note 1413 SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to ~~November 21, 2022,~~ the date that the unaudited condensed consolidated financial statements were issued. Other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the accompanying ~~unaudited~~ financial statements.

Demand Promissory Note

On October 2, 2023, the Company obtained a $43 loan from Andrew J. Poole, a former director of the Company (the “Loan”), to be used to pay for the legal fees of Mitchell Silberberg & Knupp LLP through October 2023. The Company issued to Mr. Poole a demand promissory note for $43 evidencing the Loan (the “Note”). The Loan accrues interest in arrears at a rate of 13.25% per annum. The principal sum of the Note is due on demand, and in the absence of any demand, one year from the issuance date. The Note may be prepaid, in whole or in part, without penalty at any time.

Strata Purchase Agreement

On October 13, 2023, the Company entered into a Strata Purchase Agreement (the “Strata Purchase Agreement”) with ClearThink Capital Partners, LLC (“ClearThink”), as supplemented by that certain Supplement to Strata Purchase Agreement, dated as of October 13, 2023, by and between the Company and ClearThink (the “Strata Supplement”). Pursuant to the Strata Purchase Agreement, after the satisfaction of certain commencement conditions, including, without limitation, the effectiveness of the Registration Statement, ClearThink has agreed to purchase from the Company, from time to time upon delivery by the Company to ClearThink of request notices (each a “Request Notice”), and subject to the other terms and conditions set forth in the Strata Purchase Agreement, up to an aggregate of $2,000 of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of the shares of common stock to be purchased under the Strata Purchase Agreement will be equal to 85% of the lowest daily VWAP during a valuation period of ten trading days consisting of the five trading days preceding the Purchase Date (as defined in the Strata Purchase Agreement) with respect to a Request Notice and five trading days commencing on the first trading day following delivery and clearing of the delivered shares. In addition, pursuant to the Strata Purchase Agreement, the Company agreed to issue to ClearThink 100,000 restricted shares of Common Stock (the “Commitment Shares”) as a “Commitment Fee.”

Each purchase under the Strata Purchase Agreement will be in a minimum amount of $25 and a maximum amount equal to the lesser of (i) $1,000 and (ii) 300% of the average daily trading value of the Common Stock over the ten days preceding the Request Notice date. In addition, Request Notices must be at least 10 business days apart and the shares issuable pursuant to a Request Notice, when aggregated with the shares then held by ClearThink on the Request Notice date, may not exceed 4.99% of the outstanding Common Stock. The Strata Purchase Agreement further provides that the Company may not issue, and ClearThink may not purchase, any shares of Common Stock under the Strata Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by ClearThink and its affiliates, would result in the beneficial ownership by ClearThink and its affiliates of more than 9.99% of the then issued and outstanding shares of Common Stock.

Pursuant to the Strata Purchase Agreement, if within 24 months of the date of satisfaction of the commencement conditions set forth in the Strata Purchase Agreement, the Company seeks to enter into an equity credit line or another agreement for the sale of securities with a structure comparable to the structure in the Strata Purchase Agreement, the Company will first negotiate in good faith with ClearThink as to the terms and conditions of such agreement.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

In connection with the Strata Purchase Agreement, the Company entered into a Registration Rights Agreement with ClearThink under which the Company agreed to file, within 60 days of executing definitive documents, a registration statement with the Securities and Exchange Commission covering the shares of Common Stock issuable under the Strata Purchase Agreement (the “Registration Rights Agreement”).

Concurrently with the execution of the Strata Purchase Agreement, the Company and ClearThink also entered into a Securities Purchase Agreement (the “SPA”) under which ClearThink has agreed to purchase from the Company an aggregate of 200,000 restricted shares of Common Stock for a total purchase price of $200 in two closings. The first closing occurred on October 16, 2023 and the second closing occurred on October 24, 2023.

Pursuant to the SPA, if as of the 6-month anniversary of the issuance of the initial 100,000 shares of Common Stock (the “Initial Shares”), the Registration Statement has not been declared effective and ClearThink still holds the Initial Shares and the Common Stock is no longer listed on the NYSE American or a major national exchange and is trading at a price below $1.00 per share, then, subject to the Exchange Cap (as defined below), the Company will issue additional restricted Common Stock in order to adjust the effective price for the Initial Shares to the then current market price, with a floor price of $0.20.

In addition, pursuant to the SPA, for so long as the Registration Statement has not been declared effective and ClearThink holds any of the restricted Common Stock acquired at either of the closing dates, if the Company issues equity at a lower price per share than the effective price for the Common Stock purchased pursuant to the SPA, then, subject to the Exchange Cap, ClearThink will be issued additional shares of Common Stock to make the effective cost basis of the shares purchased under the SPA still held by ClearThink equal to such lower price per share.

The SPA further provides that if ClearThink sells or otherwise transfers any of the Commitment Shares prior to selling any of the shares issued pursuant to the SPA, for purposes of determining any adjustment to be made pursuant to the SPA, the shares sold will be deemed to be first sales of the Initial Shares, and thereafter, sales of the balance of the shares acquired pursuant to the SPA.

The Strata Purchase Agreement and the SPA provide that the Company will not be permitted to issue any shares of Common Stock pursuant to the Strata Purchase Agreement or the SPA if such issuance would cause (i) the aggregate number of shares of Common Stock issued to ClearThink pursuant to such agreements to exceed 19.99% of the outstanding shares of Common Stock immediately prior to the date of such agreements, unless shareholder approval pursuant to the rules and regulations of the NYSE American (or such other exchange on which the Common Stock is then listed) has been obtained or (ii) the Company to breach any of the rules or regulations of the NYSE American or such other exchange on which the Common Stock is then listed (the “Exchange Cap”).

~~ELOC Agreement~~Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On ~~November 8, 2022, the ELOC Agreement between the Cantor Investor and~~October 31, 2023, the Company received notice from NYSE American that NYSE American had halted trading in the Common Stock until the effectiveness of the Reverse Stock Split because the Common Stock was ~~terminated~~consistently selling at a low selling price per share in violation of Section 1003(f)(v) of the NYSE American Company Guide.

On October 31, 2023, the Company amended its Second Amended and Restated Certificate of Incorporation, as amended, to implement a 1-for-10 reverse stock split, such that every 10 shares of Common Stock will be combined into one issued and outstanding share of Common Stock, with no change in the ~~corresponding prepaid offering costs were expensed.~~$0.0001 par value per share (the “Reverse Stock Split”).

The Company effected a reverse stock split on November 6, 2023 at 4:01pm Eastern Time of its issued and outstanding shares of Class A Common Stock, which was previously approved by stockholders at the Company’s annual meeting of stockholders held on May 26, 2023 to regain compliance with Section 1003(f)(v) of the NYSE Company Guide.

Trading reopened on November 7, 2023, which is when the Common Stock began trading on a post-split basis. All share information included in this Form 10-Q has been reflected as if the reverse stock split occurred as of the earliest period presented.

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

~~Forward~~Finders Fee Agreement with J. H. Darbie

On October 16, 2023, the Company filed a Current Report on Form 8-K. The disclosure references the cash fees to be paid to, and the warrants to be issued to, J.H. Darbie & Co., Inc. (the “Finder”), pursuant to the terms of the Finder’s Fee Agreement, dated as of October 9, 2023 (the “Finder Agreement”), by and between the Company and the Finder.

The Finder, a registered broker-dealer, acted as a finder in connection with the transactions contemplated by (i) that certain Strata Purchase Agreement, dated October 13, 2023, by and between the Company and ClearThink Capital Partners, LLC (“ClearThink”), as supplemented by that certain Supplement to Strata Purchase Agreement, dated as of October 13, 2023 (the “Strata Supplement”), by and between the Company and ClearThink (as supplemented by the Strata Supplement, the “Purchase Agreement”), and (ii) that certain Securities Purchase Agreement, dated October 13, 2023 (the “ClearThink SPA”), by and between the Company and ClearThink.

Pursuant to the terms the Finder Agreement, the Company will pay the Finder cash fees equal to (i) 4% of the gross proceeds received by the Company from the transactions contemplated by the Purchase Agreement and (ii) 7% of the gross proceeds received by the Company from the transactions contemplated by the ClearThink SPA.

The Company also agreed to issue to the Finder (i) a 5-year warrant to purchase 7,000 shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) (which is 7% warrant coverage based on the 100,000 shares of Class A Common Stock (the “Initial Shares”) to be issued in the first closing pursuant to the ClearThink SPA) within three days after the Initial Shares are issued to ClearThink, (ii) a 5-year warrant to purchase 7,000 shares of Class A Common Stock (which is 7% warrant coverage based on the 100,000 shares of Class A Common Stock (the “Additional Shares”) to be issued in the second closing pursuant to the ClearThink SPA) within three days after the Additional Shares are issued to ClearThink, and (iii) a 5-year warrant to purchase shares of Class A Common Stock equal to 1% warrant coverage based on the amount raised from the transactions contemplated by the Purchase Agreement. Each warrant will have an exercise price per share equal to $1.324 (which is 110% of $1.204, the closing price of the Class A Common Stock on October 13, 2023), and will be subject to anti-dilutive price protection and participating registration rights.

The term of the Finder Agreement is for 90 days (the “Term”) and both parties may terminate the Finder Agreement upon 5 days’ written notice. The Finder will be entitled to its finder’s fee if (i) during the 12 months following termination or expiration of the Finder’s Agreement, any third-party investor introduced to the Company by the Finder (an “Introduced Party”) purchases equity or debt securities from the Company or (ii) during the Term, an Introduced Party enters into an agreement to purchase securities from the Company which is consummated at any time thereafter.

Share awards granted to Mark White and Martin Ward

As previously disclosed within a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 19, 2023, the board of directors (the “Board”) of the Company appointed (i) Mark White to serve as Interim Chief Executive Officer of the Company and as a member of the Board pursuant to the terms of an employment agreement, dated as of September 19, 2023, by and between the Company and Mr. White, and (ii) Martin Ward to serve as Interim Chief Financial Officer of the Company pursuant to the terms of an employment agreement, dated as of September 19, 2023, by and between the Company and Mr. Ward.

On October 3, 2023, the Company granted Messrs. White and Ward each 250,000 shares of the Company’s Class A common stock, par value $0.0001 per share (“Class A Common Stock”), pursuant to the Company’s 2022 Equity Incentive Plan, as amended, in consideration of services rendered and to be rendered to the Company. The shares awarded are not subject to any performance or vesting criteria, are deemed fully earned as of the grant date and are not subject to forfeiture, even if their employment with the Company terminates for any reason. The Compensation Committee of the Board approved these award grants on October 3, 2023.

~~On November 11, 2022, the Forward Purchase~~

Foxo technologies inc. and subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

Master Software and Services Agreement ~~between Meteora and~~with KR8 AI Inc.

Effective January 12, 2024, the Company ~~was amended~~(the “Licensee”), entered into the Master Software and Services Agreement (this “Agreement”) with KR8 AI Inc., a Nevada corporation (the “Licensor”). Our Interim CEO and Interim CFO each are equity owners of the Licensor. Under the Agreement, the Licensor granted to ~~allow Meteora~~the Licensee a limited, non-sublicensable, non-transferable perpetual license to ~~retain 500,000~~use the “Licensor Products” listed in Exhibit A to the Agreement, to develop, launch and maintain license applications based upon Licensee’s epigenetic biomarker technology and software to develop an AI machine learning epigenetic app to enhance health, wellness and longevity. The territory of ~~shares~~the Agreement is solely within the U.S., Canada and Mexico.

Under the Agreement, the Licensee agreed to pay to the Licensor an initial license and development fee of $2,500, a monthly maintenance fee of $50, and an ongoing royalty equal to 15% of “Subscriber Revenues,” as ~~maturity consideration associated~~defined in the Agreement, in accordance with the ~~Put Date. The agreement was terminated resulting in the settlement of the forward purchase derivatives, elimination of the forward purchase collateral,~~terms and ~~repurchase of the remaining shares~~ subject to the ~~Forward Purchase Agreement that Meteora had not already sold~~minimums set forth in the ~~open market and were not part~~schedules of the ~~maturity consideration.~~

~~CEO Severance~~

InAgreement. The Licensee agreed to reimburse the Licensor for all reasonable travel and out-of-pocket expenses incurred in connection with ~~his termination,~~ the ~~Company may be obligated~~performance of the services under the Agreement, in addition to payment of any applicable hourly rates. If the Licensee fails to timely pay the ~~former CEO cash severance equal to thirty-six months of his base salary. The Company is currently reviewing its obligations to~~“Minimum Royalty,” as defined in the ~~CEO~~Agreement, due with respect to ~~compensation~~any calendar year, the License will become non-exclusive.

The initial term of this Agreement commences on the effective date of the Agreement. Unless terminated earlier in accordance with the terms, the Agreement will be perpetual. Either party may terminate the Agreement, effective on written notice to the other party, if the other party materially breaches this Agreement, and ~~severance..~~such breach remains uncured 30 days after the non-breaching party provides the breaching party with written notice of such breach, in which event, the non-breaching party will then deliver a second written notice to the breaching party terminating this Agreement, in which event the Agreement, and the licenses granted under the Agreement, will terminate on the date specified in such second notice. Either party may terminate the Agreement, effective immediately upon written notice to the other party, if the other party: (i) is unable to pay, or fails to pay, its debts as they become due; (ii) becomes insolvent, files or has filed against it, a petition for voluntary or involuntary bankruptcy or otherwise becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law; (iii) makes or seeks to make a general assignment for the benefit of its creditors; or (iv) applies for or has appointed a receiver, trustee, custodian, or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business.

Licensee may terminate the Agreement at any time upon 90 days’ notice to the Licensor provided that, as a condition to such termination, the Licensee immediately ceases using any Licensor Products. The Licensor may terminate the Agreement at any time upon 30 days’ notice to the Licensee if the Licensee fails to pay any portion of the “Initial License Fee,” as defined in the Agreement.

Under the Agreement, on January 19, 2023, the Company issued 1,300,000 shares of Common Stock to the Licensor.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References to the “Company,” “us,” “our” or “we” refer to FOXO Technologies Inc. and its consolidated subsidiaries. The following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity, capital resources and cash flows of our Company as of and for the periods presented below. ~~The~~You should read the following discussion ~~should be read~~of our financial condition and results of operations in conjunction with ~~our unaudited~~the condensed consolidated financial statements and the related notes included ~~under “Item 1. Financial Statements”~~elsewhere in this ~~Quarterly~~Form 10-Q and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC. In addition to our historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Form 10-Q, ~~(the “Report”).~~particularly in Part II, Item 1A, “Risk Factors.” We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future. Dollar amounts are in thousands, unless otherwise noted.

~~Cautionary Note Regarding Forward-Looking Statements~~Overview

This report contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available, to our management. The words such “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Actual results could differ materially from those contemplated by the forward-looking statements

Factors that could cause or contribute to such differences include, but are not limited to, those identified below, in Item 2 of this Report and those set forth in the final joint proxy statement/consent solicitation statement/prospectus filed by Delwinds Insurance Acquisition Corp, filed with the SEC on August 30, 2022 (the “Proxy Statement”) under caption “Risk Factors.” Some of the risks and uncertainties we face include:

	●	~~we have a history of losses and it may not achieve or maintain profitability in the future;~~

	●	our independent registered public accounting firms have included an explanatory paragraph relating to our ability to continue as a going concern, which could limit our ability to raise additional capital;

	●	~~we will require additional capital to commercialize our product and service offerings and grow our business, which may not be available on terms acceptable to us or at all;~~

	●	~~the loss of the services of our current executives or other key employees, or failure to attract additional key employees;~~

	●	~~the strength of our brands and our ability to develop, maintain and enhance our brands and our ability to develop and expand our customer base;~~

	●	~~access to the substantial resources to continue the development of new products and services;~~

	●	~~our ability to integrate molecular biotechnology into the life insurance industry;~~

	●	our ability to commercialize our technology enabled products and services with a high level of service at a competitive price, achieve sufficient sales volumes to realize economies of scale and create innovative new products and services to offer to our customers;

●

~~our ability to effectively and in a cost-feasible manner acquire, maintain and engage with our targeted customers;~~

	●	~~the impact on our business of security incidents or real or perceived errors, failures or bugs in our systems and/or websites;~~

	●	~~the impact of changes in the general economic conditions;~~

●

~~the impact of the continuation of the COVID-19 pandemic;~~

●

~~our plans to expand operations abroad, through planned partnerships with international life insurance carriers;~~

	●	~~our success and ability to establish and grow our epigenetic testing service and the development of epigenetic biomarkers for use in life insurance underwriting;~~

	●	~~our ability to apply the relatively new field of epigenetics to life insurance underwriting;~~

	●	~~our ability to validate and improve the results of our 2019 Pilot Study;~~

	●	~~the impact of competition in the personal health and wellness testing market;~~

	●	~~our ability to procure materials and services from third-party suppliers for our epigenetic testing services;~~

●

our ability to maintain compliance now or in the future to laws and regulations relating to laboratory testing, our underwriting technology and consumer engagement services and our use of saliva-based epigenetic biomarkers;

●

~~our ability to maintain focus on our main business line initiatives, while providing ancillary product and service offerings that support our baseline technology;~~

	●	~~our ability to satisfy the regulatory conditions that our life insurance business operates in;~~

	●	~~the ability to contract or maintain MGA (as defined below) relationships from selling life insurance products underwritten and issued by third-party carriers;~~

	●	~~our success and ability to establish and grow our MGA Model (as described below);~~

	●	~~the impact of an overall decline in life insurance product sales;~~

	●	~~competition in the life insurance industry;~~

	●	~~our ability to establish relationships necessary to execute on our business plans;~~

	●	~~our ability to underwrite risks accurately and charge competitive yet profitable premium rates;~~

	●	~~the dependence on search engines, social media platforms, content-based online advertising and other online sources to attract customers to our website;~~

	●	~~the impact of interruptions or delays in the service of our internet service providers;~~

	●	~~our ability to comply with customer privacy and data privacy and security laws and regulations;~~

	●	~~our ability to prevent or address the misappropriation of our data;~~

	●	~~our ability to comply with current and changes to the extensive insurance industry regulations in each state that we operate;~~

	●	~~our ability to maintain FOXO Life Insurance Company’s risk-based capital at the required levels;~~

	●	~~the impact of new legislation or legal requirements affecting how we communicate with our customers;~~

	●	~~our ability to retain our license for patent pending methods of identifying epigenetic biomarkers and identifying saliva-based epigenetic biomarkers or intellectual property in general;~~

	●	~~our ability to obtain sufficiently broad protection of our intellectual property throughout the world;~~

	●	~~the impact of changes in trademark or patent law in the United States and other jurisdictions;~~

	●	the impact of claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secret of their former employees;

	●	~~our ability to successfully register and enforce our trademarks;~~

	●	~~the impact of claims challenging the inventorship of our patents and other intellectual property;~~

	●	~~the impact of costs and expenses if we become involved in trademark or patent litigation or other proceedings;~~

	●	~~the adequacy of our patent terms to protect our competitive position; and~~

●

~~the risks to our proprietary software and source code from our use of open source software.~~

~~Overview~~

We are ~~a technology platform company~~ focused on commercializing health and longevity science into products and ~~services~~services. To that ~~serve~~end, FOXO is focusing its efforts on research and development but also extending its expertise in epigenetic data processing and analysis to outside groups in an effort to accelerate new discoveries. As an established hallmark of aging, we believe that epigenetics has unique and impactful capabilities pertaining to health and longevity that have yet to be unlocked. Since there remain more questions than any one team can answer, we offer our unique skill set to other researchers and partners by selling our Bioinformatics Services, which fills a major gap in the ~~life insurance industry. The products~~biomarker discovery pipeline. In conjunction with the maturation of tools to facilitate epigenetics research, recent growth in using artificial intelligence has created what we believe is an unprecedented opportunity to disrupt health testing. While our research and ~~services we are~~development is focused on developing ~~combine longevity science with life insurance~~new health testing using epigenetics and more, the core business enables the scientific community and industry by bringing to ~~simplify~~market new tools (software and hardware) and know-how (Bioinformatics Services and analytic consulting) to reduce barriers for the ~~consumer underwriting journey. Our goal is to make healthy longevity fundamental to the promise~~advancing of ~~every life insurance policy sold. We believe our products~~epigenetic research and ~~services address long-standing, core problems within the life insurance industry.~~products.

~~To simplify~~Historically, we have had two core product offerings: the ~~consumer underwriting journey, we are commercializing epigenetic biomarker technology~~“Underwriting Report,” and the “Longevity Report™.” The Underwriting Report, which has been under development and is currently paused, is intended to ~~offer~~allow us to leverage a single assay testing process to generate a panel of impairment scores that could be applied by life insurance ~~carriers~~underwriters to more efficiently assess clients during the underwriting process and provide a ~~saliva-based underwriting solution. Our underwriting technology seeks~~more personalized risk assessment. The Longevity Report, sales of which have also been paused as we redevelop and strategize around this product, was designed as a consumer-facing life insurance companion product that provided actionable insights to ~~platform seeks to incorporate saliva-based~~consumers based on their biological age and other epigenetic ~~biomarkers~~measures of ~~molecular~~ health and ~~aging to address the single biggest pain point in the industry according to the Life Insurance Marketing and Research Association or LIMRA.~~

To support consumer health and wellness engagement, we are also developing an insurance products platform, called FOXO Life, that seeks to incorporate our consumer engagement and underwriting technology to create new reasons to purchase life insurance with “Life Insurance Designed to Keep you Alive.”™ FOXO Life offers insurance products issued by third-party insurance carriers under a managing general agency (“MGA”) relationship (as described below). FOXO Life provides consumers with a personalized longevity report (which we refer to as our Longevity Report) based on proprietary epigenetic measurements of aging using an “epigenetic clock” (as described below). We believe the Longevity Report will help make longevity science core to the relationship between life insurance carriers, agents and consumers.

We expect FOXO Life to earn commission revenues, marketing allowances, and service fees by selling longevity science driven insurance products to consumers directly and through independent insurance agents. Initially, we do not expect to use epigenetic underwriting technology in the life insurance products FOXO Life sells. However, we expect the research and development studies underway will support the introduction and commercialization of our saliva-based underwriting technology in 2023. FOXO Life will be launching at a time when consumer interest in life insurance has increased due to the COVID-19 pandemic and when innovative applications of technology and molecular biotechnology are ripe to disrupt the industry.

~~We believe linking healthy longevity with life insurance provides agents with a new and meaningful way to engage consumers in life insurance coverage to protect their families’ financial futures.~~

~~FOXO Labs – Underwriting Technology~~wellness.

FOXO Labs is commercializing proprietary, patent pending, epigenetic biomarker technology to assess the same underwriting factors used in life insurance underwriting today from a saliva specimen. We believe our underwriting technology can address the core industry pain point of medical underwriting. Medical underwriting is the dominant form of assessing the relative health and longevity of insurance applicants and it is lengthy and invasive, and includes blood and urine specimen collection requirements. Insurance carriers prefer medical underwriting because it offers accurate mortality risk classifications. Our research with insurance agents indicates that medical underwriting is a significant impediment to sales, detracting agents from selling and consumers from buying life insurance. We believe that our saliva-based underwriting technology, when paired with advances in accelerated underwriting protocols, will offer insurance carriers the same, or better, risk classifications as medical underwriting. We also believe that once our saliva-based underwriting is adopted by carriers, it will have a sentinel effect within the industry that will further drive carriers to adopt our technology. We have observed that changes in life insurance industry underwriting happen infrequently, but when new innovations are introduced, adoption can be rapid and pervasive, such as when prescription data became available, blood testing became a requirement, or when smoker / non-smoker tables were adopted. We believe our saliva-based underwriting technology can follow a similar adoption pathway to prior underwriting innovations and generate significant services fee revenues.

~~FOXO Life - Insurance Sales and Distribution~~

~~FOXO Life is~~has been operationalizing a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with our Longevity Report. FOXO ~~Life markets~~has marketed and ~~sells~~sold life insurance products underwritten and issued by third-party carriers through distribution relationships. This distribution model (the “MGA ~~relationships with two~~Model”) allowed FOXO to appoint sales agents and producers to sell insurance ~~carriers: Assurity Life~~products for specific carriers and ~~Haven Life.~~earn commissions on subsequent policy sales. Depending on the terms of the agreement between FOXO and the carrier, the Longevity Report may have been included at the time of the policy purchase at no charge or may be available at an additional cost to the consumer. We ~~plan~~believed the Longevity Report will make longevity science a core aspect to ~~continue expanding FOXO Life through additional MGA relationships to include~~ the ~~various types of term and permanent~~relationship between life insurance ~~products. MGA relationships allow us to earn commission revenues, marketing allowances,~~ and service fees from the sale of insurance products sold by independent insurance agents. Independent insurance agents were responsible for 49% of all life insurance premiums sold in the United States in 2020 according to LIMRA. We expect revenues generated from our MGA product sales through independent agents to be a meaningful contributor to our business. We believe our MGA distribution relationships are critical to enabling us to introduce of our epigenetic underwriting technology into the products we sell.

We are commencing operations with systems that we believe allow for significant scaling at a time when we observe (i) burgeoning consumer interest in health and longevity; (ii) increased interest in life insurance due the COVID-19 pandemic; and (iii) a significant opportunity to disrupt a large, old, and slow life insurance industry with innovative applications of fast-moving modern technology. We believe our products and services can help reverse a general decline in household ownership of life insurance in the United States by providing a simplified pathway to purchase life insurance with longevity focused products that re-establish their relevance with consumers and restore life insurance as a tool for greater social good.

~~Business Trends~~

●

~~Life Insurance Demand.~~According to the 2021 Insurance Barometer Study, there are significant increases in consumer interest and demand for life insurance, with nearly one-third (31%) of consumers surveyed reporting COVID-19 makes them more likely to purchase life insurance within the next 12 months. In addition, the study reported the first sales gains in life insurance since 1983 and described that 22% of Americans (29 million consumers) owning life insurance believe they need more coverage and 59% of Americans (73 million consumers) without life insurance say they would like to acquire coverage. That means 102 million Americans say they either need life insurance coverage or want more of it. The study identified Millennials (ages 22-40) as the demographic most influenced by the pandemic, with 48% surveyed saying they plan to purchase coverage in the next year. Thus, despite the record-low household ownership of life insurance, the 2021 Insurance Barometer Study indicates Americans’ intent to purchase life insurance is at an all-time high.

consumers.

●

~~Product Innovation.~~ As life insurance carriers and distributors look to engage consumers renewed interest in life insurance coverage, industry analysts suggest that life insurance can succeed by adopting technology to (i) personalize every aspect of the consumer experience, transition from a traditional “assess and service” model toward a customer-centric “prescribe and prevent” model of health management; and (ii) develop innovative product solutions that place emphasis on product flexibility and innovation, including value-added services and nonmonetary benefits to attract consumers. Other analysts point to the need to reduce sales friction for both consumers and agents that stems from long underwriting timelines as a result of invasive blood and urine specimen collection.

Segments

We manage and classify our business into two reportable business segments:

~~(i)~~

~~Insurance Services Platform: FOXO Labs~~

(i) FOXO Labs

FOXO Labs performs research and development and is commercializing proprietary epigenetic biomarker technology to be used for mortality underwriting risk classification in the global life insurance industry. Our innovative biomarker technology enables the adoption of new saliva-based health and wellness biomarker solutions for underwriting and risk assessment.technology. Our research demonstrates that epigenetic biomarkers, collected from saliva or blood, provide meaningful measures of ~~individual~~ health and ~~wellness factors used in life insurance underwriting traditionally obtained through blood~~lifestyle of individuals. FOXO Labs anticipates recognizing revenue related to sales of its Bioinformatics Services and ~~urine specimens.~~from the commercialization of research and development activities, which may include the Underwriting Report, Longevity Report, or as a result of other commercialization opportunities.

FOXO Labs currently recognizes revenue from providing epigenetic testing services and collecting a royalty from Illumina, Inc. related to the sales of the Infinium Mouse Methylation Array. ~~The Company’s saliva-based health and wellness testing solutions for underwriting and risk classification is expected to be its largest source of revenue.~~ FOXO Labs conducts research and development, and such costs are recorded within research and development expenses on the condensed consolidated statements of operations.

~~(ii)~~

~~Insurance Services Platform: FOXO Life~~

FOXO Labs had operated its Bioinformatics Services as an ancillary offering, with revenue recognized as epigenetic biomarker services in our historical financial statements, but now looks to it as a primary offering. Bioinformatics Services provide a data processing, quality checking, and data analysis service using FOXO’s cloud-based bioinformatics pipeline, referred to as our epigenetics, longevity, or methylation pipeline in our historical financial statements. FOXO Labs accepts raw data from third party labs and converts that data into usable values for customers.

(ii) FOXO Life

FOXO Life ~~is redefining~~sought to redefine the relationship between consumers and ~~insurer~~insurers by combining life insurance with healthy longevity. ~~FOXO Life seeks to transform the value proposition~~The distribution of ~~the life~~ insurance ~~carrier from a provider of mortality risk protection~~ products ~~to a promoter of its customers’ health and wellness. FOXO Life’s~~that may be paired with FOXO’s Longevity Report ~~strives~~strived to provide life insurance consumers with valuable information and insights about their individual health and wellness.

FOXO Life ~~currently~~primarily has residual commission revenues from its legacy insurance agency business. FOXO Life ~~expects to begin selling insurance products under a MGA relationship with a national carrier partner in the first quarter of 2023. FOXO Life anticipates~~has also begun receiving insurance ~~commission~~commissions from the distribution and sale of life insurance policies based on the size and type of policies sold to customers. FOXO Life costs are recorded within selling, general and administrative expenses on the condensed consolidated statements of operations.

~~Acquisition~~As of ~~Insurance Entity~~October 19^th, 2023, we made the decision to sell certain assets of FOXO Life and terminate this business activity due to sustained losses.

~~We completed~~FOXO Life Insurance Company

Due to market conditions, our ~~acquisition~~capitalization following the Business Combination did not materialize in the way the Company anticipated, and we did not possess the funding that we believed would be required to satisfy state regulations and regulatory bodies to issue new life insurance policies through FOXO Life Insurance Company. As such, we decided to not move forward with the launch of FOXO Life Insurance Company.

On January 10, 2023, we entered into a merger agreement (the “Security National Merger Agreement”) with Security National Life Insurance Company, a Utah corporation (the “Security National”), FOXO Life, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“FOXO Life”), and FOXO Life Insurance Company (fka Memorial Insurance Company of America (“~~MICOA”~~MICOA”) ~~on August 20, 2021. Purchase consideration for~~), an Arkansas corporation and wholly-owned subsidiary of the ~~acquisition~~Seller, pursuant to which, subject to the terms and conditions of ~~MICOA totaled $1,155, which included an indefinite-lived insurance license intangible asset recorded at~~the Security National Merger Agreement, the Company agreed to sell FOXO Life Insurance Company to Security National. Specifically, pursuant to the Security National Merger Agreement, FOXO Life Insurance Company merged with and into the Security National, with Security National continuing as the surviving corporation.

On February 3, 2023 (the “Closing Date”), we consummated the sale of FOXO Life Insurance Company to Security National pursuant to the Security National Merger Agreement. As a ~~fair value~~result of ~~$63~~the merger, the Company is no longer required to hold cash and cash ~~of $1,092. We fair valued reinsurance recoverables and policy reserves~~equivalents required to be held as ~~part of the acquisition. The existing~~ statutory capital and surplus, ~~remains with us post-acquisition. The approval by~~as required under the Arkansas Insurance ~~Department requires us~~Code (the “Arkansas Code”).

At the closing, all of FOXO Life Insurance’s shares were cancelled and retired and ceased to ~~maintain~~exist in exchange of an amount equal to FOXO Life Insurance’s statutory capital and surplus amount of ~~no less than $5,000~~$5,002 as of the Closing Date, minus $200 (the “Merger Consideration”).

After the Merger Consideration and ~~a risk-based capital ratio of 301% or greater~~Security National’s third party expenses, the transaction resulted in the ~~regulated insurance entity. MICOA has been renamed FOXO Life Insurance Company.~~Company gaining access to $4,751 that was previously held as statutory capital and surplus pursuant to the Arkansas Code.

As part of the transaction, the former owners of MICOA continue to administer and 100% reinsure all policies outstanding as of the acquisition date. FOXO Life Insurance Company has not issued any new insurance policies since the acquisition and all premiums, reinsurance recoverables, and policy reserves relate to the 100% reinsured business. FOXO Life Insurance Company remains liable only in the event the reinsuring company is unable to meet its obligations under the reinsurance agreement.

FOXO Life Insurance Company is required to prepare statutory financial statements in accordance with statutory accounting practices prescribed or permitted by the Arkansas Insurance Department. The activity of FOXO Life Insurance Company post-acquisition is included in the consolidated financial statements in accordance with generally accepted accounting principles.

~~For additional information concerning FOXO Life Insurance Company operations, see “~~~~Recent Developments – FOXO Life Insurance Company~~~~” below.~~

Comparability of Financial Results

On September 15, 2022, we consummated the transactions contemplated by the ~~Agreement and Plan of~~ Merger dated as of February 24, 2022, as amended on April 26, 2022, July 6, 2022 and August 12, 2022 (the “Merger Agreement”), with FOXO Technologies Inc., now known as FOXO Technologies Operating Company (“FOXO Technologies Operating Company”), DWIN Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Delwinds (“Merger Sub”), and DIAC Sponsor LLC (the “Sponsor”), in its capacity as the representative of the stockholders of Delwinds from and after the closing (the “Closing”) (collectively, the “Transaction” or the “Business Combination”).Agreement. Immediately upon the Closing, the name of the combined company was changed to FOXO Technologies Inc.

FOXO Technologies Operating Company (“Legacy FOXO”) was determined to be the accounting acquirer in the Business Combination. Accordingly, the acquisition of Legacy FOXO ~~Technologies Operating Company~~ by the Company was accounted for as a reverse recapitalization. Under this method of accounting, the Company was treated as the acquiree for financial reporting purposes. The net assets of the Company were stated at their historical cost, with no goodwill or other separately identifiable intangible assets recorded. The balance sheet, results of operations and cash flows prior to the Business Combination are those of ~~FOXO Technologies Operating Company.~~

Simultaneously with the execution of the Merger Agreement, Delwinds entered into a Common Stock Purchase Agreement (the “ELOC Agreement”) with CF Principal Investments LLC (the “Cantor Investor”), pursuant to which, assuming satisfaction of certain conditions and subject to limitations set forth in the ELOC Agreement, the Company would have the right, from time to time to sell the Cantor Investor up to $40,000 in shares of the Company’s Class A common stock (the “Class A Common Stock”) until the first day of the next month following the 36-month anniversary of when the SEC has declared effective a registration statement covering the resale of such shares of Class A Common Stock or until the date on which the facility has been fully utilized, if earlier.Legacy FOXO.

In accordance with the terms of the Merger Agreement, at Closing, the Company (i) acquired 100% of the issued and outstanding Legacy FOXO ~~Technologies Operating Company~~ Class A common stock (the ~~“FOXO~~“FOXO Class A Common ~~Stock”~~Stock”) in exchange for equity consideration in the form of the Company’s Class A Common Stock, (ii) acquired 100% of the issued and outstanding shares of Legacy FOXO ~~Technologies Operating Company~~ Class B common stock (the ~~“FOXO~~“FOXO Class B Common ~~Stock”~~Stock”) in exchange for equity consideration in the form of the Company’s Class A Common Stock.

Immediately prior to the Closing, the following transactions occurred:

●

~~8,000,000~~800,000 shares of Legacy FOXO ~~Technologies Operating Company~~ Series A preferred stock (the ~~“FOXO~~“FOXO Preferred ~~Stock”~~Stock”) were exchanged for ~~8,000,000~~800,000 shares of FOXO Class A Common Stock.

●

The 2021 Bridge Debentures ~~(as defined in Note 5 to our unaudited consolidated financial statements)~~ in the principal amount, together with accrued and unpaid interest, of $24,402 were converted into ~~6,759,642~~676,007 shares of FOXO Class A Common Stock.

●

The ~~holders of the~~ 2022 Bridge Debentures ~~(as defined in Note 5 to our unaudited consolidated financial statements)~~ in the principal amount, together with accrued and unpaid interest, of $34,496 were converted into ~~7,810,509~~781,053 shares of FOXO Class A Common Stock.

As a result of and upon the Closing, among other things, (1) all outstanding shares of FOXO Class A Common Stock (after giving effect to the conversion of the FOXO Preferred Stock into shares of FOXO Class A Common Stock) and FOXO Class B Common Stock were converted into ~~15,518,705~~1,551,874 shares of the Company’s Class A Common Stock, (2) all FOXO options and FOXO warrants outstanding immediately before the Closing (“Assumed ~~Options”~~Options” and ~~“Assumed Warrants”~~“Assumed Warrants”, as applicable) were assumed and converted, subject to adjustment pursuant to the terms of the Merger Agreement, into options and warrants, respectively, of the Company, exercisable for share of the Company’s Class A Common Stock and (3) other than the Assumed Options and Assumed Warrants, all other convertible securities and other rights to purchase capital stock ofLegacy FOXO ~~Technologies Operating Company~~ were retired and terminated, if they were not converted, exchanged or exercised for Legacy FOXO ~~Technologies Operating Company~~ stock immediately prior the Closing.

Recent Developments

~~FOXO Life Insurance~~Asset Impairment

In April of 2023 and as part of the Company’s planning, the Company finalized its objectives and key results (“OKRs”) for the second quarter of 2023. As part of the OKR process, the Company’s goals to support the digital insurance platform indicated that the manner in which the digital insurance platform is used and corresponding cash flows would no longer support the asset. Accordingly, the Company recognized a $1,425 impairment loss in April of 2023 representing the remaining unamortized balance of the digital insurance platform at the date of impairment.

In ~~connection with~~June of 2023, the ~~Business Combination, we submitted various filings with~~Company determined that both the ~~Arkansas Insurance Department (the “Department”) to ensure compliance with Arkansas insurance laws. After review~~underwriting API and ~~analysis of the relevant documentation and meetings with us, on September 9, 2022, the Department advised us that~~longevity API were fully impaired as it ~~concluded that the Business Combination did not require approval~~no longer forecasted positive cash flows from the ~~Department given that there was no change in~~Longevity Report or Underwriting Report. For the ~~ultimate controlling party. Due to market conditions, our capitalization following the Business Combination did not materialize in the way~~Longevity Report, the Company ~~anticipated,~~sells the product at cost. For the Underwriting Report, the Company no longer expects sales during the amortization period. Accordingly, the Company has determined the assets are not recoverable and ~~we do not currently possess~~ the ~~funding that we believe would be required to satisfy state regulations~~cash flows no longer support the assets. The Company recognized impairment charges of $630 and ~~regulatory bodies to issue new life insurance policies through FOXO Life Insurance Company. As such, we will not move forward with~~$578 for the ~~launch of FOXO Life Insurance Company~~underwriting API and plan to evaluate opportunities relating to this entity that we believe will enhance stockholder value. The outstanding policies issued by FOXO Life Insurance will continue to be administered and reinsured by the former owners of MICOA. We intend to focus on selling products issued by third-party carriers through our MGA Model (as described above).longevity API, respectively.

~~ELOC Agreement~~Layoffs

On ~~November 8, 2022,~~July 21, 2023, the Company reduced its employee headcount via layoffs from 22 employees to 15 employees. In September and CF Principal Investments LLC (the “Cantor Investor”) mutually terminated ELOC Agreement. Upon the termination of the ELOC Agreement, the related Registration Rights Agreement, dated as of February 24, 2022 (the “Registration Rights Agreement”), by and betweenOctober a further 11 staff left the Company, leaving a headcount remaining of 4 employees. These layoffs will allow the Company to reduce its operating expenses while tailoring its strategic focus towards initiatives such as its Bioinformatics Services as described below.

Longevity Report

The Company’s data models were developed using a specific array and our provider now has an updated array. The Company needs to recompute the ~~Cantor Investor was automatically terminated~~data models. Additional content is also being developed as a result of market research findings. The Longevity Report is currently on hold as a result of these developments.

Bioinformatics Services

On July 19, 2023, the Company announced the launch of Bioinformatics Services. Bioinformatics Services offers a comprehensive platform of advanced data solutions tailored to meet the specific needs of clients in ~~accordance~~academia, healthcare, government, and pharmaceutical research.

Business Plan

The Company is in the process of reviewing its strategic goals. The recent layoffs allowed the Company to reduce its operating expenses while tailoring its strategic focus towards initiatives such as the Company’s recently announced Bioinformatics Services, which offers epigenetic data processing and analysis. The Company anticipates a continued focus on epigenetics and longevity while expanding its focus outside of life insurance and more on health and wellness.

2023 Private Placement

From July 14, 2023 through July 20, 2023 (each such date, a “First Tranche Closing Date”), the Company entered into three separate Stock Purchase Agreements (the “Stock Purchase Agreements”), which have substantially similar terms, with ~~its terms.~~ three accredited investors (the “Buyers”), pursuant to which the Company agreed to issue and sell to the Buyers, in a private placement (the “2023 Private Placement”), in two separate tranches each, an aggregate of up to 562,500 shares of Class A Common Stock at a price of $0.80 per share, for aggregate gross proceeds of $450. The Company anticipates that the aggregate net proceeds from the 2023 Private Placement, after deducting placement agent fees and other offering expenses, will be approximately $260.

Pursuant to the terms of the ~~ELOC Agreement,~~Stock Purchase Agreements, the ~~Company issued 190,476~~Buyers initially purchased an aggregate of 281,250 shares of Class A Common Stock toon the ~~Cantor Investor~~applicable First Tranche Closing Dates, and purchased an aggregate of 281,250 additional shares of Class A Common Stock on ~~September 16, 2022 as consideration for its irrevocable commitment to purchase~~August 4, 2023, following the effectiveness of the registration statement on Form S-1 (File No. 333-273377) covering all of the shares of Class A Common Stock ~~upon~~issued in the 2023 Private Placement, which occurred on August 3, 2023.

On August 23, 2023, the Company entered into three additional Stock Purchase Agreements (the “Second Round SPAs”) and Registration Rights Agreements (the “Second Round RRAs”), with the Buyers, pursuant to which the Company issued and sold to the Buyers, in the second round of the 2023 Private Placement (the “2023 PIPE Second Round”), in two separate tranches each, an aggregate of 366,876 shares of Class A Common Stock at the Per Share Price for aggregate gross proceeds of $293.5 and aggregate net proceeds of approximately $217, after deducting placement agent fees and other offering expenses. Pursuant to the terms of the Second Round SPAs, the Buyers initially purchased an aggregate of 183,438 shares of Class A Common Stock on August 23, 2023, and ~~subject~~purchased an aggregate of 183,438 additional shares of Class A Common Stock on September 7, 2023, following the effectiveness of the Second Resale Registration Statement (as defined below).

The terms of the Second Round SPAs and the Second Round RRAs are substantially similar to the ~~satisfaction~~terms of the ~~conditions set forth~~SPAs and the RRAs, respectively; provided that the Second Round RRAs required the Company to file a resale registration statement covering all of the shares of Class A Common Stock issued in the ~~ELOC Agreement. The corresponding prepaid offering costs were expensed upon termination~~2023 PIPE Second Round within two (2) calendar days following the execution of the ~~agreement.~~RRA. The Company filed a registration statement on Form S-1 (File No. 333-274221) (the “Second Resale Registration Statement”) on August 25, 2023, covering all of the shares of Class A Common Stock issued in the 2023 PIPE Second Round, which was declared effective by the SEC on September 6, 2023.

~~Forward Purchase Agreement~~Exchange Offer, PIK Note Offer to Amend and 2022 Bridge Debenture Release

On ~~November 11, 2022,~~May 26, 2023, we consummated two issuer tender offers: (i) the ~~Forward Purchase Agreement between Meteora~~Offer to Exchange Warrants to Acquire Shares of Class A Common Stock and Consent Solicitation, commenced on April 27, 2023 (the “Exchange Offer”), pursuant to which we offered all holders of Assumed Warrants 48.3 shares of Class A Common Stock in exchange for each Assumed Warrant tendered and (ii) the ~~Company was amended~~Offer to ~~allow Meteora~~Amend 15% Senior Promissory Notes and Consent Solicitation, commenced on April 27, 2023 (the “PIK Note Offer to ~~retain 500,000~~Amend”), pursuant to which we offered all holders of our 15% Senior Promissory Notes (the “Senior PIK Notes”) 0.125 shares ~~as maturity consideration associated with~~of Class A Common Stock for every $1.00 of the ~~Put Date~~Original Principal Amount (as defined in the ~~Forward~~Senior PIK Notes) of such holder’s Senior PIK Notes, in exchange for the consent by such holder of Senior PIK Notes to amendments to the Senior Promissory Note Purchase ~~Agreement)~~Agreement, dated September 20, 2022, between us and each purchaser of Senior PIK Notes (the “PIK Note Purchase Agreement”). The ~~agreement was terminated resulting in~~Exchange Offer and the ~~settlement of~~PIK Note Offer to Amend each expired at 11:59 p.m., Eastern Time, on May 26, 2023 (the “Exchange Offer Expiration Date” or the ~~forward purchase derivatives, elimination of the forward purchase collateral, and repurchase of the remaining shares subject~~“PIK Note Offer to ~~the Forward Purchase Agreement that Meteora had not already sold in the open market and were not part of the maturity consideration.~~

~~Management Changes~~

~~On November 14, 202 Jon Sabes and Steve Sabes were terminated~~Amend Expiration Date,” as the Company’s Chief Executive Officer and Chairman and Chief Operating Officer, respectively. We may be obligated to pay the former CEO cash severance equal to thirty-six months of his base salary. The Company is currently reviewing its obligations to the CEO with respect to compensation and severance. Tyler Danielson, who serves as the Company’s Chief Technology Officer, was named Interim Chief Executive Officer and principal executive officer, effectively immediately.applicable).

As part of the Exchange Offer, the Company also solicited consents from holders of the Assumed Warrants to amend and restate in its entirety the Securities Purchase Agreement, dated as of January 25, 2021 (the “Original Securities Purchase Agreement”), by and between Legacy FOXO (and assumed by the Company in connection with the Business Combination) and each purchaser of 12.5% Original Issue Discount Convertible Debentures issued in 2021 by Legacy FOXO (the “2021 Bridge Debentures”) and warrants to purchase shares of FOXO Class A Common Stock, as amended (together with the 2021 Bridge Debentures, the “Original Securities”) identified on the signature pages thereto, which governs all of the Assumed Warrants and the Original Securities (together with the Assumed Warrants, the “Securities”), pursuant to the terms of an Amended and Restated Securities Purchase Agreement (the “Amendment and Restatement”), to provide that the issuance of shares of Class A Common Stock and certain issuances of Common Stock Equivalents (as defined in the Original Securities Purchase Agreement) in connection with the Exchange Offer, the PIK Note Amendment (as defined below), the 2022 Bridge Debenture Release (as defined below), a Private Placement (as defined below) and a Public Financing (as defined below), and as Private Placement Additional Consideration (as defined below), as well as any previous issuance of Class A Common Stock or Common Stock Equivalents (as defined in the Original Securities Purchase Agreement), do not trigger, and cannot be deemed to have triggered, any anti-dilution adjustments in the Securities.

In order to tender Assumed Warrants in the Exchange Offer, holders were required to consent to the Amendment and Restatement and a general release (the “Exchange Offer General Release Agreement”). Holders who tendered their Assumed Warrants in the Exchange Offer were deemed to have authorized, approved, consented to and executed the Amendment and Restatement and the Exchange Offer General Release Agreement.

The consummation of the Exchange Offer was conditioned upon, among other things, stockholder approval of the issuance of Class A Common Stock as required by NYSE American Company Guide Section 713, and that Assumed Warrants, the holders of which purchased at least 50.01% in interest of the 2021 Bridge Debentures based on the initial Subscription Amounts (as defined in the Original Securities Purchase Agreement) thereof (which is the minimum amount required to amend and restate the Original Securities Purchase Agreement), are tendered in the Exchange Offer.

An aggregate of 164,751 Assumed Warrants were tendered in the Exchange Offer, the holders of which purchased at least 50.01% in interest of the 2021 Bridge Debentures based on the initial Subscription Amounts thereof. The Company’s stockholders approved the issuance of Class A Common Stock in connection with the Exchange Offer at the Company’s 2023 Annual Meeting of Stockholders held on May 26, 2023 (the “Annual Meeting”). We issued an aggregate of 795,618 shares of Class A Common Stock to the holders of Assumed Warrants who participated in the Exchange Offer, on the terms and subject to the conditions of the Exchange Offer. The Amendment and Restatement and the Exchange Offer General Release Agreement are each effective as of the Exchange Offer Expiration Date. As of January 19, 2024, there are 25,868 shares of Class A Common Stock issuable upon exercise of outstanding Assumed Warrants.

Pursuant to the PIK Note Offer to Amend, the Company solicited approval from holders of Senior PIK Notes to amend the PIK Note Purchase Agreement to permit the following issuances by the Company of Class A Common Stock and Common Stock Equivalents (as defined in the PIK Note Purchase Agreement) without prepaying the Senior PIK Notes: (i) the issuance of shares of Class A Common Stock in connection with the PIK Offer Note Offer to Amend, (ii) the issuance of shares of Class A Common Stock in connection with the Exchange Offer, (iii) the issuance of shares of Class A Common Stock or Common Stock Equivalents (as defined in the PIK Note Purchase Agreement) in connection with the 2022 Bridge Debenture Release (as defined below), (iv) the issuance of shares of Class A Common Stock or Common Stock Equivalents (as defined in the PIK Note Purchase Agreement) in (a) a private placement of the Company’s equity, equity-linked or debt securities resulting in gross proceeds to the Company no greater than $5 million (a “Private Placement”) and/or (b) a registered offering of the Company’s equity, equity-linked or debt securities resulting in gross proceeds to the Company no greater than $20 million (a “Public Financing”); provided that (A) the proceeds of a Private Placement resulting in gross proceeds to the Company of at least $2 million are used by the Company to prepay not less than 25% of the Outstanding Principal Balance (as defined in the Senior PIK Notes) as of the date of prepayment on a pro rata basis upon the closing of such Private Placement, and (B) the proceeds of a Public Financing resulting in gross proceeds to the Company of at least $10 million are used by the Company to prepay all of the Outstanding Principal Balance as of the date of prepayment upon the closing of such Public Financing, and (v) the issuance of shares of Class A Common Stock or Common Stock Equivalents (as defined in the PIK Note Purchase Agreement) as Private Placement Additional Consideration (as defined below) (collectively, the “PIK Note Amendment”).

In order to participate in the PIK Note Offer to Amend, in addition to consenting to the PIK Note Amendment, holders of Senior PIK Notes were required to consent to a general release (the “PIK Note Offer to Amend General Release Agreement”). Holders who participated in the PIK Note Offer to Amend were deemed to have authorized, approved, consented to and executed the PIK Note Amendment and the PIK Note Offer to Amend General Release Agreement.

The consummation of the PIK Note Offer to Amend was conditioned upon, among other things, stockholder approval of the issuance of Class A Common Stock as required by NYSE American Company Guide Section 713, and the receipt of consent of holders that purchased at least 50.01% in interest of the aggregate principal balance of the Senior PIK Notes (which is the minimum amount required to amend the PIK Note Purchase Agreement) (the “Majority Consent”).

All Senior PIK Note holders participated in the PIK Note Offer to Amend, and therefore Majority Consent was obtained. The Company’s stockholders approved the issuance of Class A Common Stock in connection with the PIK Note Offer to Amend at the Annual Meeting. We issued an aggregate of 432,188 shares of Class A Common Stock on a pro rata basis to the Senior PIK Note holders who participated in the PIK Note Offer to Amend, on the terms and subject to the conditions of the PIK Note Offer to Amend. The PIK Note Amendment and the PIK Note Offer to Amend General Release Agreement are each effective as of the PIK Note Offer to Amend Expiration Date.

Because the PIK Note Amendment was approved, if the Company conducts a Private Placement, each investor who participates in the Private Placement who was a holder of Assumed Warrants or Senior PIK Notes as of the commencement of the Exchange Offer or the PIK Note Offer to Amend, as applicable, and each former holder of 2022 Bridge Debentures, may receive additional shares of Class A Common Stock or Common Stock Equivalents (as defined in the Original Securities Purchase Agreement or the PIK Note Purchase Agreement, as applicable) in addition to the other terms of such Private Placement offered to all investors, whether or not such holder participated in the Exchange Offer or the PIK Note Offer to Amend, as applicable (the “Private Placement Additional Consideration”).

Additionally, we issued Class A Common Stock in exchange for a general release by the former holders of 10% Original Issue Discount Convertible Debentures issued in 2022 by Legacy FOXO (the “2022 Bridge Debentures”), which 2022 Bridge Debentures were automatically converted into Class A common stock of Legacy FOXO and exchanged by the Company for Class A Common Stock in connection with the Business Combination (the “2022 Bridge Debenture Release”). Each former holder of the 2022 Bridge Debentures that executed the 2022 Bridge Debenture Release received 0.067 shares of Class A Common Stock for every $1.00 of Subscription Amount (as defined in the securities purchase agreements governing the 2022 Bridge Debentures) of the 2022 Bridge Debentures previously held by such holder. Pursuant to the 2022 Bridge Debenture Release, two former holders of 2022 Bridge Debentures representing an aggregate Subscription Amount of $10,500,000 executed such general release, and we issued an aggregate of 703,500 shares of Class A Common Stock to such former holders of the 2022 Bridge Debentures.

The Company filed a registration statement on Form S-1, File No. 333-272892, covering all of the shares of Class A Common Stock issued pursuant to the Exchange Offer, the PIK Note Offer to Amend and the 2022 Bridge Debenture Release, which was declared effective by the SEC on July 6, 2023.

Delisting of Public Warrants

On May 15, 2023, NYSE American LLC (“NYSE American”) provided a written notice to the Company that NYSE American had halted trading in the Company’s warrants, each exercisable for one share of the Company’s Class A common stock at an exercise price per share of $115.00 (the “Public Warrants”), on NYSE American due to the low trading price of the Public Warrants. On May 16, 2023, NYSE American provided written notice to the Company and publicly announced that NYSE Regulation has determined to commence proceedings to delist the Public Warrants and that the Public Warrants are no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of the Public Warrants.

On May 24, 2023, the Public Warrants began trading on the OTC Pink Marketplace under the symbol “FOXOW”.

Compliance with NYSE American Continued Listing Requirements

On June 12, 2023, we received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation (“NYSE”) stating that we are below compliance with Section 1003(a)(i) in the NYSE American Company Guide (the “Company Guide”) since we reported stockholders’ deficit of $(30) at March 31, 2023, and losses from continuing operations and/or net losses in its two most recent fiscal years ended December 31, 2022. Section 1003(a)(i) of the Company Guide requires a listed company to have stockholders’ equity of $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years.

We are now subject to the procedures and requirements set forth in Section 1009 of the Company Guide. As required by the NYSE American Notice, on July 12, 2023, we submitted a plan (the “Plan”) to NYSE advising of actions we have taken or will take to regain compliance with the continued listing standards by December 12, 2024. If NYSE accepts the Plan, we will have an eighteen (18) month cure period to comply with the Plan and will be subject to periodic reviews including quarterly monitoring for compliance with the Plan. The NYSE American Notice has no immediate effect on the listing or trading of the Class A Common Stock on NYSE American. We intend to consider available options to regain compliance with the stockholders’ equity requirement, but no decisions have been made at this time. There can be no assurance that we will ultimately regain compliance with all applicable NYSE American listing standards.

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with U.S. GAAP, management periodically uses certain “non-GAAP financial measures,” as such term is defined under the rules of the SEC, to clarify and enhance understanding of past performance and prospects for the future. Generally, a non-GAAP financial measure is a numerical measure of a company’s operating performance, financial position or cash flows that excludes or includes amounts that are included in or excluded from the most directly comparable measure calculated and presented in accordance with U.S. GAAP. For example, non-GAAP measures may exclude the impact of certain items such as acquisitions, divestitures, gains, losses and impairments, or items outside of management’s control. Management believes that the following non-GAAP financial measure provides investors and analysts useful insight into our financial position and operating performance. Any non-GAAP measure provided should be viewed in addition to, and not as an alternative to, the most directly comparable measure determined in accordance with U.S. GAAP. Further, the calculation of these non-GAAP financial measures may differ from the calculation of similarly titled financial measures presented by other companies and therefore may not be comparable among companies.

Adjusted EBITDA provides additional insight into our underlying, ongoing operating performance and facilitates period-to-period comparisons by excluding the earnings impact of interest, tax, depreciation and amortization, ~~investment impairment,~~ non-cash change in fair value of convertible debentures and ~~equity-based compensation.~~warrants, stock-based compensation, and impairment. Management believes that presenting Adjusted EBITDA is more representative of our operational performance and may be more useful for investors. Adjusted EBITDA along with a reconciliation to net loss is shown in Other Operating Data within the Results of Operations below.

Results of Operations

~~The following discussion includes~~Upon closing of the Business Combination, we changed our ~~results for the three and nine ended September 30, 2022, which includes the results~~name to FOXO Technologies Inc. Results of operations included within this report pertaining to periods ending prior to the Closing of ~~Delwinds from~~the Business Combination on September 15, 2022 ~~through September 30, 2022. Accordingly, our consolidated results~~are those of ~~operations are not comparable to our consolidated results of operations for prior periods and may not be comparable with our consolidated results of operations for future periods.~~Legacy FOXO.

~~Three Months Ended September 30, 2022 and 2021~~

(Dollars in thousands) 2022 2021 Change
in $ Change
in %
Total revenue $ 14 $ 31 $ (17 ) (55 )%
Operating expenses:
Research and development 558 1,665 (1,107 ) (66 )%
Selling, general and administrative 8,269 2,721 5,548 204 %
Total operating expenses 8,827 4,386 4,441 101 %
Loss from operations (8,813 ) (4,355 ) (4,458 ) 102 %
Non-cash change in fair value of convertible debentures (3,697 ) (22,571 ) 18,874 (84 )%
Change in fair value of warrant liability 1,349 - 1,349 N/A %
Change in fair value of forward purchase put derivative (1,284 ) - (1,284 ) N/A %
Change in fair value of forward purchase collateral derivative (27,378 ) - (27,378 ) N/A %
Other expense (1,203 ) (315 ) (888 ) 282 %
Total other expense (32,213 ) (22,886 ) (9,327 ) 41 %
Net loss $ (41,026 ) $ (27,241 ) $ 13,785 51 %

Three Months Ended September 30, 2023 and 2022

(Dollars in thousands)	2023			2022			Change in $			Change in %
Total revenue	$	10		$	14		$	(4	)		(29	)%
Cost of sales		70			-			70			N/A	%
Gross profit		(60	)		14			(74	)		(529	)%
Operating expenses:
Research and development		283			558			(275	)		(49	)%
Management contingent share plan		(1,553	)		-			(1,553	)		N/A	%
Selling, general and administrative		4,717			8,269			(3,552	)		(43	)%
Total operating expenses		3,447			8,827			(5,380	)		61	%
Loss from operations		(3,507	)		(8,813	)		5,306			60	%
Non-operating expense		(153	)		(32,213	)		32,060			(100	)%
Net loss		(3,660	)		(41,026	)		37,366			(91	)%
Deemed dividend related to the Exchange Offer		-			-			-			N/A	%
Net loss to common stockholders	$	(3,660	)	$	(41,026	)	$	37,366			(91	)%

Revenues.Total revenues were $10 for the three months ended September 30, 2023, compared to $14 for the three months ended September 30, ~~2022 compared~~2022. The decrease in revenue primarily relates to ~~$31~~life insurance commissions earned as we ceased placing policies from our legacy agency business.

Research and Development. Research and development expenses were $283 for the three months ended September 30, ~~2021. The decrease of $17 was primarily due~~2023, compared to a reduction of the royalty rate on Illumina, Inc.’s license to manufacture and sell Infinium Mouse Methylation Arrays using our epigenetic research. The royalty rate was decreased from 5% to 1.25% in connection with the elimination of a purchase commitment.

~~Research and Development.~~ ~~Research and development expenses were~~ $558 for the three months ended September 30, ~~2022 compared~~2022. The decrease of $275, or 49%, was driven by lower employee-related expenses and professional services to ~~$1,665~~reduce our cost structure following the closing of the Business Combination as well as research and development projects that are no longer ongoing also contributed to the period over period decrease in research and development expenses.

Management Contingent Share Plan. Management Contingent Share Plan expenses were ($1,558) for the three months ended September 30, ~~2021.~~2023, as a result of issuing awards as part of the Business Combination. We began recognizing expense related to the performance condition for entering into a commercial research collaboration agreement. The decrease ~~of $1,107, or 66%, was~~is driven by ~~expenses incurred during~~ the ~~three months ended September 30, 2021 related to Harvard University’s Brigham~~forfeiture of these awards as a result of the employee layoffs and ~~Women’s Hospital Physicians’ Health Study (“PHS”) that did not reoccur in the 2022 comparable period.~~departures.

Selling, General and Administrative.Selling, general and administrative expenses were $4,717 for the three months ended September 30, 2023 compared to $8,269 for the three months ended September 30, ~~2022~~2022. The decrease of $3,552, or 43%, was primarily driven by the completion of the Consulting Agreement as we recognized $2,081 less of compensation costs associated with the amortization of the Consulting Agreement in the current period compared to ~~$2,721~~the prior period. Lower employee-related expenses and professional services to reduce our cost structure following the closing of the Business Combination were offset by incremental costs of being a public company and amortization expense related to our intangible assets.

Non-operating expense. Non-operating expense was $153 for the three months ended September 30, ~~2021. The increase of $5,548, or 204%, was primarily due~~2023, compared to increased costs incurred to support business growth and the implementation of our business plan, specifically employee-related expenses, software costs, as well as incremental professional services incurred in connection with the Business Combination, and $1,600 of expense related to the Cantor Commitment Fee as defined in Note 7 of the unaudited consolidated financial statements.

~~Non-Cash Change in Fair Value of Convertible Debentures.~~ ~~The non-cash change in fair value of convertible debentures was ($3,697)~~$32,213 for the three months ended September 30, ~~2022 compared~~2022. The decrease in non-operating expense primarily related to ~~($22,571) for~~ the three months ended September 30, 2021. We elected the fair value option to account for the 2021 Bridge Debentures and 2022 Bridge Debentures. The increase in fair value for the three months ended September 30, 2021 was the result of the increased likelihood of voluntary or mandatory conversion at OIP, which represents a favorable result to holders of the debentures. The change for the three months ended September 30, 2022 reflected incremental changes ~~in the likelihood of conversion for both the 2021 and 2022 Bridge Debentures.~~

~~Change in Fair Value of Warrant Liabilities.~~ ~~The change~~ in fair value of convertible debentures, warrant ~~liabilities was $1,349 during the three months ended September 30, 2022 as a result of a reduction in the fair value of derivative warrant liabilities assumed as part of the Business Combination.~~

~~Change in Fair Value of Forward Purchase Put Derivative.~~ ~~The change in fair value of~~liability, and forward purchase ~~put derivative was ($1,284)~~derivates, which we recognized $31,010 of expense for during ~~the three months ended September 30, 2022 as a result of entering into the forward purchase agreement that was entered into as part of the Business Combination which may cause us to repurchase shares.~~

~~Change in Fair Value of Forward Purchase Collateral Derivative.~~ The change in fair value of forward purchase derivative was ($27,378) during the three months ended September 30, 2022 as a result of entering into the forward purchase agreement that was entered into as part of the Business Combination which may cause us to forego receiving cash proceeds under the forward purchase agreement.

~~Other Expense.~~ ~~We recognized other expense of ($1,203) for the three months ended September 30, 2022 compared to ($315) for the three months ended September 30, 2021. This increase was the result~~ ~~expenses associated with the forward purchase agreement and~~ ~~of incremental contractual interest expense incurred as a result of the 2021 Bridge Amendment partially offset by an increase in the amount of capitalized interest for~~ the three months ended September 30, 2022.

Net Loss.Net loss was ~~($41,026)~~$3,660 for the three months ended September 30, ~~2022, an increase~~2023, a decrease of ~~$13,785~~$37,366 or ~~51%~~91% compared to ~~($27,241)~~$41,026 in the prior ~~year~~ comparable period. ~~This increase~~The decrease in net loss was primarily ~~due~~related to ~~change in fair value of~~ the ~~forward purchase derivatives and increased selling, general, and administrative expenses partially offset by lower non cash change~~changes in fair value of convertible ~~debentures.~~debentures, warrant liability, and forward purchase derivatives. Additionally, there were decreases in non-cash charges including the Management Contingent Share Plan and amortization of the Consulting Agreement.

Analysis of Segment Results:

The following is an analysis of our results by reportable segment for the three months ended September 30, ~~2022~~2023 compared to the three months ended September 30, ~~2021.~~2022. The primary income measure used for assessing reportable segment performance is earnings before interest, income taxes, depreciation, amortization, and ~~equity-based compensation (“Segment Earnings”).~~stock-based compensation. Segment Earnings by reportable segment also excludes corporate and other costs, including management, IT, and overhead costs. For further information regarding our reportable business segments, please refer to our condensed consolidated financial statements and related notes included elsewhere in this ~~quarterly~~ report.

FOXO Labs

(Dollars in thousands)	2022			2021			Change in $			Change in %			2023			2022			Change in $			Change in %
Total revenue	$	7		$	23		$	(16	)		(70	)%	$	6		$	7		$	(1	)		(14	)%
Research and development expenses		506			1,655			(1,149	)		(69	)%		275			507			(232	)		(46	)%
Segment Earnings	$	(499	)	$	(1,632	)	$	1,133			(69	)%	$	(269	)	$	(500	)	$	231			(46	)%

Revenues.Total revenues were $7$6 and ~~$23~~$7 for the three months ended September 30, 2023 and 2022, ~~and 2021, respectively, and consisted~~respectively. The decrease in revenue was primarily driven by lower royalty revenue in the three months ended September 30, 2023 compared to the prior period related to a reduction of ~~earned royalties from~~the royalty rate on Illumina, Inc.’s license to manufacture and sell Infinium Mouse Methylation Arrays using our epigenetic research.

Segment Earnings. Segment Earnings increased from ($500) for the three months ended September 30, 2022 to ($269) for the three months ended September 30, 2023. The increase of $231 was driven by lower employee-related expenses and professional services to reduce our cost structure following the closing of the Business Combination as well as research and development projects that are no longer ongoing also contributed to the period over period decrease ~~of $16 was due to a reduced royalty rate.~~in research and development expenses.

FOXO Life

(Dollars in thousands)	2023			2022			Change in $			Change in %
Total revenue	$	4		$	7		$	(3	)		(43	)%
Selling, general and administrative expenses		143			1,165			(1,022	)		(88	)%
Segment Earnings	$	(139	)	$	(1,158	)	$	1,019			(88	)%

~~Segment Earnings.~~Revenues. ~~Segment Earnings increased from ($1,632)~~Total revenues were $4 for the three months ended September 30, ~~2021~~2023 compared to ~~($499)~~$7 for the three months ended September 30, 2022. ~~The increase of $1,133 was driven by expenses incurred during the three months ended September 30, 2021 related to the commencement of PHS that did not reoccur in the 2022 comparable period.~~

~~FOXO Life~~

(Dollars in thousands) 2022 2021 Change in $ Change in %
Total revenue $ 7 $ 8 $ (1 ) (13 )%
Selling, general and administrative expenses 1,164 839 325 39 %
Segment Earnings $ (1,157 ) $ (831 ) $ (326 ) 39 %

~~Revenues.~~ ~~Total revenues were $7 for the three months ended September 30, 2022 compared to $8 for the three months ended September 30, 2021.~~ The decrease was due to reduced life insurance commissions earned as we ceased placing policies from our legacy agency business.

Segment Earnings. Segment Earnings ~~decreased~~increased from ($~~831)~~1,158) for the three months ended September 30, ~~2021~~2022 to ($~~1,157)~~139) for the three months ended September 30, ~~2022.~~2023. The ~~decrease of ($326)~~increase was ~~primarily due to increased~~driven by lower employee-related expenses and ~~costs for~~ professional ~~services.~~services to reduce our cost structure following the closing of the Business Combination.

~~Nine Months Ended September 30, 2022 and 2021~~

(Dollars in thousands) 2022 2021 Change in $ Change in %
Total revenue $ 93 $ 93 $ - - %
Operating expenses:
Research and development 2,160 4,321 (2,161 ) (50 )%
Selling, general and administrative 17,239 7,640 9,599 126 %
Total operating expenses 19,399 11,961 7,438 62 %
Loss from operations (19,306 ) (11,868 ) (7,438 ) 63 %
Non-cash change in fair value of convertible debentures (28,180 ) (24,890 ) (3,290 ) 13 %
Change in fair value of warrant liability 1,349 - 1,349 N/A %
Change in fair value of forward purchase put derivative (1,284 ) - (1,284 ) N/A %
Change in fair value of forward purchase collateral derivative (27,378 ) - (27,378 ) N/A %
Other expense (2,133 ) (856 ) (1,277 ) 149 %
Total other expense (57,626 ) (25,746 ) (32,363 ) 124 %
Net loss $ (76,932 ) $ (37,614 ) $ (39,318 ) 105 %

Nine Months Ended September 30, 2023 and 2022

*(Dollars in thousands)*	2023			2022			Change in $			Change in %
Total revenue	$	35		$	93		$	(58	)		(62	)%
Cost of sales		70			-			70			N/A	%
Gross profit		(35	)		93			(128	)		(138	)%
Operating expenses:
Research and development		925			2,160			(1,235	)		(57	)%
Management contingent share plan		(141	)		-			(141	)		N/A	%
Impairment		2,633			-			2,633			N/A	%
Selling, general and administrative		15,052			17,239			(2,187	)		(13	)%
Total operating expenses		18,469			19,399			(930	)		(5	)%
Loss from operations		(18,504	)		(19,306	)		802			(4	)%
Non-operating expense		(4,088	)		(57,626	)		53,538			(93	)%
Net loss		(22,592	)		(76,932	)		54,340			(71	)%
Deemed dividend related to the Exchange Offer		(2,466	)		-			(2,466	)		N/A	%
Net loss to common stockholders	$	(25,058	)	$	(76,932	)	$	51,874			(67	)%

Revenues.Total revenues were ~~$93~~$35 for ~~both~~ the nine months ended September 30, ~~2022 and 2021. During~~2023, compared to $93 for the nine months ended September 30, ~~2022,~~2022. The decrease in revenue was primarily driven by lower royalty revenue of $53 in the ~~Company recognized $4 of additional revenue~~nine months ended September 30, 2023 compared to the prior period ~~in earned royalties from~~related to a reduction of the royalty rate on Illumina, Inc.’s license to manufacture and sell Infinium Mouse Methylation Arrays. ~~This increase was offset by a $4~~The remaining decrease inprimarily relates to life insurance commissions earned as we ceased placing policies from our legacy agency business.

Research and Development.Research and development expenses were $925 for the nine months ended September 30, 2023, compared to $2,160 for the nine months ended September 30, ~~2022 compared to $4,321 for~~2022. The decrease of $1,235, or 57%, was driven by $489 of expenses incurred in the nine months ended September 30, 2021. The decrease of $2,161, or 50%, was driven by $3,076 of expenses incurred during the nine months ended September 30, 2021 related to PHS that were insignificant in the comparable period. Costs incurred for PHS during the nine months ended September 30, 2021 included two milestone payments due at commencement and upon the transfer of clinical data, as well as costs related to supplies and processing fees. This decrease was partially offset by incremental research and development costs2022 associated with a clinical trial agreement with The Brigham and Women’s Hospital, Inc. ~~(“VECTOR”)~~, specifically a $424 payment at contract inception. ~~Additional~~The research study associated with this arrangement is no longer being pursued by the Company. Lower employee-related expenses ~~incurred during~~and professional services to reduce our cost structure following the closing of the Business Combination as well as research and development projects that are no longer ongoing also contributed to the period over period decrease in research and development expenses.

Management Contingent Share Plan. Management Contingent Share Plan expenses were ($141) for the nine months ended September 30, ~~2022 also partially~~2023, as a result of issuing awards as part of the Business Combination. We began recognizing expense related to the performance condition for entering into a commercial research collaboration agreement. The decrease is driven by the forfeiture of these awards as a result of the employee layoffs and departures, offset by expense recognized during the ~~decrease in research and development expenses over the comparison~~ period.

Impairment of Intangible Assets and Cloud Computing Arrangements. During the nine months ended September 30, 2023, we determined that the cash flows would no longer support the digital insurance platform, underwriting API, and longevity API and recognized impairment losses of $1,425, $630, and $578, respectively or $2,633 in total.

Selling, General and Administrative.Selling, general and administrative expenses were $15,052 for the nine months ended September 30, 2023 compared to $17,239 for the nine months ended September 30, ~~2022 compared to $7,640 for the nine months ended September 30, 2021.~~2022. The ~~increase~~decrease of ~~$9,599,~~$2,187, or ~~126%~~13%, was primarily ~~due to increased~~driven by the completion of the Consulting Agreement as we recognized $891 less of compensation costs incurred to support business growth and the implementation of our business plan, specifically employee-related expenses, software costs, as well as incremental professional services incurred in connectionassociated with the ~~Business Combinations, and~~amortization of the Consulting Agreement in the current period compared to the prior period. Additionally, we incurred $1,600 of expense related to the Cantor Commitment Fee ~~as defined~~ in ~~Note 7~~September 2022 with no comparable expense in 2023. This decrease is offset by incremental costs of ~~the unaudited consolidated financial statements.~~being a public company and amortization expense related to our intangible assets.

~~Non-Cash Change in Fair Value of Convertible Debentures.~~Non-operating expense. ~~The non-cash change in fair value of convertible debentures~~Non-operating expense was ~~($28,180)~~$4,088 for the nine months ended September 30, ~~2022~~2023, compared to ~~($24,890)~~$57,626 for the nine months ended September 30, ~~2021. We elected the fair value option~~2022. The decrease in non-operating expense primarily related to ~~account for the 2021 Bridge Debentures and 2022 Bridge Debentures. The increase in fair value for the nine months ended September 30, 2021 was the result~~a decrease of the increased likelihood of voluntary or mandatory conversion at OIP, which represents a favorable result to holders of the debentures. The change for the nine months ended September 30, 2022 also reflected the increase in fair value associated with incurring additional debt. Additionally, the likelihood of conversion for both the 2021 and 2022 Bridge Debentures increased throughout the nine months ended September 30, 2020 representing a favorable result$55,737 related to the ~~holders of the debentures.~~

~~Change in Fair Value of Warrant Liabilities.~~ ~~The change~~changes in fair value of convertible debentures, warrant ~~liabilities was $1,349 during the nine months ended September 30, 2022 as a result of a reduction in the fair value of derivative warrant liabilities assumed as part of the Business Combination.~~

~~Change in Fair Value of Forward Purchase Put Derivative.~~ ~~The change in fair value of~~liability, and forward purchase put derivative was ($1,284) during the nine months ended September 30, 2022 as a result of entering into the forward purchase agreement that was entered into as part of the Business Combination which may cause us to repurchase shares.derivates.

~~Change in Fair Value of Forward Purchase Collateral Derivative.~~ The change in fair value of forward purchase collateral derivative was ($27,378) during the three months ended September 30, 2022 as a result of entering into the forward purchase agreement that was entered into as part of the Business Combination which may cause us to forego receiving cash proceeds under the forward purchase agreement.

~~Other Expense.~~ ~~We recognized other expense of ($2,133) for the nine months ended September 30, 2022 compared to ($856) for the nine months ended September 30, 2021. This increase was the result of~~ ~~expenses associated with the forward purchase agreement and~~ incremental contractual interest expense incurred as a result of the 2021 Bridge Amendment partially offset by an increase in the amount of capitalized interest for the nine months ended September 30, 2022.

Net Loss.Net loss was ~~($76,932)~~$22,592 for the nine months ended September 30, ~~2022, an increase~~2023, a decrease of ~~$39,318~~$54,340 or ~~105%~~71% compared to ~~($37,614)~~$76,932 in the prior ~~year~~ comparable period. ~~This increase~~The decrease in net loss was primarily ~~due~~related to ~~change~~the conversion of our Bridge Debentures. Additionally, a deemed dividend of $2,466 related to the Exchange Offer was recognized for the nine months ended September 30, 2023 resulting in ~~fair value~~a net loss to common stockholders of ~~the forward purchase derivatives and increased selling, general, and administrative expenses partially offset by lower non cash change in fair value of convertible debentures.~~$25,058.

Analysis of Segment Results:

The following is an analysis of our results by reportable segment for the nine months ended September 30, ~~2022~~2023 compared to the nine months ended September 30, ~~2021.~~2022. The primary income measure used for assessing reportable segment performance is earnings before interest, income taxes, depreciation, amortization, and ~~equity-based~~stock-based compensation. Segment Earnings by reportable segment also excludes corporate and other costs, including management, IT, and overhead costs. For further information regarding our reportable business segments, please refer to our condensed consolidated financial statements and related notes included elsewhere in this ~~quarterly~~ report.

FOXO Labs

(Dollars in thousands)	2022			2021			Change in $			Change in %			2023			2022			Change in $			Change in %
Total revenue	$	71		$	67		$	4			6	%	$	20		$	71		$	(51	)		(72	)%
Research and development expenses		2,023			4,335			(2,312	)		(53	)%		893			2,023			(1,130	)		(56	)%
Segment Earnings	$	(1,952	)	$	(4,268	)	$	2,316			(54	)%	$	(873	)	$	(1,952	)	$	1,079			(55	)%

Revenues. Total revenues were ~~$71~~$20 and ~~$67~~$71 for the nine months ended September 30, 2023 and 2022, ~~and 2021, respectively, and consisted~~respectively. The decrease in revenue was primarily driven by lower royalty revenue of ~~earned royalties from~~$53 in the nine months ended September 30, 2023 compared to the prior period related to a reduction of the royalty rate on Illumina, Inc.’s license to manufacture and sell Infinium Mouse Methylation Arrays using our epigenetic research.

Segment Earnings.Segment Earnings increased from ~~($4,268) for the nine months ended September 30, 2021 to~~ ($1,952) for the nine months ended September 30, ~~2022. The increase of $2,316 was driven by $3,076 of expenses incurred during~~2022 to ($873) for the nine months ended September 30, ~~2021 related to PHS that were insignificant~~2023. The increase of $1,079 was driven by $489 of expenses incurred in the nine months ended September 30, 2022 ~~comparable period which were offset by~~associated with a clinical trial agreement with The Brigham and Women’s Hospital, Inc., specifically a $424 payment at contract ~~inception for VECTOR~~inception. The research study associated with this arrangement is no longer being pursued by the Company. Lower employee-related expenses and professional services to reduce our cost structure following the closing of the Business Combination as well as ~~additional employee-related~~research and development projects that are no longer ongoing also contributed to the period over period decrease in research and development expenses.

FOXO Life

(Dollars in thousands)	2022			2021			Change in $			Change in %			2023			2022			Change in $			Change in %
Total revenue	$	22		$	26		$	(4	)		(15	)%	$	15		$	22		$	(7	)		(32	)%
Selling, general and administrative expenses		3,092			1,693			1,399			83	%		1,044			3,092			(2,048	)		(66	)%
Segment Earnings	$	(3,070	)	$	(1,667	)	$	(1,403	)		84	%	$	(1,029	)	$	(3,070	)	$	2,041			(66	)%

Revenues.Total revenues were $15 for the nine months ended September 30, 2023 compared to $22 for the nine months ended September 30, ~~2022 compared to $26 for the nine months ended September 30, 2021.~~2022. The decrease was due to reduced life insurance commissions earned as we ceased placing policies from our legacy agency business.

Segment Earnings.Segment Earnings ~~decreased~~increased from ~~($1,667) for the nine months ended September 30, 2021 to~~ ($3,070) for the nine months ended September 30, ~~2022.~~2022 to ($1,029) for the nine months ended September 30, 2023. The ~~decrease of ($1,403)~~increase was ~~primarily due to increased~~driven by lower employee-related expenses and ~~costs for~~ professional ~~services.~~

services to reduce our cost structure following the closing of the Business Combination partially offset by a $251 loss on the sale of FOXO Life Insurance Company.

Other Operating Data:

We use Adjusted EBITDA to evaluate our operating performance. Adjusted EBITDA does not represent and should not be considered an alternative to net income as determined by U.S. GAAP, and our calculations thereof may not be comparable to those reported by other companies. We believe Adjusted EBITDA is an important measure of operating performance and provides useful information to investors because it highlights trends in our business that may not otherwise be apparent when relying solely on U.S. GAAP measures and because it eliminates items that have less bearing on our operating performance. Adjusted EBITDA, as presented herein, is a supplemental measure of our performance that is not required by, or presented in accordance with, U.S. GAAP. We use non-GAAP financial measures as supplements to our U.S. GAAP results in order to provide a more complete understanding of the factors and trends affecting our business. Adjusted EBITDA is a measure of operating performance that is not defined by U.S. GAAP and should not be considered a substitute for net (loss) income as determined in accordance with U.S. GAAP.

We reconcile our non-GAAP financial measure to our net loss, which is its most directly comparable financial measure calculated and presented in accordance with U.S. GAAP. Our management uses Adjusted EBITDA as a financial measure to evaluate the profitability and efficiency of our business model. Adjusted EBITDA is not presented in accordance with U.S. GAAP. Adjusted EBITDA includes adjustments for provision for income taxes, as applicable, interest income and expense, depreciation and amortization, ~~equity-based~~stock-based compensation, ~~(including the non-cash charges related to the consulting agreement),~~ and certain other infrequent and/or unpredictable non-cash charges or benefits, such as changes in fair value of convertible debentures ~~warrant liabilities,~~ and ~~the forward purchase derivative.~~impairment.

	For the three months ended September 30,						For the nine months ended September 30,						For the three months ended September 30,						For the nine months ended September 30,
(Dollars in thousands)	2022			2021			2022			2021			2023			2022			2023			2022
Net loss	$	(41,026	)	$	(27,241	)	$	(76,932	)	$	(37,614	)	$	(3,660	)	$	(41,026	)	$	(22,592	)	$	(76,932	)
Add: Depreciation		74			25			159			71
Add: Interest expense (income)		424			313			1,250			825
Add: Equity-based compensation⁽¹⁾		3,866			42			5,556			8
Add: Non-cash change in fair value of convertible debentures		3,697			22,571			28,180			24,890
Add: Depreciation and amortization														75			74			1,251			159
Add: Interest expense														148			424			865			1,250
Add: Stock-based compensation ⁽¹⁾														(1,312	)		3,866			2,582			5,556
Add: Change in fair value of warrant liability		(1,349	)		-			(1,349	)		-			(36	)		(1,349	)		(244	)		(1,349	)
Add: Change in fair value of forward purchase put derivative		1,284			-			1,284			-			-			1,284			-			1,284
Add: Change in fair value of forward purchase collateral derivative		27,378			-			27,378			-			-			27,378			-			27,378
Add: Impairment of intangible assets and cloud computing arrangements														-			-			2,633			-
Add: Loss from PIK Note Amendment and 2022 Debenture Release														-			-			3,521			-
Add: Non-cash change in fair value of convertible debentures														-			3,697			-			28,180
Adjusted EBITDA	$	(5,652	)	$	(4,290	)	$	(14,474	)	$	(11,820	)	$	(4,785	)	$	(5,652	)	$	(11,984	)	$	(14,474	)

(1)

Includes expense recognized related to the shares issued to the ~~Consultant and for the Cantor Commitment Fee as defined in Notes~~Consultant. See Note 6 ~~and 7~~ of the unaudited condensed consolidated financial ~~statements~~statements.

Liquidity and Capital Resources

Sources of Liquidity and Capital

We had cash and cash equivalents of ~~$10,454~~$42 and ~~$6,856~~$5,515 as of September 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively. Excluding amounts required to be held as statutory capital and surplus byat FOXO Life Insurance Company we had ~~$5,453~~cash and ~~$1,856~~cash equivalents of $42 and $513 as of September 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively. We have incurred net losses since our inception. For the nine months ended September 30, ~~2022~~2023 and ~~2021,~~2022, we incurred net losses of ~~$76,932~~$22,592 and ~~$37,614,~~$76,932, respectively. We had an accumulated deficit of ~~$128,908~~$172,289 and ~~$51,976,~~$147,231, respectively, as of September 30, ~~2022~~2023, and December 31, ~~2021.~~2022. We have generated limited revenue to date and expect to incur additional losses in future periods.

As part of the Business Combination, we entered into a Forward Purchase Agreement and ELOC Agreement to fund our business; however, these agreements have since been terminated as a result of the performance of our stock. The Business Combination ultimately resulted in a significant number of redemptions limiting our proceeds. Additionally, we are unlikely to receive proceeds from the exercise of outstanding Warrants as a result of the difference between our current trading price of our Class A Common Stock and the exercise price of the various Warrants, as further discussed below. Our current revenue is not adequate to fund our operations in the next twelve months, as further described under “Liquidity Update” below, and requires us to fund our business through other avenues until the time we achieve adequate scale. Securing additional capital is necessary to execute on our business strategy.

FOXO Life Insurance Company Sale

As discussed above under “FOXO Life Insurance Company,” we consummated the sale of FOXO Life Insurance Company to Security National pursuant to the Security National Merger Agreement. After the Merger Consideration and Security National’s third party expenses, the transaction resulted in the Company gaining access to $4,751 that was previously held as statutory capital and surplus pursuant to the Arkansas Code.

Prior Financings

Prior to the closing of the Business Combination, we ~~have~~ financed our business through a combination of equity and debt, consisting of proceeds from a subscription receivable and proceeds from convertible debenture offerings. The subscription receivable initially totaled $20,000, with the last installment being received during the third quarter of 2021.

During the first quarter of 2021, we entered into separate ~~Securities Purchase Agreements~~securities purchase agreements with ~~the 2021 Bridge Investors,~~certain investors, pursuant to which we issued convertible debentures for $11,812 in aggregate principal. After an original issue discount of 12.5% we received cash proceeds of $10,500 for this issuance. Additionally, we incurred an incremental $888 of fees and expenses related to the offering. The 2021 Bridge Debentures were issued in three tranches, on January 25, 2021, February 23, 2021, and March 4, 2021.

Additionally, during the first quarter of 2022, we entered into separate ~~Securities Purchase Agreements~~securities purchase agreements with ~~the 2022 Bridge Investors,~~certain investors, pursuant to which we issued the 2022 Bridge Debentures for $24,750 in aggregate principal. After an original issue discount of 10.0% we received cash proceeds of $22,500 for this issuance. In the second quarter of 2022, we issued additional 2022 Bridge Debentures pursuant to which we raised an additional $5,500 in cash proceeds or $6,050 in aggregate principal amount under the same terms as the issuance of the 2022 Bridge Debentures in the first quarter of 2022, resulting in total cash proceeds of $28,000 from the issuance of the 2022 Bridge Debentures.

Immediately prior to the Closing, the 2021 Bridge Debentures and 2022 Bridge Debentures were converted into ~~6,759,642~~676,007 and ~~7,810,509,~~781,053, respectively, shares of FOXO Class A Common Stock and were subsequently exchanged for shares of the Company’s Class A Common Stock at the Closing of the Business Combination.

During the third quarter of 2022, we entered into separate ~~Securities Purchase Agreements~~securities purchase agreements pursuant to which we issued our Senior PIK Notes in the aggregate principal of ~~$3,458~~.$3,458. We received net proceeds of ~~$2,918~~,$2,918, after deducting fees and expenses of ~~$540~~.$540.

Exchange Offer and PIK Note Offer to Amend

As discussed above under “Recent Developments – Exchange Offer, PIK Note Offer to Amend and 2022 Bridge Debenture Release,” we consummated an Exchange Offer whereby holders of the Assumed Warrants were able to exchange such Assumed Warrants for shares of Class A Common Stock. Pursuant to the Exchange Offer, we solicited consents from a sufficient amount of holders of Assumed Warrants to amend and restate the Original Securities Purchase Agreement, pursuant to the terms of the Amendment and Restatement, to provide that certain previous and future issuances of Class A Common Stock and Common Stock Equivalents (as defined in the Original Securities Purchase Agreement) do not trigger, and cannot be deemed to have triggered, any anti-dilution adjustments in the Securities. Additionally, we consummated the PIK Note Offer to Amend, whereby we amended our Senior PIK Notes to permit certain issuances of Class A Common Stock and Common Stock Equivalents (as defined in the PIK Note Purchase Agreement), without prepaying the Senior PIK Notes as required by the terms of the PIK Note Purchase Agreement. Both the Exchange Offer and PIK Note Amendment were designed to facilitate future capital raises.

2023 Private Placement

As discussed above under “Recent Developments – 2023 Private Placement,” we completed two Tranches of the 2023 Private Placement that provided gross proceeds of $450 and $293.5. After deducting placement agent fees and other offering expenses, the net proceeds from the 2023 Private Placement were $260 and $217, respectively.

On October 13, 2023, FOXO Technologies Inc. (the “Company”) entered into a Strata Purchase Agreement (the “Strata Purchase Agreement”) with ClearThink Capital Partners, LLC (“ClearThink”), as supplemented by that certain Supplement to Strata Purchase Agreement, dated as of October 13, 2023, by and between the Company and ClearThink (the “Strata Supplement”). Pursuant to the Strata Purchase Agreement, after the satisfaction of certain commencement conditions, including, without limitation, the effectiveness of the Registration Statement (as defined below), ClearThink has agreed to purchase from the Company, from time to time upon delivery by the Company to ClearThink of request notices (each a “Request Notice”), and subject to the other terms and conditions set forth in the Strata Purchase Agreement, up to an aggregate of $2,000,000 of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of the shares of common stock to be purchased under the Strata Purchase Agreement will be equal to 85% of the lowest daily VWAP during a valuation period of ten trading days consisting of the five trading days preceding the Purchase Date (as defined in the Strata Purchase Agreement) with respect to a Request Notice and five trading days commencing on the first trading day following delivery and clearing of the delivered shares. In addition, pursuant to the Strata Purchase Agreement, the Company agreed to issue to ClearThink 100,000 restricted shares of Common Stock (the “Commitment Shares”) as a “Commitment Fee.”

Each purchase under the Strata Purchase Agreement will be in a minimum amount of $25,000 and a maximum amount equal to the lesser of (i) $1,000,000 and (ii) 300% of the average daily trading value of the Common Stock over the ten days preceding the Request Notice date. In addition, Request Notices must be at least 10 business days apart and the shares issuable pursuant to a Request Notice, when aggregated with the shares then held by ClearThink on the Request Notice date, may not exceed 4.99% of the outstanding Common Stock. The Strata Purchase Agreement further provides that the Company may not issue, and ClearThink may not purchase, any shares of Common Stock under the Strata Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by ClearThink and its affiliates, would result in the beneficial ownership by ClearThink and its affiliates of more than 9.99% of the then issued and outstanding shares of Common Stock.

In connection with the Strata Purchase Agreement, the Company entered into a Registration Rights Agreement with ClearThink under which the Company agreed to file, within 60 days of executing definitive documents, a registration statement (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) covering the shares of Common Stock issuable under the Strata Purchase Agreement (the “Registration Rights Agreement”).

Concurrently with the execution of the Strata Purchase Agreement, the Company and ClearThink also entered into a Securities Purchase Agreement (the “SPA”) under which ClearThink has agreed to purchase from the Company an aggregate of 200,000 restricted shares of Common Stock for a total purchase price of $200,000 in two closings. The first closing will occur on or about October 17, 2023, or such other mutually agreed upon time but in no event later than October 18, 2023. The second closing will be within five days after the filing of the Registration Statement.

Going Concern

Our primary uses of cash are to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term to support the growth of our business. Capital expenditures have historically not been material to our consolidated operations, and we do not anticipate making material capital expenditures in ~~2022~~2023 or beyond. We expect that our liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business. Based on our current planned operations, we do not have sufficient capital to fund our operations for at least 12 months from the date hereof. We expect to address our liquidity needs through the pursuit of additional funding through a combination of equity or debt financings to enable us to fund our ~~operations for at least 12 months from~~operations.

We have taken various actions to bolster our cash position, including raising funds through the ~~date hereof. We also expect revenue from our MGA relationships to contribute in funding our operations. To~~transactions with ClearThink described herein and conserving cash by issuing the ~~extent that we require additional funds more than 12 months from the date hereof,~~Payment Shares and the ~~revenue from~~Rights to the Selling Stockholders in satisfaction of outstanding amounts payable by us to the Selling Stockholders, issuing shares of Class A Common Stock in lieu of salary to our ~~MGA relationships cannot~~non-executive employees (for the period of September 4, 2023 through September 30, 2023), and reducing our employee headcount. Based on our current operating plan, our cash position as of September 30, 2023, and after taking into account the actions described above, we expect to be able to fund our ~~needs, we may utilize a combination of equity and debt financings. In the absence of sufficient proceeds from these sources, however, we~~operations through January 2024. We will need additional ~~financial support, which cannot be assured,~~financing or ~~we will have~~other increase in our cash and cash equivalents balance to ~~significantly reduce~~enable us to fund our ~~expenditures or delay certain business initiatives to sustain operations. As such, until additional equity or debt capital is secured~~operations beyond January 2024. We are in ongoing negotiations with funders for future funding requirements and ~~the Company begins generating sufficient revenue, there is substantial doubt about the Company’s ability to continue as a going concern.~~remain positive on these discussions.

We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing sooner than currently projected, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We may raise additional capital through equity offerings, debt financings or other capital sources. If we do raise additional capital through public or private equity offerings, or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely impact our existing stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take certain actions. As discussed above under “Recent Developments – Exchange Offer, PIK Note Offer to Amend and 2022 Bridge Debenture Release,” we consummated the Exchange Offer and the PIK Note Offer to Amend, whereby we solicited consents from a sufficient amount of holders of Assumed Warrants and Senior PIK Notes, as applicable, to amend the agreements governing such securities in order to help us raise additional capital.

Liquidity Update

In connection with the evaluation of the Business Combination, our management prepared and provided to our Board of Directors and Delwinds’ financial advisor unaudited prospective financial information. The prospective financial information was prepared using a number of assumptions, including assumptions with respect to general business, economic, market, regulatory and financial conditions and various other factors, all of which are difficult to predict and many of which are beyond FOXO’s control. Due to several factors including but not limited to the timing and lack of funding from the Business Combination that has caused us to limit our expenditures and initiatives, we do not expect to achieve the projected revenue for 2023. As a result, we never sold policies through FOXO Life Insurance Company and some research activities that were previously anticipated have not been conducted or have been postponed which has impacted our ability to offer our underwriting services in 2023. We launched our MGA Model, but have not been able to provide it with the resources previously anticipated. We also assumed that with sufficient scale we would reduce the costs of our testing. We have yet to achieve these cost savings that would make our offerings more attractive to consumers. Given the already mentioned leadership changes and that the prospective financial information was prepared prior to the Business Combination, we believe such projections should not be used as a frame of reference by investors.

Cash Flows

Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022

The following table summarizes our cash flow data for the nine months ended September 30, ~~2022~~2023 and ~~2021~~2022 (dollars in thousands):

	Cash Provided by / (Used in)						Cash Provided by / (Used in)
Nine Months Ended September 30	2022			2021
Nine Months Ended September 30,							2023			2022
Operating Activities	$	(19,232	)	$	(11,746	)	$	(6,165	)	$	(19,232	)
Investing Activities	$	(1,730	)	$	(195	)	$	-		$	(1,730	)
Financing Activities	$	24,560		$	14,250		$	692		$	24,560

Operating Activities

Net cash used for operating activities in the nine months ended September 30, ~~2022~~2023 was ~~$19,232~~$6,165 compared to ~~$11,746~~$19,232 in the nine months ended September 30, ~~2021.~~2022. Operating cash flow ~~decreased $7,486,~~increased $13,067, or ~~64%~~68%, from the nine months ended September 30, ~~2021~~2023 to the nine months ended September 30, 2022. The ~~decrease~~increase was the result of ~~an increased~~a lower net loss, ~~primarily~~ driven by non-cash items, as well as ~~increased~~less cash used for working ~~capital.~~capital purposes.

Investing Activities

Net cash used for investing activities in the nine months ended September 30, ~~2022~~2023 was ~~$1,730~~$0 compared to ~~$195~~$1,730 in the nine months ended September 30, ~~2021.~~2022. This investing cash flow ~~decrease~~increase of ~~$1,535~~$1,730 was primarily due to ~~incremental costs incurred to develop~~the completion of the development of our internal use ~~software and increased capital expenditures, partially offset by a decrease in investments made.~~software.

Financing Activities

Net cash provided by financing activities in the nine months ended September 30, ~~2022~~2023 was ~~$24,560~~$692 compared to ~~$14,250~~$24,560 in the nine months ended September 30, ~~2021.~~2022. This financing cash flow ~~increase~~decrease was primarily the result of ~~higher~~non-recurring debt proceeds of $28,000 from the 2022 Bridge Debentures and $2,918 net proceeds from the Senior PIK Notes compared to $10,500 from the 2021 Bridge Debentures. This was partially offset by reduced proceeds received on our Subscription Receivable duringfinancing that occurred in the nine months ended September 30, ~~2021, warrant repurchases and the series of transactions associated with the Business Combination.~~2022.

Off-Balance Sheet Financing Arrangements

We have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.

We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or entered into any non-financial assets.

Contractual Obligations

Our contractual obligations as of September 30, ~~2022~~2023 include:

	Amounts Due by Period										Amounts Due by Period
(Dollars in thousands)	Less than 1 Year (d)		1 - 3 years		3 - 5 years		More than 5 years		Total (d)		Less than 1 Year		1 - 3 years		3 - 5 years		More than 5 years		Total
License agreements (a)	$	25		80		80		-	$	185	$	20		40		40		-	$	100
Research agreements (b)		53		-		-		-		53
Senior PIK Notes (c)		-		3,458		-		-		3,458
Senior PIK Notes (b)												4,006		-		-		-		4,006
Supplier and other commitments (c)												14		-		-		-		14
Total	$	78		3,538		80		-	$	3,696	$	4,080		40		40		-	$	4,160

(a)	License ~~agreements remain~~agreement remains in place until the licensor’s patents expire or are abandoned. Amounts do not include development milestones that have not been reached as of September 30, ~~2022.~~2023.

(b)	~~Amounts relate to completing CHOP in the upcoming year. See Note 13 of the unaudited consolidated financial statements.~~

~~(c)~~

Represents the principal balance ~~at inception.~~as of September 30, 2023. The Senior PIK Notes are subject to prepayment penalties and interest ~~may be~~is paid through the issuance of additional Senior PIK Notes. The ultimate amount required to settle the Senior PIK Note will vary depending on when it is settled. See Note 5 of the unaudited condensed consolidated financial statements.

~~(d)~~(c)

~~Does not include $425 of potential milestone payments related to~~The Company has supplier and other commitments comprising the ~~VECTOR study. The milestone payments are within the control of the Company and as of September 30, 2022 the milestones have not been met.~~balance shown. See Note 1312 of the unaudited condensed consolidated financial statements.

Critical Accounting Policies

The preparation of the unaudited condensed consolidated financial statements and related notes included under “Item 1. Financial Statements” and related disclosures in conformity with GAAP. The preparation of these condensed consolidated financial statements requires the selection of the appropriate accounting principles to be applied and the judgments and assumptions on which to base accounting estimates, which affect the reported amounts of assets and liabilities as of the date of the balance sheets, the reported amounts of revenue and expenses during the reporting periods, and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances at the time such estimates are made. Actual results and outcomes may differ materially from our estimates, judgments, and assumptions. We periodically review our estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates are reflected in the condensed consolidated financial statements prospectively from the date of the change in estimate.

We define our critical accounting policies and estimates as those that require us to make subjective judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations as well as the specific manner in which we apply those principles. We believe the critical accounting policies used in the preparation of our financial statements which require significant estimates and judgments are as follows:

~~Equity-Based Compensation~~

Historically, prior to the Business Combination, we offered equity-based compensation to employees and nonemployees in the form of stock options and restricted stock. We measure and recognize all equity-based payments to employees, service providers and board members at fair value. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statements of operations based on the estimated fair value of those awards on the grant date or reporting date, if required to be remeasured, and amortized on a straight-line basis over the requisite service period. We recognize forfeitures as incurred. We utilize a Black-Scholes valuation model to estimate the fair value of stock options and this model requires the input of assumptions, including the exercise price, volatility, expected term, discount rate, and the fair value of the underlying membership or stock on the date of grant. These inputs are provided at the grant date for an equity classified award and each measurement date for a liability classified award. Equity-based compensation awards are considered granted (i) when there is a mutual understanding of key terms, (ii) we are contingently obligated to issue the options, and (iii) the option holder begins to benefit or be adversely impacted by changes in our stock price. This primarily occurs at the time the stock option agreements are executed.Going Concern

~~Our option pricing model requires~~For the ~~input~~three and nine months ended September 30, 2023, the Company incurred a net loss of highly subjective assumptions, including the fair value of the underlying units or stock, the expected term of the equity-based award, the expected volatility of the price of our common units or stock, risk-free interest rates,$3,660 and the expected dividend yield of our common units or stock. The assumptions used in our option pricing model represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, our equity-based compensation expense could be materially different in the future.

~~These assumptions were estimated as follows:~~

●

~~Fair Value of Our Common Stock:~~$22,592 respectively. As ~~FOXO Technologies Operating Company’s common stock was not publicly traded, we estimated the fair value of our common stock, as discussed in the section “Common Stock Valuations” below.~~

●

Risk-Free Interest Rate: We based the risk-free interest rate used in the Black-Scholes option pricing model on the implied yield to maturity available on a U.S. Treasury constant maturity security with a term commensurate with the expected term of the stock options.

●

Expected Term: We estimated the expected term using the simplified method due to the lack of historical exercise activity for our common stock. The simplified method calculates the expected term as the mid-point between the vesting term and the contractual term of the award.

●

Volatility: As FOXO Technologies Operating Company was a privately held company with no trading history prior, we estimated the stock price volatility factor by referencing historical volatilities of comparable peer companies. To determine a set of comparable peer companies, we considered similar public companies and selected those that are most similar to us in size, stage of life cycle, and financial leverage. We intend to continue to apply this process using the same or similar public companies until sufficient historical information regarding the volatility of our own common stock share price becomes available, or unless circumstances change such that the identified companies are no longer comparable to our business, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation.

●

Dividend yield: We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero.

~~Common Stock Valuations~~

As FOXO Technologies Operating Company’s common stock was not publicly traded, the fair value of our equity, which is the basis upon which all of our equity-based compensation awards was measured and recognized, was determined by our board of directors, with input from management and third-party valuation specialists. The third-party valuation specialists apply valuation techniques and methods that conform to generally accepted valuation practices and standards established by the American Society of Appraisers in accordance with Uniform Standards of Professional Appraisal Practice. The valuation methodologies and techniques utilized are also consistent with guidance issued by the American Institute of Certified Public Accountants in its ~~Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, 2013~~~~. The specialists used a variety of both objective and subjective factors, including:~~

●

~~the nature of our business and its history since inception;~~

●

~~the prices, rights, preferences, and privileges of our preferred units relative to those of our common units;~~

●

~~our stage of development;~~

●

~~our operating and financial performance and forecast;~~

●

~~the present value of estimated future cash flows;~~

●

the likelihood of achieving a liquidity event for the shares of common units underlying the options to purchase common stock, such as an initial public offering or sale of our company, given prevailing market conditions and the nature and history of our business;

●

~~any adjustment necessary to recognize a lack of marketability for our common stock;~~

●

~~the market performance of comparable publicly traded companies; and~~

●

~~conditions in the U.S. and global capital markets.~~

A valuation was performed by an independent third-party valuation specialist in November 2019, concurrent with the formation of FOXO Technologies Operating Company as a limited liability company. In this valuation, the Cost Approach was used to determine enterprise value based on the fair market value of our assets. This approach was utilized given our lack of earnings history and the start-up nature of our business and operations, both of which brought into question our ability to continue as a going concern. At the time of this valuation, the estimated enterprise value was primarily based on the subscription receivable.

Another valuation was performed by an independent third-party valuation specialist in November 2020 following the corporate conversion of FOXO Technologies Operating Company and in anticipation of issuing stock options. The valuation was performed using the same methodology, but also considered a liquidation preference for preferred stock calculated using a Black-Scholes valuation model. At the time of this valuation, the majority of the subscription receivable had already been collected, causing a reduction in the estimated enterprise value. The liquidation preference for preferred stock and a discount for lack of marketability also had an adverse impact on valuation, which was determined to be $0.21 per share of common stock.

~~We have historically refreshed enterprise valuations to determine the fair value of our equity-based compensation at grant date for stock options.~~

We conduct performance reviews twice annually following the end of the second and fourth quarter. Our first stock option grant occurred following our biannual review after the fourth quarter of 2020, with the formal grant occurring when the stock option agreements were executed in April 2021. At that time, the fair value of our common stock was $0.09 per share. While the preferred stock is outstanding, holders have protection from share issuance at a price below the original issue price, as adjusted (“nine”). Accordingly, for stock options granted in April 2021, the exercise price per option was set at an amount slightly above the anticipated nine. Stock options granted in April 2021 comprise the majority of stock options outstanding as of September 30, ~~2022.~~

~~We completed our biannual review following~~2023, the ~~second quarter~~Company had an accumulated deficit of ~~2021 as we entered into negotiations with Delwinds. At this time, stock options were issued with~~$172,289. Cash used in operating activities for the ~~same exercise price as~~nine months ended September 30, 2023 was $6,165. As of September 30, 2023, the ~~April 2021 grant. This was determined to be a good faith estimate as a result~~Company had $42 of ~~the uncertainty of the transaction, prior values of common stock,~~available cash and the historical investment of our preferred stockholder. As a result of a letter of intent (the “Letter of Intent”) to merge with Delwinds, we considered it prudent to have another valuation performed to record equity-based compensation expense in the consolidated financial statements reflective of the updated circumstances surrounding our company. This valuation report was received subsequent to the grant of the stock options but is reflected in the consolidated financial statements for this grant.cash equivalents.

This valuation report reflected a change in methodology due to the letter of intent related to the Business Combination and development of our Company as a result of the in-process August order to acquire MICOA. This valuation report used a probability weighting of the Market Approach and Income Approach. The Market Approach reflected the offer from Delwinds based on the pre-money valuation of FOXO plus a Monte Carlo simulation to capture the value from earn-out shares based on exceeding specified per share price targets after closing. The Income Approach utilized a discounted cash flow analysis to provide an estimate of enterprise value based on the present value of anticipated future cash flows. As with prior valuations, a Black-Scholes valuation model was used to value each equity class by creating a series of call options on our equity value, with exercise prices based on the liquidation preferences and participation rights. The non-marketability discount in this valuation report was 20%.

Stock options were granted in January and February of 2022 after the completion of our biannual review following the fourth quarter of 2021 based on the valuation discussed above as the circumstances surrounding our common stock remained relatively stable during the timeframe from the valuation report to the option grant.

Application of these approaches and methodologies involves the use of estimates, judgment and assumptions that are highly complex and subjective, such as those regarding our expected operations, the selection of comparable public companies, and the probability of and timing associated with possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact our valuations as of each valuation date and may have a material impact on the valuation of our common stock.

~~Fair Value of Convertible Debentures~~

We elected the fair value option to account for the 2021 Bridge Debentures and 2022 Bridge Debentures. The fair value option provides an election that allows a company to irrevocably elect to record certain financial assets and liabilities at fair value on an instrument-by-instrument basis at initial recognition. We elected the fair value option to better depict the ultimate liability associated with the debentures, including all features and embedded derivatives. The debentures accounted for under the fair value option election represent debt host financial instruments containing certain embedded features that would otherwise be required to be bifurcated from the debt host and recognized as separate derivative liabilities subject to initial and subsequent periodic fair value measurement in accordance with U.S. GAAP. When the fair value option election is applied to financial liabilities, bifurcation of embedded derivatives is not required, and the financial liability in totality is recorded at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis as of each balance sheet date thereafter. Upon remeasurement, the portion of a change in estimated fair value attributable to a change in instrument-specific credit risk is recognized as a component of other comprehensive income (loss) and the remaining amount of a change in estimated fair value is to be recognized in the consolidated statements of operations.

During 2021, the fair value of the 2021 Bridge Debentures was determined using a Monte Carlo simulation, which is commonly used to value convertible debt instruments, and is intended to provide an estimated fair value that approximates the equity value that would be received upon conversion. The significant assumptions used in those models were as follows:

●

Likelihood of term extension: The Securities Purchase Agreements gave us the right to extend the maturity date for each issuance of convertible debentures for an additional three-month period and incur an extension amount rate of 110% of the outstanding balance. Increases in the likelihood of term extension as of a given reporting date increase the potential principal amount and thus the estimated fair value of the convertible debentures derived from the Monte Carlo simulation. Conversely, in the event that term extension is less likely as of a given reporting date, the principal is less likely to be increased, meaning the estimated fair value is likely to stay nearer to the issuance-date fair value.

●

Likelihood of conversion: The convertible debentures allowed for both: (i) voluntary conversion of aggregate principal and accrued and unpaid interest to shares of Class A common stock at the option of the holder at a price per share equal to nine and (ii) mandatory conversion of aggregate principal and accrued and unpaid interest upon FOXO consummating an offering of common stock, including a special purpose acquisition company transaction, for an aggregate price of at least $5,000 at a price per share equal to the lower of (a) 70% of the offering price per share or (b) nine. Given the terms of the convertible debt, and depending upon the fair value of our equity as of a given reporting date, voluntary and mandatory conversion features are often beneficial to holders and thus have the potential to materially increase the estimated fair value of the convertible debentures. For mandatory conversion, increases in the fair value of our equity as of a given reporting date make conversion at nine more likely, which is a favorable result to holders of the convertible debentures as compared to conversion at a price per share equal to 70% of a qualified offering price and thus increases the estimated fair value. Conversely, and while still beneficial to holders, conversion at a price per share equal to 70% of a qualified offering price increases the estimated fair value of the convertible debentures to a lesser degree than conversion at nine. Voluntary conversion is considered in the Monte Carlo simulation and affects the estimated fair value in scenarios in which a qualified offering event that would affect mandatory conversion does not take place.

~~Other notable, but not significant, assumptions utilized in the Monte Carlo simulations included, but were not limited to, implied borrowing and annualized volatility rates.~~

As a result of the execution of the Merger Agreement on February 24, 2022, the ultimate value to holders of the 2021 Bridge Debentures and 2022 Bridge Debentures upon voluntary or mandatory conversion became clearer, and thus management determined that a Monte Carlo simulation was no longer appropriate for purposes of estimating fair value. Thus, for the first and second quarters of 2022, the estimated fair value of the 2021 Bridge Debentures and 2022 Bridge Debentures was calculated using a probability-weighted expected return model. The significant assumptions used in the models were as follows:

●

Timing of conversion: The probability-weighted expected return model required management to estimate, based on known facts and circumstances at the time of valuation, the date on which conversion of the debentures will take place. That estimate drives the discount factor utilized in the model, which impacts the derived fair value. If the conversion date is set further in the future, a greater discount rate would be applied, driving down the fair value of the debt in a conversion scenario.

●

Likelihood of conversion: The 2021 Bridge Debentures contain voluntary and mandatory conversion provisions, which are discussed at length above. As the fair value of our equity increases, both conversion mechanisms represent an increasingly favorable result to holders and thus as the likelihood of conversion increases, so too does the estimated fair value of our liability related to the 2021 Bridge Debentures. The 2022 Bridge Debentures allow for both: (i) voluntary conversion of aggregate principal and unpaid interest thereon to shares of Class A common stock at any time after two hundred seventy days following the original issue dates, at a conversion price equal to $5.00 per share, except that if there has been no mandatory conversion within three hundred sixty days following the original issue date, the conversion price following such three hundred sixty-day period would be equal to $4.00 per share; and (ii) mandatory conversion of aggregate principal and unpaid interest thereon upon consummation of an offering of common stock, including a special purpose acquisition company transaction, for an aggregate price of at least $5,000, at a conversion price equal to 75% of the offering price per share. In the conversion scenario, the probability-weighted expected return model determines which conversion mechanism is most favorable to holders and assumes holders will choose the most favorable option in estimating fair value. Depending upon the fair value of our equity as of a given reporting date, these conversion features are often beneficial to holders and thus, increases in the likelihood of conversion increase the estimated fair value of our liability related to the 2022 Bridge Debentures.

~~Other notable, but not significant, assumptions used in the probability-weighted expected return model included, but were not limited to, implied borrowing rates.~~

~~Going Concern~~

On a quarterly basis, we assess going concern uncertainty for our condensed consolidated financial statements to determine if we have sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date our condensed consolidated financial statements are issued or are available to be issued (the “look-forward period”). Based on conditions that are known and reasonably knowable to us, we consider various scenarios, forecasts, projections, and estimates, and we make certain key assumptions, including the timing and nature of projected cash expenditures or programs, among other factors, and our ability to delay or curtail those expenditures or programs within the look-forward period, if necessary. Until additional equity or debt capital is secured and the Company begins generating sufficient revenue, reducing losses, and improving future cash flows, there is substantial doubt about the Company’s ability to continue as a going concern. The Company will continue ongoing capital raise initiatives and has demonstrated previous success in raising capital to support its operations.

During the first quarter of 2023, the Company completed the sale of FOXO Life Insurance Company in order to gain access to the cash held as statutory capital and surplus at FOXO Life Insurance Company. See Note 10 of our unaudited condensed combined financial statements for more information. The Company used the cash previously held at FOXO Life Insurance Company to fund its operation as it continues to (i) pursue additional avenues to capitalize the Company and (ii) commercialize its products to generate revenue. See Notes 5 and 7 of our unaudited consolidated financial statements for additional information on the Exchange Offer and PIK Note Offer to Amend that were structured to allow the Company to more easily raise capital. In July and August 2023, we completed the 2023 Private Placement that provided gross proceeds of $450. The Company anticipates that the aggregate net proceeds from the 2023 Private Placement, after deducting placement agent fees and other estimated offering expenses, will be approximately $260.

On June 12, 2023, the Company received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation (“NYSE”) stating that the Company is below compliance with Section 1003(a)(i) in the NYSE American Company Guide since the Company reported stockholders’ deficit of $(30) at March 31, 2023, and losses from continuing operations and/or net losses in its two most recent fiscal years ended December 31, 2022. As required by the NYSE American Notice, on July 12, 2023, the Company submitted a compliance plan (the “Plan”) to NYSE advising of actions it has taken or will take to regain compliance with the NYSE American continued listing standards by December 12, 2024, and if NYSE accepts the Plan, the Company has an eighteen (18) month period to comply with the Plan. Should the Plan not be accepted or the Company be unable to comply with the Plan, then it may make it more difficult for the Company to raise capital.

However, the Company can provide no assurance that these actions will be successful or that additional sources of financing will be available on favorable terms, if at all. As such, until additional equity or debt capital is secured and the Company begins generating sufficient revenue, there is substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the issuance of these consolidated financial statements. In the event that the Company is unable to secure additional financing by mid-January 2024, it will be unable to fund its operations and will be required to evaluate further alternatives, which could include further curtailing or suspending its operations, selling the Company, dissolving and liquidating its assets or seeking protection under the bankruptcy laws. A determination to take any of these actions could occur at a time that is earlier than when the Company would otherwise exhaust its cash resources.

Recent Accounting Pronouncements

See Note 3 to our unaudited consolidated financial statements “Summary of Significant Accounting Policies – Recently Issued Accounting Standards” included elsewhere in this Report for more information.None.

Factors That May Adversely Affect our Results of Operations

Our results of operations may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond our control. Our business could be impacted by, among other things, downturns in the financial markets or in economic conditions, increases in oil prices, inflation, increases in interest rates, supply chain disruptions, declines in consumer confidence and spending, the ongoing effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and geopolitical instability, such as the military conflict in the Ukraine. We cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact our business.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer (the ~~“Certifying Officers”~~“Certifying Officers”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our Certifying Officers, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the foregoing, our Certifying Officers concluded that our disclosure controls and procedures were effective as of September 30, ~~2022.~~2023.

Changes in Internal Control over Financial Reporting

~~As discussed elsewhere~~There has been no change in ~~this Report on Form 10-Q, we completed~~ the Business Combination on September 15, 2021. Delwinds was a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more target businesses, and FOXO Technologies Operating Company was a privately held company.

~~The~~ Company’s ~~operations prior the Business Combination were materially different compared to the Company post- Business Combination. The design and implementation of~~ internal ~~controls~~control over financial reporting, ~~for~~as defined in Rules 13a-15(f) of the ~~post-Business Combination Company~~Exchange Act, during the Company’s quarter ended September 30, 2023, that has ~~required and will continue~~materially affected, or is reasonably likely to ~~require significant time and resources from management and other personnel.~~materially affect, the Company’s internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

~~From time~~Smithline Family Trust II vs. FOXO Technologies Inc. and Jon Sabes

On November 7, 2023, Smithline, on the one hand, and the Company and its subsidiaries, on the other hand, entered into a settlement agreement (the “Settlement Agreement”), pursuant to ~~time,~~which the parties agreed to resolve and settle all disputes and potential claims which exist or may exist among them, including without limitation those claims asserted in the Action, as more specifically set forth in, and subject to the terms and conditions of, the Settlement Agreement. Upon the execution of the Settlement Agreement, the parties agreed to jointly dismiss the Action without prejudice.

In addition, the Company agreed to use commercially reasonable efforts to pay $300,000 in cash to Smithline by December 31, 2023 toward the Cash Settlement Payment. In the event that the Company has not paid in full the Cash Settlement Payment prior to the Settlement Deadline, Smithline will be entitled to retain all proceeds received pursuant to the Settlement Agreement, the Mutual Release (as defined below) will be returned to their respective parties, and Smithline may pursue any claims against, among others, the Company.

In addition, the parties agreed that prior to Smithline receiving $300,000 in cash from the Company toward the Cash Settlement Payment, the Company may ~~become involved in litigation relating to claims arising out~~not file any resale registration statements and any amendments or supplements thereto without Smithline’s written consent, except for those that cover the resale of our operations in the normal course of business. The Company is not currently involved in any material pending legal proceedings, and to the best of our knowledge, no governmental authority is contemplating any proceeding to which the Company is a party or to which anyshares of the Company’s ~~properties~~Class A common stock, $0.0001 par value (“Common Stock”), currently issued or issuable to Mitchell Silberberg & Knupp LLP, Joseph Gunnar & Co., LLC or under the Strata Purchase Agreement, dated October 13, 2023, by and between the Company and ClearThink Capital Partners, LLC (“ClearThink”), as supplemented by that certain Supplement to Strata Purchase Agreement, dated as of October 13, 2023, by and between the Company and ClearThink (as supplemented, the “Strata Purchase Agreement”).

In addition, the parties agreed that after Smithline has received $300,000 in cash from the Company, in the event the Company registers for resale shares of Common Stock which are not issued or issuable as of the effective date of the Settlement Agreement, for a selling stockholder other than under the Strata Purchase Agreement, during the Settlement Period, then the Company will be required to issue Smithline shares of Common Stock equal to 4.99% of the then outstanding shares of Common Stock after giving effect to such issuance (such shares, the “Settlement Shares”) at the closing price of the Common Stock immediately prior to their issuance, subject to the authorization of NYSE American if the Common Stock is ~~subject,~~then traded on such exchange, which ~~would reasonably~~Settlement Shares will be ~~likely~~included for resale in such registration statement, provided, however, that the amount of Settlement Shares, if any, when aggregated with other Settlement Shares, if any, will be reduced to ~~have a material adverse effect~~ensure that such aggregate amount will not exceed 19.9% of the outstanding shares of Common Stock as of the date of issuance (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations, and other similar transactions that occur after the date of the Settlement Agreement). Any net proceeds (after taking into account all brokerage, transfer agent, legal and other expenses incurred in connection with the sale of the Settlement Shares, if any) received by Smithline on the ~~Company’s business, financial condition and operating results.~~sale of the Settlement Shares, if any, will be credited against the Cash Settlement Payment (the “Net Proceeds”).

ITEM 1A. RISK FACTORS

~~Our Current~~We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. In addition to the risk factors set forth below and the other information set forth in this Form 10-Q, you should carefully consider the factors disclosed in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form ~~8-K,~~10-K for the year ended December 31, 2022, filed with the SEC on ~~September 21, 2022, describes important risk factors that~~March 31, 2023, which report is incorporated by reference herein, all of which could ~~cause~~materially affect our business, financial condition ~~results~~and future results.

Risks Related to Our Business and Industry

We have a history of losses and may not achieve or maintain profitability in the future.

We are a development stage company and have not been profitable since our inception in 2019, accumulating deficits of $172,289,000 and $147,231,000 as of September 30, 2023 and December 31, 2022, respectively. We incurred net losses to common stockholders of $3,660,000 and $25,058,000 for the three and nine months ended September 30, 2023, respectively, $41,026,000 and $76,932,000 for the three and nine months ended September 30, 2022, respectively, and $95,255,000 and $38,488,000 in the years ended December 31, 2022 and 2021, respectively. We expect we will require significant capital in connection with our efforts, and we will be required to continue to make significant investments to further develop and expand our business. In particular, we expect to expend financial and other resources on sales and marketing as part of our strategy to develop and increase product and service sales, as well as on research and development activities regarding our epigenetic technology. In addition, to the extent our business ramps up as we expect, we will need to increase our headcount in the coming years. As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We expect that our net loss will increase in the near term as we continue to make such investments to grow our business. Despite these investments, we may not succeed in increasing our revenue on the timeline that we expect or in an amount sufficient to lower our net loss and ultimately become profitable. Moreover, if our revenue does not increase, we may not be able to reduce costs in a timely manner because many of our costs are fixed, at least in the short term. In addition, if we reduce variable costs to respond to losses, this may limit our ability to enter into agreements with new customers and grow our revenues. Accordingly, we may not achieve or maintain profitability and we may continue to incur significant losses in the future.

We do not have adequate cash resources to fund our operations through the 12 months ending December 31, 2024 and will require additional capital to commercialize our product and service offerings and grow our business, which may not be available on terms acceptable to us or at all. If we are unable to secure additional funds, we may be forced to delay, reduce or eliminate our commercialization efforts or cease all operations.

Our present capital may be insufficient to meet operating requirements or to cover losses, and therefore we may need to raise additional funds through financings to carry out our business plans. Many factors will affect our capital needs as well as their amount and timing, including our growth ~~prospects~~and profitability as well as market disruptions and other developments.

On October 13, 2023, entered into a Strata Purchase Agreement (the “Strata Purchase Agreement”) with ClearThink Capital Partners, LLC (“ClearThink”), as supplemented by that certain Supplement to ~~differ materially~~Strata Purchase Agreement, dated as of October 13, 2023, by and between the Company and ClearThink (the “Strata Supplement”). Pursuant to the Strata Purchase Agreement, after the satisfaction of certain commencement conditions, including, without limitation, the effectiveness of the Registration Statement (as defined below), ClearThink has agreed to purchase from ~~those indicated or suggested by forward-looking statements made in this Quarterly Report on Form 10-Q or presented elsewhere by management~~the Company, from time to ~~time. There have been no material changes~~time upon delivery by the Company to ClearThink of request notices (each a “Request Notice”), and subject to the other terms and conditions set forth in the ~~risk factors~~Strata Purchase Agreement, up to an aggregate of $2,000,000 of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of the shares of common stock to be purchased under the Strata Purchase Agreement will be equal to 85% of the lowest daily VWAP during a valuation period of ten trading days consisting of the five trading days preceding the Purchase Date (as defined in the Strata Purchase Agreement) with respect to a Request Notice and five trading days commencing on the first trading day following delivery and clearing of the delivered shares. In addition, pursuant to the Strata Purchase Agreement, the Company agreed to issue to ClearThink 100,000 restricted shares of Common Stock (the “Commitment Shares”) as a “Commitment Fee.”

Historically, we have funded our operations, marketing expenditures and capital expenditures primarily through equity issuances and debt instruments. We evaluate financing opportunities from time-to-time, and our ability to obtain financing will depend, among other things, on our development efforts, business plans and operating performance, and the condition of the capital markets at the time we seek financing. We cannot be certain that ~~appear~~additional financing will be available to us on favorable terms, or at all.

If we raise additional funds through the issuance of equity, equity-linked or debt securities, our existing stockholders may experience dilution. Any debt financing secured by us in the future could require that a substantial portion of our ~~Current Report~~operating cash flow be devoted to the payment of interest and principal on ~~Form 8-K,~~such indebtedness, which may decrease available funds for other ~~than those listed below. Additional risks~~business activities, and ~~uncertainties not currently known~~could involve restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities.

Our ability to raise additional funds in the short-term will depend on financial, economic and market conditions and the willingness of potential investors or lenders to provide funding, all of which are outside of our control, and we may be unable to raise financing in the short-term, or on terms favorable to us, or at all. Furthermore, high volatility in the capital markets has had, and could continue to have, a negative impact on the price of the Class A Common Stock, and could adversely impact our ability to raise additional funds. If we are unable to obtain sufficient funding, we may be forced to delay, reduce or eliminate our commercialization efforts or cease all operations, and our stockholders could lose all or part of their investment in our Company.

If we are unable to raise sufficient capital in the short-term, we will be unable to fund our operations and will be required to evaluate further alternatives, which could include dissolving and liquidating our assets or seeking protection under the bankruptcy laws. A determination to take any of these actions could occur at a time that is earlier than when we ~~currently deem~~would otherwise exhaust our cash resources.

Former or current members of our management team or the Board may, from time to time, be ~~immaterial may also materially and adversely affect~~associated with negative media coverage or become involved in legal or regulatory proceedings or investigations unrelated to our business.

Former or current members of our management team or the Board have been involved in a wide variety of businesses, including transactions, such as sales and purchases of businesses, and ongoing operations. As a result of such involvement, former or current members of our management team or the Board may from time to time be associated with negative media coverage or become involved in legal or regulatory proceedings or investigations unrelated to our business. Any negative media coverage, regulatory proceedings or investigations related to our management team or the Board may be detrimental to the reputation of our management team or the Board or result in other negative consequences or damages, which could cause a material adverse impact on our business and the stock price of our Company.

Covenants in our indebtedness could limit our flexibility and adversely affect our financial condition.

Our outstanding indebtedness contains several restrictive covenants, including that we cannot, without the prior written consent of 50.01% of the holders of our ~~senior promissory notes (the “Notes”),~~Senior PIK Notes, create or incur any other ~~indebtedness.~~indebtedness, with the exception of certain exempt issuances, including but not limited to issuances of Class A Common Stock or Common Stock Equivalents in connection with a Private Placement or Public Financing (each as defined in “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Recent Developments – Exchange Offer, PIK Note Offer to Amend and 2022 Bridge Debenture Release”). If any of our covenants are breached and not cured within applicable cure periods, the breach could result in acceleration of our indebtedness and penalties. Limitations on our ability to incur new indebtedness under the terms of our debt securities may limit the amount of new investments we make.

The Senior PIK Notes mature on April 1, 2024 (the ~~“Maturity Date”~~“Maturity Date”), and accrue interest at an annual interest rate of 15%, commencing on the issuance date, compounded quarterly on each December 20, March 20, June 20 and September 20 until the Maturity Date and on the Maturity Date itself (each, an ~~“Interest~~“Interest Payment Due ~~Date”~~Date”). Interest is payable by increasing the principal amount of the ~~Note~~Senior PIK Notes (with such increased amount accruing interest as well) on each Interest Payment Due Date (“PIK ~~Interest”~~Interest”). Monthly payments on the outstanding principal amount of the ~~Note,~~Senior PIK Notes, as such amount may be increased as the result of the payment of PIK Interest (the ~~“Outstanding~~“Outstanding Principal ~~Balance”~~Balance”), ~~will~~were due to commence on November 1, 2023, until the Outstanding Principal Balance has been paid in full on the Maturity Date, or, if earlier, upon acceleration, or prepayment of the ~~Note~~Senior PIK Notes in accordance with the Senior PIK Notes ~~terms. A~~terms.. We are negotiating with the PIK note holders to restructure the notes are we are currently in default ~~by us on the Notes would have a material adverse effect on our business, liquidity and the market price~~ of ~~our common stock.~~payments terms.

The ~~warrants issued by FOXO under its January 2021 bridge financings and assumed by the Company as part of the Business Combination~~Assumed Warrants have anti-dilution rights that could be triggered as part of future financings.

If FOXO raises additional funds through the issuance of equity, equity-linked or debt securities, with the exception of certain exempt issuances, with an exercise price lower than ~~$6.21~~$62.10 per share, ~~at such time as the warrants issued under the January 2021 bridge financing are outstanding (the “Assumed Warrants”),~~ the anti-dilution protection provisions in the Assumed Warrants will be triggered. Specifically, the exercise price and number of warrant shares of the Assumed Warrants will be adjusted to reflect such lower issuance price as the new equity is sold and the number of shares issuable under the Assumed Warrant will be increased such that the aggregate exercise price after the lower price adjustment shall be equal to the aggregate exercise price prior to adjustment. This anti-dilution adjustment will have a dilutive effect on the Company’s equity and may hamper its ability to complete future financings.

There is no guarantee that the exercise price of our Warrants will ever be less than the trading price of the Class A Common Stock, and they may expire worthless. In addition, we may reduce the exercise price of the Private and Public Warrants in accordance with the provisions of the Warrant Agreement, and a reduction in exercise price of the Private and Public Warrants would decrease the maximum amount of cash proceeds we could receive upon the exercise in full of the Private and Public Warrants for cash.

As of the date of this Report, the exercise price for the Public and Private Warrants is $115.00 per share of Class A Common Stock, and the exercise price for the Assumed Warrants is $62.10 per share of Class A Common Stock. On January 18, 2024, the closing price of the Class A Common Stock was $0.276. If the price of our shares of Class A Common Stock remains below the respective exercise prices of the Warrants, we believe our warrant holders will be unlikely to cash exercise their Warrants, resulting in little or no cash proceeds to us. There is no guarantee that the Warrants will be in the money prior to their expiration and, as such, the Warrants may expire worthless. In addition, at the current exercise price of $115.00 per share for the Public and Private Warrants, and $62.10 per share for the Assumed Warrants, we will receive up to $121 million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. However, we may lower the exercise price of the Public Warrants and the Private Warrants in accordance with Section 9.8 of the Warrant Agreement to induce the holders to exercise such warrants. The Company may effect such reduction in exercise price without the consent of warrant holders and such reduction would decrease the maximum amount of cash proceeds we would receive upon the exercise in full of the Warrants for cash. In addition, in the event the Company issues Class A Common Stock or common stock equivalents that trigger the full ratchet anti-dilution provision in the Assumed Warrants, then the exercise price of the Assumed Warrants may be reduced and any subsequent exercises would decrease the amount of proceeds the Company receives for each share of Class A Common Stock.

If we are unable to maintain effective internal control over financial reporting and disclosure controls and procedures, the accuracy and timing of our financial reporting may be adversely affected.

We are required to comply with Section 404 of the Sarbanes-Oxley Act, which requires management assessments of the effectiveness of internal control over financial reporting and disclosure controls and procedures. Prior to our Business Combination, although we had effective internal controls and procedures, we were a private company with limited accounting and finance personnel, review processes and other resources with which to address our internal controls and procedures.

Based on the evaluation of our internal controls over financial reporting, we concluded that such controls were effective as of December 31, 2022. In addition, based on the evaluation of our disclosure controls and procedures as of September 30, 2023, we concluded such controls were effective. However, due to the current size of our Company and our limited personnel, we may not be able to maintain effective internal control over financial reporting and disclosure controls and procedures in the future.

We can give no assurance that we will be able to maintain effective internal control over financial reporting and disclosure controls and procedures, or that no “material weaknesses” in our internal control over financial reporting will be identified in the future. If we encounter “material weaknesses” in our internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis, it could lead to errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations. Further, If we are unable to maintain effective internal control over financial reporting or disclosure controls and procedures, our ability to record, process and report financial information accurately and to prepare financial statements within required time periods could be adversely affected, which could subject us to litigation or investigations requiring management resources and payment of legal and other expenses, negatively affect investor confidence in our financial statements, restrict access to capital markets and adversely impact our stock price.

We have been subject to regulatory and other government or regulatory investigations or inquiries under national, regional and local laws, as amended from time to time, and may be required to comply with data requests, or requests for information by government authorities and regulators in the United States or other jurisdictions in which we operate and any resulting enforcement action could have a materially adverse effect on us.

As a publicly trading reporting company with operations in the United States and internationally, we interact regularly with regulatory and self-regulatory agencies in the United States or other jurisdictions in which we operate, including the SEC and the NYSE American. We have been and may in the future be the subject of SEC and other regulatory investigations or inquiries and may be required to comply with informal or formal orders or other requests for information or documentation from such government authorities and regulators regarding our compliance with national, regional and local laws and regulations, including the rules and regulations under the Securities Act and the Exchange Act. Such laws and regulations and their interpretation and applications may also change from time to time. Responding to requests for information from regulators in connection with any such investigations or inquiries could have a materially adverse effect on our business through, among other things, significantly increased legal fees and the time and attention required of the Company’s management and employees to be diverted from our normal business operations and growth plans. Moreover, if a regulator were to initiate an enforcement action against us, such any action could further consume our resources, require us to change our business practices and have a material adverse effect on our business, financial condition, results of operations and cash flows.

Risks Related to Our Epigenetic Testing Services

We currently have research projects planned and underway designed to further discover, improve and/or validate the use of our epigenetic biomarkers for our commercial purposes, but we cannot guarantee the results of such research and any negative results may negatively impact our ability to pursue our business plans.

Our current and planned research projects are designed to further discover, improve and/or validate the use of epigenetic biomarkers for commercial use. The main research projects we have underway are the Physicians’ Health Study and two other research projects that are intended to inform the utility and capabilities of epigenetics for health assessment.

While we believe these research projects will lead to the discovery, improvement, and commercialization of our proprietary epigenetic biomarker technology, we cannot guarantee positive and immediately commercializable results from these studies, nor can we guarantee that potential customers will use our products and services based on the results of such studies. Our results may be misleading or inaccurate, which could adversely impact the acceptance of our products and services, and our overall ability to continue pursuing our business plans. If the results from our research studies differ from what we expect, or if such results are not accepted by our customers, it will adversely impact our ability to pursue our business plans and generate revenue, which could result in a complete loss of your investment.

Risks Related to Owning Our Securities

We are subject to the continued listing standards of the NYSE American and our failure to satisfy these criteria may result in delisting of the Class A Common Stock.

The Class A Common Stock is listed on the NYSE American. In order to maintain this listing, we must maintain a certain share price, financial and share distribution targets, including maintaining a minimum amount of stockholders’ equity and a minimum number of public stockholders. In addition to these objective standards, the NYSE American may delist the securities of any issuer (i) if, in its opinion, the issuer’s financial condition and/or operating results appear unsatisfactory; (ii) if it appears that the extent of public distribution or the aggregate market value of the security has become so reduced as to make continued listing on the NYSE American inadvisable; (iii) if the issuer sells or disposes of principal operating assets or ceases to be an operating company; (iv) if an issuer fails to comply with the NYSE American’s listing requirements; (v) if an issuer’s securities sell at what the NYSE American considers a “low selling price” which the exchange generally considers $0.20 per share and the issuer fails to correct this via a reverse split of shares after notification by the NYSE American; or (vi) if any other event occurs or any condition exists which makes continued listing on the NYSE American, in its opinion, inadvisable. There are no assurances how the market price of the Class A Common Stock will be impacted in future periods as a result of the general uncertainties in the capital markets and any specific impact on our Company as a result of the recent volatility in the capital markets.

On June 12, 2023, we received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation (“NYSE”) stating that we are below compliance with Section 1003(a)(i) in the NYSE American Company Guide (the “Company Guide”) since we reported stockholders’ deficit of $(30,000) at March 31, 2023, and losses from continuing operations and/or net losses in its two most recent fiscal years ended December 31, 2022. Section 1003(a)(i) of the Company Guide requires a listed company to have stockholders’ equity of $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years.

If we are unable to retain compliance with all applicable NYSE American listing standards, the Class A Common Stock would be subject to delisting. If the NYSE American delists the Class A Common Stock, investors may face material adverse consequences, including, but not limited to, a lack of trading market for the Class A Common Stock, reduced liquidity and market price of the Class A Common Stock, decreased analyst coverage of the Class A Common Stock, and an inability for us to obtain any additional financing to fund our operations that we may need.

If the Class A Common Stock is delisted, the Class A Common Stock may be subject to the so-called “penny stock” rules. The SEC has adopted regulations that define a penny stock to be any equity security that has a market price per share of less than $5.00, subject to certain exceptions, such as any securities listed on a national securities exchange. For any transaction involving a penny stock, unless exempt, the rules impose additional sales practice requirements and burdens on broker-dealers (subject to certain exceptions) and could discourage broker-dealers from effecting transactions in our stock, further limiting the liquidity of our shares, and an investor may find it more difficult to acquire or dispose of the Class A Common Stock on the secondary market.

These factors could have a material adverse effect on the trading price, liquidity, value and marketability of the Class A Common Stock.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~Information regarding all equity securities~~From July 14, 2023 through July 20, 2023 (each such date, a “First Tranche Closing Date”), the Company entered into three separate Stock Purchase Agreements (the “Stock Purchase Agreements”), which have substantially similar terms, with three accredited investors (the “Buyers”), pursuant to which the Company agreed to issue and sell to the Buyers, in a private placement (the “2023 Private Placement”), in two separate tranches each, an aggregate of up to 562,500 shares of Class A Common Stock at a price of $0.80 per share, for aggregate gross proceeds of $450.

Pursuant to the terms of the ~~registrant sold~~Stock Purchase Agreements, the Buyers initially purchased an aggregate of 281,250 shares of Class A Common Stock on the applicable First Tranche Closing Dates. The shares above were issued in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the ~~Company during the period covered by this Report that were not registered~~SecuritiesAct and Rule 506(b) of Regulation D under the Securities Act, based in part on the representations of the investors.

There were ~~included~~$24 in ~~a Current Report on Form 8-K filed by the Company with the SEC on September 21, 2022, and therefore is not required~~sales commissions paid to ~~be furnished herein.~~J.H. Darbie & Co., Inc.

~~ITEM 3. DEFAULTS UPON SENIOR SECURITIES~~

~~None.~~

~~ITEM 4. MINE SAFETY DISCLOSURES~~

~~Not applicable.~~

ITEM 5. OTHER INFORMATION

~~The information set forth below is included herein for the purpose~~Disclosure Pursuant to Item 5.02 of ~~providing the disclosure required under “Item 1.02 – Termination~~Current Report on Form 8-K - Departure of ~~a Material Definitive Agreement.”~~Directors or Certain Officers; Election of ~~Form 8-K.~~Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~November 8, 2022,~~August 9, 2023, Murdoc Khaleghi, a member of the Company’s Board of Directors (the “Board”), notified the Company ~~and CF Principal Investments LLC (the “Cantor Investor”) mutually terminated that certain Common Stock Purchase Agreement, dated~~of his resignation from the Board, effective as of ~~February 24, 2022 (the “Purchase Agreement”), by~~such date. Mr. Khaleghi’s decision to resign from the Board was for personal reasons and ~~between~~not related to any disagreement with the Company and the Cantor Investor. Upon the termination of the Purchase Agreement, the related Registration Rights Agreement, dated as of February 24, 2022 (the “Registration Rights Agreement”), by and between the Company and the Cantor Investor was automatically terminated in accordance with its terms. Pursuant to the terms of the Purchase Agreement, the Company issued 190,476 shares of Class A Common Stock to the Cantor Investor on September 16, 2022 as consideration for its irrevocable commitment to purchase the shares of Class A Common Stock upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement.

On November 11, 2022, the Company and Meteora Special Opportunity Fund I, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Capital Partners, LP (collectively, “Meteora”) mutually terminated that certain Forward Share Purchase Agreement, dated as of September 13, 2022 (the “Forward Purchase Agreement”), by and between the Company and Meteora, in exchange for 500,000 shares. Upon the termination of the Forward Purchase Agreement, the related escrow agreement was terminated.

The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement are not complete and are qualified in their entirety by reference to the full text of the Purchase Agreement and the Registration Rights Agreement, copies of which are filed as Exhibit 10.4 and 10.5, respectively,any matter relating to the Company’s Current Report on Form 8-K filed with the SEC on March 2, 2022. The foregoing description of the Forward Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of the Forward Purchase Agreement, a copy of which is filed as Exhibit 10.14 to the Company’s Current Report on Form 8-K filed with the SEC on September 21, 2022.operations, policies or practices.

ITEM 6. EXHIBITS

The following exhibits are filed as part of, or incorporated by reference into, this Report.

Exhibit ~~Number~~No.	Description of	Included	Form	Referenced Exhibit	Filing Date
~~2.1~~31.1	Agreement and Plan of Merger, dated as of February 24, 2022, by and among Delwinds Insurance Acquisition Corp., FOXO Technologies Inc., DWIN Merger Sub Inc., and DIAC Sponsor LLC, in its capacity as Purchaser Representative thereunder. (1)
~~2.2~~	Amendment to Agreement and Plan of Merger, dated as of April 26, 2022, by and among Delwinds Insurance Acquisition Corp., FOXO Technologies Inc. and DIAC Sponsor LLC, in its capacity as Purchaser Representative. (1)
~~2.3~~	Amendment No. 2 to Agreement and Plan of Merger, dated as of July 6, 2022, by and among Delwinds Insurance Acquisition Corp., FOXO Technologies Inc. and DIAC Sponsor LLC, in its capacity as Purchaser Representative. (1)
~~2.4~~	Amendment No. 3 to Agreement and Plan of Merger, dated as of August 12, 2022, by and among Delwinds Insurance Acquisition Corp., FOXO Technologies Inc. and DIAC Sponsor LLC, in its capacity as Purchaser Representative. (1)
~~3.1~~	~~Certificate of Incorporation of FOXO Technologies Inc. (1)~~
~~3.2~~	~~Bylaws of FOXO Technologies Inc. (1)~~
~~4.1~~	~~Form of Assumed Warrant. (1)~~
~~4.2~~	~~Form of 15% Senior Promissory Note. (1)~~
~~10.1~~	~~FOXO Technologies Inc. 2022 Equity Incentive Plan. (1)~~
~~10.2~~	~~2022 Management Contingent Share Plan (including Notice of Grant). (1)~~
~~10.3~~	Forward Share Purchase Agreement, dated September 13, 2022, by and between (i) Delwinds, (ii) Meteora Special Opportunity Fund I, LP, a Delaware limited partnership (“MSOF”), (iii) Meteora Select Trading Opportunities Master, LP, a Cayman Islands limited partnership (“MSTO”) and (iv) Meteora Capital Partners, LP, a Delaware limited partnership. (1)
~~10.4~~	~~Form of Revised Backstop Subscription Agreement, dated September 13, 2022. (1)~~
~~10.5~~	~~Insider Letter Amendment. (1)~~
~~10.6~~	~~Form of Indemnification Agreement. (1)~~
~~10.7~~	~~Form of Senior Promissory Note Purchase Agreement. (1)~~
~~10.8~~	~~Placement Agency Agreement. (1)~~
~~10.9~~	~~Form of Lock-Up Release Agreement. (1)~~
10.10*	~~Form of Securities Purchase Agreement, dated as of January 25 2021, by and among FOXO Technologies Inc. and purchaser signatories thereto.~~
~~10.11#~~	~~Form of Employment Agreement of Jon Sabes.~~
~~10.12#~~	~~Form of Tyler Danielson’s Offer Letter.~~
~~10.13#~~	~~Form of Employment Agreement of Robby Potashnick.~~
~~10.14#~~	~~Form of Amended and Restated Employment Agreement of Brian Chen.~~
~~10.15#~~	~~Form of Michael Will’s Offer Letter.~~
31.1*	Certification of the Principal Executive Officer ~~pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted~~ pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Filed Herewith

31.2	Certification of the Principal Financial ~~Officer pursuant to Rule 13a-14(a)~~ and ~~Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted~~Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Filed Herewith

32.1#	Certification of the Company’s Principal Executive Officer and pursuant to 18 U.S.C. ~~1350, as adopted pursuant to~~ Section ~~906 of the Sarbanes-Oxley Act of 2002.~~1350.
32.2**	~~Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.~~Furnished Herewith

101.INS*101.INS	Inline XBRL Instance Document.*	Filed Herewith

101.SCH*101.SCH	Inline XBRL Taxonomy Extension Schema Document.*	Filed Herewith

101.CAL*101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.*	Filed Herewith

101.DEF*101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.*	Filed Herewith

101.LAB*101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.*	Filed Herewith

101.PRE*101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.*	Filed Herewith

104*104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).*	Filed Herewith

*	~~Filed herewith.~~
**	~~Furnished herewith.~~
#	~~Indicates management contract~~This certification is deemed not filed for purposes of Section 18 of the Exchange Act or ~~compensatory plan or arrangement.~~
~~(1)~~	~~Incorporated~~otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference tointo any filing under the ~~Company’s Current Report on Form 8-K, filed with~~Securities Act or the ~~SEC on September 21, 2022.~~Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	FOXO TECHNOLOGIES INC.

Date: ~~November 21, 2022~~January 19, 2024	/s/ ~~Tyler Danielson~~Mark White
	Name:	~~Tyler Danielson~~Mark White
	Title:	Interim Chief Executive Officer
		(Principal Executive Officer)

Date: ~~November 21, 2022~~January 19, 2024	/s/ ~~Robert Potashnick~~Martin Ward
	Name:	~~Robert Potashnick~~Martin Ward
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

~~0001812360 foxo:BridgeDebentures2022Member 2021-12-31~~ iso4217:USD xbrli:shares

	Three Months Ended September 30, 2022			Three Months Ended September 30, 2021			Nine Months Ended September 30, 2022			Nine Months Ended September 30, 2021
Net loss available to common shares	$	(41,026	)	$	(27,241	)	$	(76,932	)	$	(37,614	)
Basic and diluted weighted average number of Class A Common Stock		6,122			5,826			5,975			5,817
Basic and diluted net loss available to Class A Common Stock	$	(6.70	)	$	(4.68	)	$	(12.88	)	$	(6.47	)

	2022 Bridge Debentures		2021 Bridge Debentures		Total
Balance, June 30, 2021	$	-	$	12,819	$	12,819
Losses included in net loss		-		22,571		22,571
Balance, September 30, 2021	$	-	$	35,390	$	35,390

	2022 Bridge Debentures			2021 Bridge Debentures			Forward Purchase Put Derivative		Forward Purchase Collateral Derivative		Total
Balance, June 30, 2022	$	46,733		$	37,953		$	-	$	-	$	84,686
Losses included in net loss		2,810			887			-		-		3,697
Balance at Conversion		49,543			38,840			-		-		88,383
Transfer out		(49,543	)		(38,840	)		-		-		(88,383	)
Losses included in net loss		-			-			1,284		27,378		28,662
Balance, September 30, 2022	$	-		$	-		$	1,284	$	27,378	$	28,662

(Dollars in thousands)	2022			2021			Change in $			Change in %
Total revenue	$	14		$	31		$	(17	)		(55	)%
Operating expenses:
Research and development		558			1,665			(1,107	)		(66	)%
Selling, general and administrative		8,269			2,721			5,548			204	%
Total operating expenses		8,827			4,386			4,441			101	%
Loss from operations		(8,813	)		(4,355	)		(4,458	)		102	%
Non-cash change in fair value of convertible debentures		(3,697	)		(22,571	)		18,874			(84	)%
Change in fair value of warrant liability		1,349			-			1,349			N/A	%
Change in fair value of forward purchase put derivative		(1,284	)		-			(1,284	)		N/A	%
Change in fair value of forward purchase collateral derivative		(27,378	)		-			(27,378	)		N/A	%
Other expense		(1,203	)		(315	)		(888	)		282	%
Total other expense		(32,213	)		(22,886	)		(9,327	)		41	%
Net loss	$	(41,026	)	$	(27,241	)	$	13,785			51	%